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ANALYSIS OF A PARTIAL DIFFERENTIAL EQUATION MODEL FOR
NECROTIZING ENTEROCOLITIS
Mark D. Tronzo, PhD
University of Pittsburgh, 2014
This thesis presents and analyzes a mathematical model for necrotizing enterocolitis (NEC), a
devastating disease that attacks the gastrointestinal tract of pre-term infants. Mathematical
models for NEC have been developed in the past. These modes are extremely valuable and
provide important insights into the disease. However, all of the models developed previously
are one dimensional, ordinary dierential equation models and, therefore, simulate only the
transient eects of NEC but do not fully model its spatial eects. The mathematical model
presented here is a three dimensional model in the form of a system of nonlinear partial
dierential equations. A three dimensional model is needed to accurately simulate diusion
and advection of the major factors in NEC, to account for the dierent eects of NEC in
the dierent regions in the body, and to fully integrate all the eects of such mechanisms as
epithelial cell degradation and migration.
This thesis presents medical research regarding NEC, constructs inammatory cascades
related to the disease, and develops the system of partial dierential equation system. Also,
full mathematical analysis of the system of equations. The mathematical analysis of the
system of partial dierential equations and the associated a mixed nite element analysis
are, perhaps, the most important parts of the thesis. The results of this analysis have
signicance for the NEC system and have signicance independent of the NEC system. For
example, existence, uniqueness, and regularity analysis is presented in the weak mixed form
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where f1 and f2 are nonlinear functions. Furthermore, nite element analysis (using the
mixed method) is done on this coupled system and convergence is proven, a new and very
important result. No mixed method nite element analysis has previously been published
for this system. Similar analysis is done on the rest of the partial dierential equations in
the system. At the end of the thesis, computer simulations are done using the mathematical
model. These simulations demonstrate that the NEC mathematical model presented here
produces realistic results consistent with the actual progression of the disease.
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1.0 NECROTIZING ENTEROCOLITIS
Necrotizing Enterocolitis(NEC) is a devastating and often fatal disease that attacks the gas-
trointestinal tract of newborns. NEC is characterized by intestinal inammation, intestinal
tissue death including destruction of the intestine, and sepsis. NEC most often attacks
preterm infants. Ironically, as the survival rate of preterm infants increases, so does the
incidence of NEC. NEC is diagnosed in about 2 out of 1000 live births per year [6]. NEC
occurs in approximately 7% of those infants with birth weights between 1 and 3 pounds.
The overall death rate among those infants diagnosed with NEC is between 20% and 30%
[101].
The purpose of this thesis is twofold. First of all this work presents a three dimensional
mathematical model of Necrotizing Enterocolitis(NEC). This model consists of a system of
partial dierential equations (PDE) that models both the temporal and spatial aspects of
NEC. Secondly, this work analyses that NEC PDE system. That is, existence, uniqueness,
and regularity analysis is done on the entire PDE system. Also, a mixed nite element
analysis is done on the system of equations. This second purpose has signicance for the
NEC PDE system and it has signicance independent of the NEC PDE system. For the
NEC system, this analysis provides a strong mathematical foundation for the equations and
their interrelation with each other. On the other hand, some of the classes of equations in
the NEC PDE system occur, in a slightly dierent form, in other contexts but, in some cases,
no existence, uniqueness, and regularity results for these equations exist in the literature.
Even more importantly, the mixed nite element analysis presented later contains some new
and very signicant results.
This rst chapter will investigate much of the current medical research regarding NEC
in order to accumulate information for creating the NEC model. Much more material will
1
be presented in this chapter than will ultimately be used to build the model. This additional
material is included for a number of reasons. First of all, when constructing the NEC model it
is important to weigh all of the factors involved in NEC in order to decide what will and what
will not be included in the model. This can only be done after each mechanism and player in
the disease is investigated and evaluated in order to determine its importance to the model.
Therefore, much information is presented in this chapter and, then, in chapter two, the
evaluation process will be done and the factors to be included in the model will be determined.
Secondly, even though some of this material will not be used directly in the NEC model, the
material will still be used as a guide for setting simulation runs. Therefore, this material
will be of great help for creating realistic the initial conditions for the computer simulations
presented in chapter seven as well as for computer simulations in the future. Finally, the
additional material will provide background and motivation for a more advanced, extensive
NEC model in the future. This will be particularly relevant as new medical discoveries come
to light.
1.1 OVERVIEW OF THE DISEASE
NEC usually attacks the intestines resulting in severe, often irreparable damage. Bacteria
from the lumen may pass through the protective epithelial cells that line the intestines and
seeps into the underlying tissue. This triggers an inammatory response within and around
the intestines that involves bacteria, macrophages, neutrophils, cytokines, as well as many
other biological components. If this inammatory response is left unchecked it will cause
tissue death and, ultimately permanent damage to the intestine.
The causes of NEC are multifaceted. The main risk factor for NEC appears to be
prematurity - the more premature, the higher the risk for NEC. Formula feeding is another
risk factor for NEC which may also contribute to the disease once the disease has been
initiated. As mentioned above, the translocation of bacteria from the lumen to the underlying
tissue of the intestine is a critical factor in NEC, as well as the breakdown of the epithelial
layer of cells that protect the intestines. Many of these causes of NEC are interrelated and it
2
is not always clear which of these factors is most involved in initiating the disease and which
are secondary responses. These causes, their eects, and the physical mechanisms involved
will now be investigated.
1.2 SMALL INTESTINE STRUCTURE AND FUNCTION
In general, Necrotizing Enterocolitis strikes the gastrointestinal tract. Usually, NEC may
attack either the small or large intestine but the eects of NEC discussed in this thesis
will usually apply in either case. In this thesis, the small intestine will be used as the
representative organ of the GI tract that NEC attacks. Therefore,it will be worthwhile to
study the structure and function of the small intestine in some detail.
The study will begin by considering the components of the small intestine that are
directly aected by NEC. The open passage way of the GI tract in the small intestine will
here be referred to as the lumen. The interior radial surface on the lumen side of the small
intestine is covered with nger-like projections called villi (singular:villus). Throughout the
thesis, the villi will be represented by gure 1. These villi are covered by a gel layer called
mucus. On the outer part of the villi is a layer of cells called the epithelium. The epithelium
is supported below by the basal lamina or extracellular matrix (ECM). In the central portion
of each villus is the lamina propria. These (the mucus layer, the epithelium, the extra cellular
matrix, and the lamina propria) together make up what is called the mucosa.
The mucosa is responsible for functions critical for digestion such as absorption (of
nutrients) and secretion (of mucus). The epithelium is a layer of connected cells that
covers the villi and protects the underlying tissue. Throughout the thesis, the epithelium
will be represented by gure 2. These cells move at approximately 5-10 m per hour and the
cells are renewed every 2 to 5 days [64]. The cells of the epithelium are primarily enterocytes,
which absorb nutrients and transfer these nutrients into the underlying tissue. Also included
in the epithelium are some goblet cells, which secrete mucus (a thick uid which serves are a
protective layer for the epithelium) as well as intraepithelial lymphocytes (IELs). The small
intestine contains one IEL for every four to nine epithelial cells [35]. The regions between
3
Figure 1: Representation of intestinal villi and crypts. Throughout this thesis, the intestinal villi and
crypts will be represented by diagrams similar to this one.
the villi are called the crypts (see gure 1). In the crypts are found Paneth cells, which play
an important defensive role. Paneth cells secrete a wide variety of antimicrobial proteins
and peptides, such as lysozyme and phospholipase -defensins, that ght many types of
bacteria, viruses, and fungi [106]. They are stimulated to secrete defensins when exposed to
bacteria or lipopolysaccharides (LPS) [100]. Paneth cells are also believed to play a major
role in protecting epithelial cell proliferation - the Paneth cells' location adjacent to the
crypts is an ideal place from which they may protect stem cells from invading bacteria [106],
[100]. Between the enterocytes are tight junction proteins (see gure 2), which serve as a
barrier that keeps pathogens from passing from the lumen into the underlying tissue, and
gap junction proteins, which are important for cell-cell communication.
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Figure 2: Representation of the epithelium. (This is the region of gure 1 that is enclosed by the rectangle.)
Throughout this thesis, the epithelium will be represented by diagrams similar to this one.
The mucus layer consists of mucus which is made up of water, lipids, and mucin [6].
Mucins are glycoproteins produced by goblet cells and have the ability to form viscoelastic
gels [6], [35]. Mucins provide lubrication and protection of the epithelium from mechanical
damage caused by dietary constituents [91]. Mucus forms a continuous covering for the villi.
The average mucus layer thickness for the three major sections of the small intestines have
been determined to be 170 m for the duodenum, 123 m for the jejunum, and 480 m for
the ileum [11]. The mucus layer is the site at which the body rst encounters gut bacteria
[31]. All bacteria, including commensal bacteria, increase mucus production [60]. The mucus
layer serves as protection for the epithelium. Particles, bacteria, and viruses are trapped in
the mucus layer and, eventually expelled before they reach the underlying epithelium [131],
[140]. Mucus also keeps antimicrobial compounds near the epithelium where they may kill
some of the entrapped organisms [140]. Since mucus is continuously created and expelled
from the body, any material trapped in the mucus layer, including pathogenic bacteria, is
swept away with the exiting mucus [140]. The mucus layer is also a reservoir for secretory
immunoglobulin A (IgA). Secretory IgA's bind pathogen and prevents attachment to the
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epithelial cells [131].
The mucus layer greatly aids digestion. Mucus forms a constant, unstirred layer thereby
keeping digestive enzymes near the epithelium where they may aid normal absorbtion [91].
Molecules in the unstirred layer are, therefore, not taken away by peristalsis [128], [91]. (See
discussion of peristalsis later in this chapter.) In addition, mucins lower the diusion of
large pathogenic bacteria but allows the passage of the smaller nutrient molecules [100]. It is
most benecial for the host that the mucus layer be populated by normal ora or indigenous
bacteria, that is, the bacteria that is common to that particular host. This bacteria is often
referred to as commensal bacteria.
An important resident in the mucus layer is commensal bacteria. Commensal Bacteria
or Normal Flora plays a protective, benecial role in the Mucus Layer. The human gut con-
tains between 10 x 1012 and 100 x 1012 organisms per ml of this commensal bacteria [35],[10].
Whenever it is operating properly, the immune system recognizes commensal bacteria and,
therefore, such bacteria does not illicit an inammatory response. The commensal bacteria
protects by: 1) Competing with harmful bacteria for essential nutrients 2) Competing with
harmful bacteria for attachment sites 3) Producing substances that kill harmful bacteria
[35]. Commensal bacteria also facilitates the digestion, absorption and storage of certain
nutrients that would not otherwise be accessible to the host [10], [91].
While population of the mucus layer with commensal bacteria is benecial to the host, x-
ation of pathogenic bacteria in the mucus may be good or bad, as Montage [91] points out.
Whenever pathogenic bacteria is xed in the mucus, it cannot reach the underlying epithelial
cells and, as long as there are only small amounts of trapped bacteria, the bacteria will be
removed together with the mucins during the normal mucus erosion process. On the other
hand, if the pathogenic bacterial accumulation in the mucus is at very high levels, so that it
exceeds the normal turnover rate of the mucus, then bacterial colonization occurs eventually
leading to infection and/or damage to the underlying epithelium [91].
The epithelium lies on what is called basal lamina or the extra cellular matrix (ECM).
(The ECM may be seen in gure 2.) The extra cellular matrix consists primarily of the pro-
tein collagen, elastin, bronectin. Collagen provides strength to the extra cellular matrix.
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Fibronectin binds the epithelial cells to the extracellular matrix and guides cell migration
[3].
The lamina propria mucosae is the tissue section that lies beneath the epithelium and
extra cellular matrix (see gure 2). It consists of smooth muscle cells and broblasts [35]. The
lamina propria mucosae has been described as 'loose' connective tissue because it does not
have a large amount brous reinforcement that characterizes more dense connective tissue.
Loose connective tissues are easily distorted. Such tissues may move freely with respect to
one another.[103] Among the important cells found in the lamina propria are macrophages
and dendritic cells [60], [35].
1.3 CELLS OF THE EPITHELIUM
Enterocytes. The majority of cells on the external surface of the small intestine are ente-
rocytes. Enterocytes are formed in the crypts and move out toward the villus tips. These
column shaped cells (these are the yellow cells in gures 2 and 3) are responsible for di-
gestion and absorption of nutrients. They transfer substances from the intestinal lumen to
the circulatory system. They also obstruct bacteria from entering the underlying lamina
propria. Enterocytes release inammatory cytokines such as IL-6, IL8, and TNF- and
anti-inammatory cytokines IL-10 and IL-15 [96]. Intestinal enterocytes also secrete anti-
microbial peptides such as defensins, cathelicidins, and calprotectins [10].
On top of the enterocytes is the actin-rich microvillar extension surface known as the
brush border (see gure 3). The brush border serves to impede microbial attachment
and invasion. It contains digestive enzymes and transporter systems involved in uptake and
metabolism [10].
Goblet Cells. Goblet cells secrete mucus that covers and protects the epithelium (see
gure 3). Goblet cells mature in the crypts and, after maturation, travel for 5-7 days to
the villus tips. When necessary these cells will secrete large amounts of mucus in response
to bacterial insult [100]. Goblet cells have the ability to secrete mucins that promote colo-
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nization by commensal bacteria. Also, there is evidence that goblet cells, after coming into
contact with specic pathogenic bacteria, can produce mucus to which that bacteria will
bind. This will prevent the bacteria from binding to enterocytes [31].
M-Cells. These are specialized epithelial cells that lie over the Peyer's Patch and lym-
phoid follicles. (The Peyer's Patch consists of bundles of lymphatic tissue. See gure 3.
The Peyer's Patch plays some role, not yet fully known, in immune response.) Unlike other
epithelial cells, M cells do not have long, fully developed microvilli (microvilli are the small
ngerlike projections on the top surface of many cells) and they lack certain surface glyco-
proteins. Instead, their microvilli are short and irregular. All of this means that antigen
have easy access to the apical surface of M cells. In fact, the primary function of M cells is
to transport material from the lumen, across the epithelium, to the underlying tissue [28].
In particular, M-Cells constantly sample the contents of the lumen and deliver antigen to
cells in the underlying tissue where inammatory cells will be recruited if necessary [10].
Paneth Cells. These cells originate in the crypt stem cell region (see gure 4) but un-
like enterocytes, goblet, and M cells, Paneth cells move down toward the base of the crypts
[100]. Paneth cells secrete antimicrobial peptides and play a general defensive role. These
peptides apparently play a key role in destroying pathogenic bacteria while promoting col-
onization of favorable bacteria. Therefore, the proper functioning of Paneth cells is critical
for intestinal homeostasis [18].
1.4 IMPORTANT MECHANICAL AND PHYSICAL FACTORS.
1.4.1 Cell Death and Renewal of the epithelium
Cell death is an ongoing event of the epithelium. This death may be due to natural causes
or due to injury. Three types of cell death have been identied:
1. Apoptosis (Programmed Cell Death). This is cell death in an organized, well co-
8
Figure 3: Cells of the epithelium. (This gure is similar to gure 2 but shows dierent detail.) The
brush border on enterocytes prevents microbes from attaching to the enterocytes. Goblet cells secrete
mucins. Mucus (mucins) helps to provide lubrication and protection for the epithelium. Mucus also keep
enzymes near the epithelium, away from the eects of intestinal peristalsis, so that the enzymes may be
easily absorbed. M-Cells constantly sample the lumenal contents and transport bacteria (gram-positive and
gram-negative bacteria) to the underlying Peyer's patch.
Figure 4: Function of Paneth Cells. Paneth Cells are located in a strategic defensive position near the
crypts. There these cells are able to defend the stem cells located in the crypts. Paneth cells secrete
antimicrobial peptides that destroy pathogenic bacteria and promote colonization by benecial bacteria.
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ordinated fashion followed by an organized removal of the dying cells. Apoptosis is usually
timely and desirable as it removes malfunctioning, senescent, or potentially dangerous cells.
However, if apoptosis occurs at too high a rate, the epithelial barrier function may be com-
promised [122]. It is not clear what causes apoptosis but TNF has been implicated as a
major factor in cell apoptosis/cell shedding [58].
2. Cell Shedding (Cell Suicide). Cell shedding is usually restricted to the surface cells
or villus tip cells where cells are loosely attached and may be easily shed into the lumen.
This shedding may involve single cells or sheets of cells [44]. It must be noted that some
believe that cell shedding is the result of apoptosis and, therefore, should not be classied
as a distinct form of cell death. On the other hand, others have observed that cell shedding
regularly occurs even among cells that have no evidence of initiation of apoptosis [138].
3. Cell Necrosis. This may be the result of injury and is characterized by the rapid
breakdown of the membrane integrity. The result is the release of cellular contents which
may damage nearby cells and create an unwanted cellular response. For example, HMGB1,
which is known to activate TLR4, is often released from damaged cells [44],[122].
An important mechanism in the small intestine is the process of renewal of the epithe-
lium. Under normal circumstances, intestinal epithelial cell turnover in nonhuman mammals
is about 2 days for adults but 4-5 days for infants [100]. In the absence of injury, cells are
shed at the villus tips and they are replaced by cells migrating up the villus from the crypts.
As a cell is in the process of being shed it induces its neighboring cells to shed and, in fact,
these neighboring cells shed about 5-10 minutes later [48]. In this way, the epithelium is
constantly renewed.
There are times during which epithelial cells shed at a higher rate than the rate at which
new cells move in to replace them. The result is that there are often gaps in the epithelium.
A paper published in 2005 indicated that about 3 % of the epithelium does not have cells
covering it at any given time [138]. This result appears to have been widely accepted,
however, a more recent study indicates that these gaps amount to a little less than 1 %
of the epithelium [48]. Either of these estimates would suggest that large passages exist in
the epithelium through which pathogenic bacteria might easily pass. Yet, during this entire
process of cell shedding and replacement, the epithelial barrier function is maintained, i.e.,
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Figure 5: Cell Shedding. The top row shows the top view of the epithelium and the bottom row shows the
side view of the epithelium. 1.) An actin/myosin ring forms around and under the dying cell (the dying cell
is colored gray). 2.) This actin/myosin ring begins to contract and, thereby, begins to force the dying cell up
and out of the epithelium [118]. At the same time, neighboring cells begin to move under the dying cell and
tight junctions begin to redistribute under the cell (see Guan,[48]). 3.) The dying cell is forced completely
out of the epithelium and the tight junction proteins seal the resulting gap.
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the epithelium remains sealed. This can be explained by either (1) cytoplasmic extensions
from neighboring cells, (2) an extracellular substance is secreted, perhaps by neighboring
epithelial cells, that lls the gap [138], (3) tight junction proteins will form connections
between the cells neighboring the departing cell [48]. The most recent research favors a
combination of (1) and (3): As a cell leaves the epithelium, its neighboring cells move in
underneath the dying cell and ZO1 (a tight junction protein) redistribution occurs. This
redistribution seals the gap created by the shed cell [48].
Therefore, current knowledge suggests the following model for cell shedding and the
continued maintenance of the epithelium: First, an actin/myosin ring forms around and
under the dying cell. Secondly, this actin/myosin ring begins to contract and, thereby, begins
to force the dying cell up and out of the epithelium [118]. At the same time, neighboring
cells begin to move under the dying cell and tight junctions begin to redistribute under the
cell [48]. Thirdly, the dying cell is forced completely out of the epithelium and the tight
junction proteins seal the resulting gap. (This model is illustrated in gure 5.)
1.4.2 Wound Healing
NEC is usually accompanied by some injury to the epithelium. Any injury to the epithelium
reduces its barrier function, thereby bacteria and other toxins may invade the underlying tis-
sue causing sustained inammation to the host. Rapid and ecient resealing of the wounded
area is, therefore, essential to full recovery from NEC. Proper wound healing depends upon
many factors including proper cell migration, proliferation, and dierentiation as well as
restoration of tight junctions between the cells [94]. Some important features of these pro-
cesses will be mentioned here.
After injury to the small intestine epithelium, a number of processes (processes which
may overlap) go into motion. 1 Villus Contraction. Almost simultaneous with the injury,
the villus dramatically contracts. This contraction greatly reduces the wounded area, thereby
aiding the healing process. 2 Within minutes after the injury, epithelial cell restitution
begins. Epithelial cells adjacent to the injured area begin to migrate to cover the exposed
area. This process does not usually involve cell proliferation. 3 About 18-24 hours after
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injury, cell proliferation occurs in the crypts. This replenishes cells lost during injury.
4 The nal, and essential, step in repairing the epithelium and all of its functions is the
restoration of tight junctions [19], [82].
1. Villus Contraction A most interesting feature of wound healing in the small intes-
tine is the phenomenon of villus contraction which greatly aids restitution. After an injury,
the villus actually contracts to reduce the surface area that needs to be resealed by epithelial
cells. (see gure 7) Specically, the villus contracts enough to reduce the "open area" by
about one half. It has been discovered that one large contraction of the villus occurs imme-
diately after injury. After that, the villus continues to contract, albeit at a slower rate, in
the hours following the injury [92].
2. Restitution Wound healing depends upon the cells' ability to move across the
extracellular matrix. Immediately after injury, the cells adjacent to the wound begin to
migrate in order to cover the exposed part of the ECM. The leading edge of the cell attens
and stretches forward attaching to the ECM at some point of the uncovered area of the
wound. In the process of stretching and reaching, elastic forces are generated in the cell.
These elastic forces cause the back of the cell to detach from the ECM. The cell then contracts
and the process is repeated. (see gure 6).
The attachment to the ECM is accomplished by activated integrins located at the bottom
of the cell. The integrin's proper adherence to the ECM is essential for ecient cell motility.
This adherence must be strong enough for the cell to get enough traction to pull itself across
the ECM and, yet, it must not be too strong otherwise the integrins at the the back of the
cell will not detach from the ECM in a timely manner.
The whole process of cell motility is very complex. However, a crude summary of the
process may be presented here: 1) A prerequisite to cell motility is sucient integrin expres-
sion on the bottom of the cell - enough expression to rmly adhere to the ECM. 2) There
is a "spreading" or a shape changing of the cell from a round to a attened shape. This
"attening" tends to be more pronounced at the leading edge of the cell. This front attened
part of the cell is known as a lamellipod. 3) Due to the "stretched" state of the cell, forces
will be generated within the cell tending to pull the leading edge and trailing edge of the
cell toward the middle. 4) The trailing edge of the cell detaches from the ECM. 5) The cell
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Figure 6: 1. Stationary Cells 2. Cell moves by reaching forward. In the process of stretching, elastic forces
are built up in the cell. 3. Elastic forces cause the back of the cell to detach from the ECM.
changes shape again, returning to a somewhat rounded shape. 6) The whole process begins
again.
Thus it can be seen that if the adherence of the cell to the ECM is not great enough,
i.e. there is not enough integrin expression or the integrins do not bind properly to the
ECM, too little "traction" will be generated at the front of the cell for it to grip and pull
itself eciently across the ECM. This results in slow cell movement. On the other hand,
if the adherence is too strong, the cells may still have the ability to reach forward, stretch
and attach at a forward point on the ECM but the elastic forces generated within the cell
will not be strong enough for the trailing edge of the cell to "break free" from the ECM.
Again, resulting in little or no cell movement. Experiments have shown that exposing cells
to large amounts of bacterial LPS leads to overexpression of integrins and, therefore, greatly
inhibited cell movement [113].
Not surprisingly, then, maximum cell migration speed occurs at an intermediate ratio of
cell-ECM adhesiveness to intracellular contractile forces. This intermediate ratio occurs at
levels at which the cell can both properly adhere at the front end while still being able to
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Figure 7: Villus loses epithelial cells due to injury or other insult to the intestinal villi (left), the villus
immediately gets shorter (right) thereby reducing the surface area that must be covered by the migrating
cells.
detach at the rear of the cell [107].
3 Epithelial Cell proliferation Even though the wound has been covered during the
restitution process, many less cells are present in the epithelial. About 18-25 hours after the
injury, new cells are formed in the crypts which replenish cells lost during the injury [19].
4 Restoration of Tight Junctions After the wound has been closed, the tight junction
proteins begin to be restored. However, studies have determined that adherens junctions are
restored prior to the tight junctions. Adherens junctions, which form just below tight junc-
tions, have a belt-like structure and appear to hold adjoining cells together like a thread in
clothing even though the cadherins do the actual adhesion. (see gure 8). It is only after
the reestablishment of the adherens junctions that the tight junctions begin to be formed
[49], [3], [19]. Only after the tight junctions are fully formed is the barrier function of the
epithelium restored.
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Figure 8: Tight Junction, Adherens, Cadherins, Integrins. During the restitution process, adherens junc-
tions are reestablished. Only after that, do the tight junctions begin to be restored.
Growth Factors and Cytokines that enhance restitution.
Several growth factors and cytokines enhance epithelial restitution. Some of these operate
through a transforming growth factor beta (TGF-) dependent pathway while others work
through a TGF- independent mechanism. TGF-, which is a product of lamina propria
cells and epithelial cells, is required for normal epithelial cell migration even in the absence
of injury or insult [32], [82]. TGF- itself stimulates the migration of intestinal epithelial
cells and mediates the work of other migration-promoting growth factors and cytokines [44].
Such growth factors and cytokines act on the basolateral part of the epithelial cells and
include TGF-, EGF, HGF, and FGF peptides as well as the cytokines IL-1, IL-2, IFN-
[32].
Some of the members of the trefoil factor family (TFF) of peptides play an important
role in epithelial restitution. These peptides work from the apical side of the epithelial cells
and work in conjunction with glycoproteins through a TGF- independent mechanism
[32]. Many of the TFFs are secreted by intestinal goblet cells and remain in the lumen.
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Figure 9: Members of the trefoil factor family (TFF) of peptides are secreted by goblet cells. TGF-Beta
is secreted by epithelial cells and lamina propria cells. These, along with the other factors and cytokines
shown in the gure, promote epithelial restitution.
Their special structure allow these peptides to survive in the lumen - they are resistant to
degradation by luminal enzymes [44]. TFFs interact with the mucus and inuence epithelial
restitution [82].
EGF which is primarily known to stimulate epithelial cell proliferation (see below), has
also been shown to promote epithelial restitution. One study showed that EGF promoted
Caco-2 enterocyte sheet migration that was dependent upon the make up of the extracellu-
lar matrix. In particular, EGF was observed to stimulate migration over laminin and this
migration was independent of cell proliferation [15].
Growth Factors and Cytokines that enhance cell proliferation.
EGF and TGF-, which is a product of most intestinal epithelial cells, are among the
most important stimulators of intestinal epithelial cell (IEC) proliferation. To a much lesser
extent, other growth factors, peptides and cytokines stimulate proliferation. These include
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Figure 10: Disruption and restoration of the epithelium. At the top of the illustration we see that nitric
oxide destroys gap junction protein (GJP), epithelial cells and tight junction protein(TJP). Also, proxynitrite
(ONOO-) destroys epithelial cells and IFN-gamma downregulates the production of tight junction protein.
In the middle and the bottom of the illustration, we see the eects on epithelial restitution and proliferation:
P means that the cytokine or growth factor contributes somewhat to epithelial proliferation. +P means
that the cytokine or growth factor contributes greatly to epithelial proliferation. -P means that the cytokine
or growth factor inhibits epithelial proliferation. +R means that the cytokine or growth factor contributes
greatly to epithelial restitution . -R means that the cytokine or growth factor inhibits epithelial restitution.
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Figure 11: Intestinal Peristalsis. 1.Peristalsis keeps bacteria and other material moving through the lumen.
2.Bacteria and other components that are xed in the mucus layer are not eected by peristalsis.
FGF, IGF, HGF, and IL-2 [32]. Interestingly, TGF- inhibits cell proliferation. If not for
its inhibitory eects, cell growth might continued uncontrolled [32].
1.4.3 Intestinal Peristalsis
. This mechanism is initiated by wave-like muscular contractions that causes contents of
the lumen to move along the GI tract. As noted earlier, bacteria and other material that is
trapped in the mucus layer will not normally be aected by peristalsis. On the other hand,
peristalsis, when working properly, has the eect of limiting the amount of time antigen
are able to interact with the epithelial cells thereby limiting bacterial translocation [61]
(see gure 11). If this mechanism is impaired or underdeveloped, then bacteria, which is
supposed to keep moving through the lumen, may build up and remain in contact with the
mucosa for long periods of time possibly resulting in bacterial translocation and damage
to the epithelium [6]. As will be seen later (see the subsection on prematurity), intestinal
peristalsis is, in fact, underdeveloped in preterm infants and this plays a role in NEC.
1.4.4 Bacterial Translocation
The movement of bacteria (translocation of bacteria) from the lumenal side of the epithelium
to the underlying tissue is a key factor in the inammatory cascade and, therefore, a critical
19
factor in NEC. Three of the most important bacterial pathways from the lumen into the
underlying tissue are A) through a disruption in the epithelium; B) by a paracellular pathway,
in between epithelial cells; and C) transcellular pathway, phagocytosis by the enterocytes.
(see gure 12.)
Disruption of the epithelium. The intestinal epithelium may be injured in many
ways including interaction with microbes, inammation, oxidative stress, toxic substances in
the lumen, as well as by normal functions such as digestion [64]. Any such injury will result
in a loss of cells in the epithelium and, therefore, the free ow of bacteria into the underlying
tissue.
Paracellular Pathway. As noted above, tight junction proteins prevent large particles,
such as whole bacteria, from passing between epithelial cells. (Note: it may be possible
for smaller particles, such as LPS, to pass between epithelial cells even when tight junction
protein is in tact.) However, any disruption of the tight junction barrier, for example by
nitric oxide, will result in increased "leakage" between cells of the epithelium allowing even
whole bacteria to pass.
Transcellular Pathway. There is speculation bacteria is able to move through entero-
cytes of the epithelium. This speculation is the result of studies that prove that enterocytes
are capable of phagocytosis of gram-negative bacteria. These same studies indicate that
TLR4 is required for the process of enterocyte phagocytosis [97].
1.5 FACTORS CRITICAL TO NEC
1.5.1 Aects of Prematurity
Preterm infants are much more susceptible than term infants to many diseases including
NEC. Preterm infants are vulnerable to NEC because many of their bodily systems are
severely underdeveloped. The preterm infant suers from underdeveloped intestinal peristal-
sis, an immature GI immune system, excessive immune response, immature glycosylation,
lower levels of antimicrobial peptides, and lower levels of EGF.
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Figure 12: Three important pathways of bacteria from the lumen into the tissue are A) through a disruption
in the epithelium B) In-between cells, after tight junction protein is missing or degraded C) phagocytosis by
enterocytes.
Underdeveloped Intestinal Peristalsis. As noted above, peristalsis is required for
the sustained movement and distribution of luminal contents. In particular, properly working
peristalsis keeps bacteria and other antigen from congregating and lingering too long at any
one location on the epithelium. Premature infants do not have fully developed peristalsis.
The associated migrating complexes are not present in the preterm infant until around 34
weeks gestation [120]. Therefore, in the context of undeveloped or limited peristalsis, large
amounts of gram-negative bacteria may congregate near the mucus layer and, if the build-
up is great enough, the bacteria may colonize the mucus layer and eventually contact the
underlying epithelium. This may result in an inammatory response, epithelial cell death,
and bacterial translocation [6].
Immature Gastrointestinal Immune System The gastrointestinal immune system
in the premature infant is underdeveloped. In particular, the premature infant has less
protective mucus, less gastric acid production, and lower levels of secretory IgA. In addition,
the premature infant has increased mucosal permeability. [26]. Pathogenic organisms are
more likely to attach to and translate across the epithelium in immature animals than in
mature animals. [26].
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The mucin layer is rather sparse in the premature infant. This may be due to the fact
that immature goblet cells secrete less mucin than mature cells [51], [99]. As a consequence
of this sparse layer, pathogenic bacteria have easier access to the underlying epithelium.
Also, pathogenic bacteria adhere to the complex carbohydrates of mucin, another defence
mechanism provided by mucin. Therefore, the reduced mucin levels results in this mechanism
being severely handicapped [91].
Bile acids, which play a critical role in digestion, may cause damage to the immature
epithelium. The accumulation of Bile acids near the epithelium has been shown to cause
damage to the epithelial cells. In particular, bile acids have been shown to reduce the amount
of Mucin 2 produced by intestinal goblet cells. Evidence shows that this reduction on mucin
secretion by goblet cells is much more pronounced in immature than mature cells [86].
Gastric acid, which acts as a barrier to microorganisms, is much lower in very low birth
weight (VLBW) preterm infants, compared to full term normal sized infants [100]. For all
preterm infants, the gastric PH levels are initially much higher than for term infants but
these levels come back to normal as time passes [62].
Finally, preterm infants have lower levels of secretory IgA, an antibody which binds
bacteria [26], [51].
Excessive Immune Response It has been determined that the immature intestine
has an exaggerated response to certain stimuli. In particular, studies have shown that both
Caco-2 and H4 cells exhibited increased secretion of IL-8 in response to LPS and IL-1 [96].
Immature Glycosylation Glycosylation results in the creation of carbohydrate recep-
tors on the microvilli. These carbohydrate receptors serve as binding sites for gram-negative
bacteria. Glycosylation is a developmentally regulated process and, therefore, is not complete
in the pre-mature infant [26],[34]. On the one hand, the lack of binding sites for bacteria may
seem advantageous (i.e. it may be less likely for bacteria to colonize near the epithelium).
On the other hand, these binding sites may also serve as another layer of protection for the
epithelium - another obstacle for the bacteria. As a result, immature glycosylation results
in more pathogenic bacteria crossing the epithelium and penetrating the underlying tissue.
Furthermore, colonization by commensal bacteria is benecial to the host as it competitively
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excludes pathogenic bacteria from congregating near the epithelium. Such colonization by
commensal bacteria is not possible without the carbohydrate receptors on the microvilli.
Lower levels of antimicrobial peptides Defensins are antimicrobial peptides of which
certain types, such as HD5 and HD6, are produced by Paneth Cells. Like other antimicrobial
peptides, these defensins kill pathogenic bacteria and are, therefore, critical to epithelial
layer defense. There is strong evidence to suggest that Paneth cell production of defensins is
signicantly lower in premature infants compared to term infants and increases with gestation
age [119].
Low Levels of EGF Epidermal Growth Factor (EGF) is extremely important for ep-
ithelial cell proliferation and, in some cases, aids restitution of the epithelium. Therefore,
lack of EGF may result in slow repair to the epithelium after injury or insult. EGF may
come from many sources but the great majority of EGF is produced in the salivary glands.
Studies have shown that infants at earlier gestational ages have lower levels of EGF during
their rst days of life compared to other infants [136].
Low levels of PAF-degrading enzyme PAF-acetylhydrolase (PAF-AH) As will
be noted later in this chapter, Platelet Activating Factor (PAF) plays a large part in the
pathology of NEC. In an adult, PAF may normally be kept under control by the PAF-
degrading enzyme PAF-acetylhydrolase (PAF-AH). In the newborn, PAF synthesis pathways
are increased and the newborn has low circulating activity of PAF-AH [121], [93]. There are
strong indications that PAF-AH is found in even lower quantities, or may not exist at all, in
the pre-term infant [93].
1.5.2 Advantages of Breast Feeding vs. Formula Feeding in NEC
The advantages of breast feeding over formula feeding are well documented. The incidence of
NEC is much higher in formula-fed compared to breast-fed neonates [79]. Richter, et al notes
that breast-feeding has antimicrobial, ant-inammatory, and immunomodulating properties
and inuences the intestinal ora.
Among the advantages of breast feeding in the case of NEC are: 1) Breast feeding results
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Figure 13: Some of the advantages of breast feeding: 1. Benecial colonization of the gut competitively
excludes pathogenic bacteria. 2. Secretory IgA specically targets bacteria to which the mother has been
exposed. 3. Oligosaccharides have similar structures as binding cites on epithelial cells, therefore, pathogenic
bacteria will bind these rather than epithelial cells. 4. Breast feeding causes glycosylation of the epithelial
microvilli that attracts favorable bacterial colonization. 5. EGF in breast milk promotes epithelial cell resti-
tution and proliferation. 6. Anti-inammatory factors cause downregulation of certain cytokines including
IL-8 and IL-18.
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in a more benecial colonization of the gut (that is, the gut is colonized with primarily
gram-positive bacteria) and, thereby, "competitively excludes" more harmful pathogen from
accumulating near the epithelium. 2) There are anti-inammatory factors in breast milk. 3)
Antibodies in breast milk such as secretory IgA bind specic pathogens to which the mother
has been exposed. 4) Oligosaccharides in breast milk act as decoys - bacteria binds to the
oligosaccharides rather than to the epithelial cells. 5) Breast milk facilitates maturation
of the intestinal mucosal barrier and 6) Breast feeding results in favorable glycosylation
patterns on the intestinal microvilli.
1. Benecial bacterial colonization of the GI tract. Current opinion suggests that
the gram-positive bacteria bidobacteria and lactobacilli are the most benecial bacteria that
can colonize the infant gut. On the other hand, staphylococci and clostridia are potentially
pathogenic. [111] Breast feeding results, primarily, in gram-positive colonization of the GI
tract (e.g colonization primarily bidobacterium, along with some lactobacillus, streptococ-
cus. In particular, lactoferrin and -lactalbumin in breast milk stimulate the growth of
bidobacterium [17]). Even though some enterobacteria (gram-negative bacteria) is present
in breast-fed infants, it is the bidobacterium that predominates the breastfed infant gut
[102], [51]. Gram-positive bacteria tends to attenuate the growth of gram-negative bacteria
and leads to the production of lactic acid which is easily absorbed in the small intestine
[83],[112]. Just as importantly, gram-positive bacteria competes with pathogenic bacteria
for binding sites and nutrients.
While it is true that there is some gram-positive lactobacilli in the gut of formula-
fed infants, there are sucient pathogenic species such as staphylococcus, escherichia coli,
and clostridia to be a potential danger [26], [51]. In general, formula feeding may lead to
proliferation of gram-negative bacteria (e.g. coliforms) in the intestine [13]. Gram-negative
colonization of the GI tract will intensify any inammatory cascade and will make the host
vulnerable should any insult to the intestine occur. Also, gram-negative bacteria can lead to
the production of hydrogen, carbon dioxide, and organic acids. All of which are not easily
expelled from the body [112].
Infants delivered vaginally and born at home have the most benecial gut colonization
(the most bidobacteria and the least C. dicile and E. Coli).Hospitalization and prematu-
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rity are both associated with C. dicile. [111] Antibiotics reduced both bidobacteria and
bacteroides [111].
2. Anti-inammatory factors in human milk. Goldman [45] lists several anti-
inammatory factors in human milk: cytoprotectives, epithelial growth factors, matura-
tional factors, binders of enzymes, modulators of leukocytes, antioxidants. Also, TGF-1 is
in human breast milk. Human milk suppresses IL-1 induced IL-8 production in intestinal
epithelial cells [100].
3. Antibodies in breast milk. Among the most important components of human
milk that serve as antimicrobial agents include IgA, lactoferrin, and lysozyme [26].
Antibodies in breast milk such as Polymeric IgA (pIgA) and secretory IgA bind anti-
gens, bacteria and endotoxin. In infants, this secretory IgA binds to pathogens before the
pathogens attach to the epithelial lining of the intestinal wall [6]. Polymeric IgA and secre-
tory IgA are produced by the mother's immune system and are created to bind the specic
pathogens to which the mother has been exposed [26], [102]. It is likely that mother and
infant will be exposed to many of the same pathogens, therefore, these antibodies provide a
particularly relevant and valuable defensive tool.
Kohler, et. al. [72] report that human milk is rich in immunoglobulins of which about
90% is secretory IgA. The Kohler study showed that IgA concentrations in the feces of
breast-fed infants was three times high than in formula-fed infants.
Lactoferrin and lysozyme are nonspecic anti-microbial factors. [26] Lactoferrin has been
shown to have anti-microbial activities against a broad range of bacteria but all the types of
bacteria and all the conditions under which it is eective have not yet been fully established
[39], [102]. Lactoferrin also appears to work synergistically with lysozyme against bacteria
[39].
Finally, Goldman [45] notes that these antimicrobial peptides have further advantages:
they are resistant to digestive enzymes and they operate without causing an inammatory
response.
Defensins are endogenous antimicrobial peptides produced by the epithelial surface,
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which provide nonspecic defense against against a multitude of microorganisms. In the
small intestine,  defensins are expressed predominantly by Paneth cells.
4. Oligosaccharides in breast milk act as decoys Human milk oligosaccharides
are complex carbohydrate structures that are normally attached to lactose and which sur-
vive the passage through the intestine [102]. Oligosaccharides actually bind to bacteria be-
fore the bacteria are able to attach to glycoconjugates on the microvillous membrane [102].
Oligosaccharides act as decoys (homologues of of host surface glycoconjugates) so that bac-
teria bind to the Oligosaccharides rather than to the glycoconjugates on the microvillus
membrane. Pathogenic bacteria will bind intestinal epithelial cells via protein adhesions but
many oligosaccharides in human milk have the same sugar sequences as the carbohydrate
chains of glycolipids and glycoproteins on human epithelial cell surfaces [34]. Thus they
prevent binding of pathogen to the intestinal epithelial cells. [26] [102], (Goldman 1993).
Oligosaccharides may also act as nutrients for benecial commensal bacteria [100], [99].
5. Breast Milk Facilitates Maturation of Intestinal Mucosal Barrier EGF is
found in large amounts in the breast milk of the mothers of preterm infants (actually it
is found in colostrum - milk generated just before giving birth). In fact, the more pre-
mature the infant, the higher the level of EGF in breast milk [137]. Not only does EGF
promote epithelial cell restitution and proliferation but also downregulates the production
of the inammatory cytokine IL-18 and upregulates the anti-inammatory cytokine IL-10
[137]. Another study showed that HB-EGF, a member of the EGF family, promoted cell
migration/proliferation and resulted in reduced epithelial cell necrosis/apoptosis as well as
lower levels of Nitric Oxide [40]. Thus, EGF is particularly important to help prevent and/or
relieve NEC.
6. Favorable Glycosylation Patterns As noted above, bacteria binds to the microvilli
on the apical side of the epithelial cells. Of course, it is desirable for non-pathogenic bacteria
to bing to these cells. According to Bernt [17], certain bacteria will bind to specic glyco-
conjugate compositions on the microvilli of cells. Specic hormones in breast milk, cortisol
in particular, induces glycosylation patterns on the microvilli that results in colonization by
non-pathogenic bacteria [17]. Thus, breast feeding results in favorable glycosylation.
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7. PAF-degrading enzyme PAF-acetylhydrolase (PAF-AH) As noted above,
the newborn has low circulating activity of PAF-AH and evidence suggest that even lower
quantities of PAF-AH are found in the pre-term infant [93]. Formula does not contain PAF-
AH but human milk contains large quantities of PAF-AH. Interestingly, studies indicate that
milk from mothers of pre-term infants contain signicantly higher amounts of PAF-AH than
even normal breast milk [121], [93].
1.5.3 Particular Advantages of Breast Feeding in case of Prematurity
When one carefully considers the facts given in the last two sections, it is impossible not to
notice that for many of the disadvantages of prematurity, there is a corresponding advantage
in breastfeeding. For some reason, this fact does not appear to be emphasized in the journal
articles. Perhaps because it is so obvious? In any case, this is summarized in the following
table.
1.6 DESCRIPTION OF INFLAMMATORY CELLS, CYTOKINES, AND
OTHER FACTORS IN NEC
Macrophages. Macrophages reside in the blood stream, epithelial layer, and tissue. These
large and powerful phagocytes play a variety of roles. They are antigen presenting cells, they
secrete cytokines, they rid the body of dead cells and they ingest pathogens. Macrophages
live approximately two to four months [81].
Upon contact with bacterial LPS, macrophages release pro-inammatory cytokines and
Nitric Oxide which can cause destruction to the tight junction protein that seals the para
cellular space between epithelial cells. Whenever (resting) macrophages come in contact with
cytokines, cytokines bind to the receptors on macrophages to cytokine-receptor complexes.
These complexes are then internalized into the macrophages. [12]
Neutrophils. Neutrophils reside in the blood stream until activated. After activation,
28
Eects of Prematurity Corresponding Advantage
of Breastfeeding
Immature glycosylation Favorable glycosylation patterns
Low levels of IgA production pIgA and sIgA in breast milk
Lower levels of Antimicrobial Antimicrobial peptides
peptides in breast milk
EGF is found in large
Low levels of EGF amounts in breast milk of mothers
of preterm infants
Elevated levels of PAF PAF-AH is found in large
Low levels of PAF-AH amounts in breast milk of mothers
of preterm infants
Excessive Immune Antimicrobial factors in
response breast milk
Table 1: Aects of prematurity and the corresponding advantages of breast feeding.
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they move to the site of injury/insult through the blood vessels and through tissue. Neu-
trophils tend to accumulate in the tissue below the epithelium during inammation [19].
After arriving at the site of injury/insult, the neutrophils phagocyte the pathogens and they
aid in sterilizing the wound. Unlike macrophages, neutrophils have a short life, one or two
days [81], [19].
Neutrophils can have very positive eects on wound healing such as producing IL-1
which promotes epithelial repair. On the other hand, if the neutrophils do not encounter
pathogen in a timely manner, they cause tissue damage, in particular they may damage the
extra cellular matrix and they may release elastase which causes epithelial cell death and
permanent damage to the tight junctions. Furthermore, they may cross from the tissue side
of the epithelium to the lumenal side and in the process cause damage to the epithelium
barrier function by increasing the paracellular space. The larger paracellular space makes it
easier for toxins to cross the epithelium into the underlying tissue [19].
IL-1. This inammatory cytokine is released by macrophages. There are two distinct IL-
1 genes: IL-1  and IL-1 . IL-1  promotes the inammatory response. It has been shown
that there is a high correlation between IL-1 synthesis and tissue damage and inammation.
In particular, IL-1  levels in the tissue have been correlated with intestinal necrosis [27].
These ndings have been corroborated by studies that have shown signicant reduction of
inammatory cell inltration after the introduction of IL-1ra [27]. (The description of IL-
1ra may be found below.) IL-1 helps to promote the inammatory cascade by stimulating
other cells to produce cytokines. [33]. IL-1  contributes to the production of nitric oxide.
In particular, it has been shown that exposing epithelial cells to TNF-, in combination
with IFN- and IL-1 , leads to increased expression of nitric oxide [53]. Increased levels of
Nitric Oxide leads to increased epithelial layer permeability (see below). IL-1  stimulates
the production of IL-8 which, in turn, causes neutrophils to congregate near the site of the
inammation [33], [90]. Interestingly, there is some evidence that IL-1  may have a positive,
protective eect on intestinal mucosa integrity by stimulating the increase of Glial cells which
are critical to intestinal gut integrity [83].
IL-1ra. Interleukin-1 receptor antagonist binds to the same cell receptors as IL-1 and
thereby prevents IL-1 from binding to these sites. Upon binding, IL-1ra produces no biolog-
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ical response. Thus, IL-ra has the eect of dampening the inammatory cascade.
IL-4. This is an anti-inammatory cytokine. IL-4 serves to dampen the inammatory
cascade. It is produced by TH2 cells as well as by bone marrow stroma [83]. IL-4 has been
found to inhibit human macrophage colony formation [83] [66], IL-4 also inhibits monocyte-
derived hydrogen peroxide production [83] and the release of certain inammatory mediators
such as TNF- and IL-1. It also reduces the tissue destruction caused by oxygen radicals
associated with ischemia and reperfusion injury [83]. IL-4/IL-13 have been shown to inhibit
macrophages' ability to phagocyte pathogens [87], [132].
IL-6. IL-6 is produced by T cells, B cells, monocytes, broblasts, endothelial cells as
well as many other cell types [69]. Studies have found that intestinal epithelial cells, as well,
make IL-6 [124]. The release of IL-6 is stimulated by IL-1 and TNF- as well as by other
pro-inammatory cytokines [83]. IL-6 stimulates B cell growth [42]. There are indications
that IL-6 may play a dual role in NEC as studies show that it has both inammatory and
anti-inammatory eects. The inammatory eects of IL-6 are well know. High levels of IL-6
have been shown to be associated with NEC severity [83]. Harris showed that IL-6 levels were
signicantly higher in nonsurvivors compared to survivors of NEC [57]. On the other hand,
IL-6 appears to have certain anti-inammatory aects. IL-6 can drive TGF- activation.
Some research indicates that IL-6 may be responsible for increased local and circulating IL-
1ra, increased production of tissue inhibitors of metalloproteinases (TIMPs), and has been
shown to inhibit the production of superoxides [83]. As noted above, any up-regulation of
IL-1ra competes for the same binding cites as IL-1 but with no inammatory eects. The
increased production of TIMPs results in the inhibition of the enzymes that degrade the
extra cellular matrix (see discussion of MMPs below). Finally, superoxides produce tissue
damage and, therefore, any inhibition thereof will help protect the host.
IL-8. IL-8 plays a major role in inammation. IL-8 is a chemokine (a chemokine is a
special type of cytokine that is involved in cell migration) produced by enterocytes that causes
neutrophils to congregate near the site of inammation [33], [90], [80]. For example, it has
been shown that in the midst of inammatory cascades, the administration of neutralizing
antibodies against IL-8 resulted in reduced neutrophil inltration and prevented neutrophil-
related tissue damage [56]. Studies have shown that, in general, IL-1 induces the production
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of IL-8 [33], [90]. Other studies indicate that both IL-1 and endotoxin induce the production
of IL-8. [96]. For example, some studies have shown that, in the presence of TNF- and LPS,
the inhibition of IL-1 does not fully eliminate the production of IL-8 and neutrophils leading
to speculation that TNF- and LPS, even without the help of IL-1, may lead directly to the
production of IL-8 and neutrophils [56]. In summary, for the case of intestinal epithelial cells
(IEC's), both IL-1 and endotoxin may lead to the secretion of IL-8. However, it appears
that IL-1 is far more eective than endotoxin in inducing IL-8 secretion by the IECs in
both pre-term and full-term infants [90],[96]. Since the IECs are prominent in the study of
NEC, IL-1 activation of IL-8 warrants a few more comments.
Studies have shown that IL-1 activation of IL-8 occurs through activation of nuclear
factor (NF- B). Studies by Claud, et. al. [25],[26] indicate that IL-1 activation of IL-8 is
muted by various factors found in breast milk [25]. In particular, it has been shown these
factors (e.g. TGF-1, Epo) in breast milk inhibit the activation of NF- and, thereby, results
in reduced secretion by IECs [90], [25].
As a side note, one of the studies by Claud [25] indicated that the presence of the anti-
inammatory cytokine IL-10 did not inhibit TNF or IL-1 secretion of IL-8 by IECs. This
surprising result conicted with the expected aects IL-10. However, the authors noted the
other anti-inammatory features of IL-10 may result in reduced inammation by aecting
macrophages and speculate that IL-10 may even aect IECs in an indirect way. (This same
study by Claud produced another unexpected result - EGF appears to increase secretion
of IL-8 by IECs. The authors of the report observed that pretreating IECs with EGF and,
afterwards, stimulating the cells with TNF resulted in increased secretion of IL-8 by IECs.
This phenomenon cannot be fully explained at the present time.)
Finally, the presence of high concentrations of IL-8 is a signicant indicator of the severity
of NEC. For example, studies have shown that within the rst day of the onset of the disease,
IL-8 concentrations are signicantly higher in infants with stage 3 NEC compared to infants
with stage 2 NEC [36].
IL-10. This is an anti-inammatory cytokine that is produced by TH2 cells, B cells,
and monocytes [117]. Like IL-4, this cytokine serves to dampen the inammatory response.
It has been shown that the addition of IL-10 suppressed inducible nitric oxide synthase
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(iNOS), messenger RNA (mRNA), and nitric oxide expression in the small bowel, liver, and
serum by 60%, 89%, and 11%, respectively (Markel [83] quoting Kling [70]). IL-10 decreases
production of IL-2 [125]. It inhibits the activation of macrophages, TNF-, IL-1, IL-6,
and IL-8. It was discovered that IL-10 decreases the production of metalloproteinases (by
inhibiting T cell activation at its earliest stages.) [110]. It inhibits the synthesis of the
cytokines IL1, IL-6, IL-8, IL-10, and IL-12 [55]. Furthermore, IL-10 is a good indicator of
the severity of NEC, as concentrations of this cytokine were observed to be much higher
in infants with stage 3 NEC compared with stage 2 NEC. One study has shown that these
dierences in concentrations between the stages continued until 72 hours after the onset of
the disease [36].
IL-12. This pro-inammatory cytokine is secreted by B cells and macrophages and
induces the release of small amounts of IFN- from T cells and natural killer (NK) cells.
IL-12 is able, by itself, to stimulate the production of IFN-. However, in collaboration
with IFN--Inducing Factor (IGIF) causes T cells to produce signicantly greater amounts
of IFN- [2]. This appears to be due to the fact that IL-12 causes the expression of receptor
IGIF on certain cell lines [2]. In the same way, IL-12 induces the expression of the IL-18
receptor on Th1 cells. Therefore, IL-12 in collaboration with IL-18 causes T cells to produce
exponentially large amounts of IFN- [24].
IL-18. This pro-inammatory cytokine, like IL-12, induces the release of small amounts
of IFN- but unlike IL-12, it is secreted by macrophages and IECs. Levels of IL-18 tend to
increase in step with the increased severity of NEC. [52].
There is some speculation that IL-18 is a negative regulator of TNF- production by
IFN-. IFN- usually induces the production of TNF-. However, in the presence of IL-12
and IL-18, even high levels of IFN- failed to produce TNF-.[24].
IL-18 in combination with IL-12 leads to the production of nitric oxide and oxygen
radicals in macrophages and neutrophils. These, in turn, have both positive and negative
eects - the radicals are toxic to the microbial pathogens but also destructive to tissue [68].
(As noted above, IL-18 and IL-12 together cause the production of IFN-. IFN-, in turn,
induces macrophages and neutrophils to produce nitric oxide and oxygen radicals.)
TNF- This cytokine can induce other cells to release IL-1, IL-2, IL-6, and IL-8 [139].
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Although TNF- is released from a variety of sources, they mostly come from activated
macrophages [139]. TNF- is not only released by macrophages but is also a major activator
of macrophages. For this study, it is particularly important that TNF- causes macrophages
to produce proinammatory cytokines and nitric oxide [139].
IFN- This cytokine is secreted from T cells and NK cells. IL-12 causes T cells to
produce IFN- while IL-1,IL-2, and TNF together induce NK cells to produce IFN- [104].
This induces NO and TNF- production. It has been shown to cause mucosal inammation.
It has been shown that IL-12 and IL-18 individually induce T cells to produce IFN- while
together induce the production of very large amounts of IFN- (see discussion under IL-12
above). Interestingly, mice injected with large amounts of IFN- without the presence of
IL-12 or IL-18 did not have pathological eects [24]. There is some speculation that NO
inhibits IFN- production (see discussion under NO below). It is very important to note
that IFN- downregulates the production of the tight junction protein ZO1 [53] [35] and
IFN- reduces gap junction communication [76].
Platelet Activating Factor (PAF) Platelet Activating Factor is a powerful inamma-
tory mediator and, therefore, an important player in NEC. PAF is produced by neutrophils,
macrophages, endothelial cells, and enterocytes in response to endotoxin and hypoxia [121].
PAF leads to the activation of IL-1 , IL-6, and IL-8 [83], [22].
Its specic role in NEC is unclear. On the one hand, patients with NEC exhibit high
levels of PAF. In rat experiments, injection with PAF leads to intestinal necrosis. Also,
other experiments on rats have shown that PAF receptor antagonist prevents injury in-
duced by hypoxia, bacteria, and TNF- [59]. Furthermore, the PAF degrading enzyme
PAF-acetylhydrolase (PAF-AH) blocks the initiation of NEC [22]. On the other hand, PAF
without the presence of bacteria failed to cause bowel injury in rat experiments [67]. There-
fore, PAF plays a major role in NEC but appears to require bacteria to cause inammation
and damage.
PAF activates apoptosis of intestinal epithelial cells[22].
Matrix Metalloproteinases (MMPs). These are enzymes that degrade the extra
cellular matrix which supports the intestinal epithelial cells. It has been shown that TNF-
drives the production of the MMPs. It has also been shown that activated lamina propria
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T cells will begin a cascade that results in the production of MMPs. On the other hand,
IL-10 will inhibit T cell activation thereby reducing the destruction of the ECM by MMPs
[110]. Tissue Inhibitor of Metalloproteinases (TIMPs) controls the local activity of MMPs
in tissues. However, if the MMP production is too high, an imbalance will result and it will
not be possible for the TIMPs to control the MMPs [109],[108].
Nitric Oxide. Nitric oxide plays a number of critical roles in NEC. Nitric Oxide is asso-
ciated with epithelial barrier dysfunction. In particular, nitric oxide reduces the functional
levels of tight junction proteins. In addition, nitric oxide impairs communication between
epithelial cells by interfering with the normal function of the gap junction proteins. Nitric
oxide is, also, involved in epithelial cell death and has been shown to lead to destruction of
the tissue that underlies the epithelial layer.
Nitric oxide is produced from nitrogen oxide synthase (NOS). There are three isoforms of
NOS. However, for our study, we are particularly interested in inducible nitric oxide synthase
(iNOS). iNOS is produced from macrophages and other inammatory cells. For example,
TNF- and IFN- stimulate macrophages to produce iNOS. Nitric oxide is then produced
by oxidation of L-arginine mediated by iNOS [84], [77].
It is very important to note that nitric oxide usually only acts locally. This is partially
due to the fact that its metabolic lifespan is, perhaps, only a few seconds [84]. Specically,
Levy et al [77] report that its half life is .1 to 10 seconds. Thus, the eects of nitric oxide are
limited to the area near where it is produced. On the other hand, iNOS expression usually
leads to the production of large quantities of nitric oxide over an extended period of time
[77]. As a result, even though nitric oxide dies out before it moves beyond the local area, its
sustained production can have devastating eects in the area near where it is produced.
The body naturally produces some NO and, in fact, moderate amounts of NO are bene-
cial to the epithelium - nitric oxide plays an anti-microbial role and inhibits the growth of
gram-positive bacteria. [65] [77] However, under stressed conditions, large amounts of NO
can be produced causing damage to the epithelial layer, the tight junction proteins, and the
gap junction proteins [77].
Nitric oxide is strongly linked to epithelial layer permeability. Tight junction proteins
are responsible for maintaining a barrier to pathogen attempting to pass between epithelial
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cells into the underlying tissue layer. Nitric Oxide has been shown to reduce the functional
levels of the tight junction proteins, ZO1, ZO3, and occludin [53].
It is theorized that NO impairs phosphorylation of the gap junction protein Cx43, re-
sulting in reduced cell-to-cell communication. This communication is required for epithelial
cell migration. Therefore, NO impairs epithelial cell migration that is required for mucosal
repair [5].
Nitric Oxide also reacts with superoxide O 2 to produce the oxidant peroxynitrite
(ONOO ). Peroxynitrite inhibits the proliferation and dierentiation of epithelial cells [130].
Gap Junction Proteins. These are intercellular membrane channels that facilitate the
passage of ions and solutes between adjacent cells. These membrane channels are composed
of the gap junction protein connexin 43 (Cx43). Leaphart, et al [76] have demonstrated that
epithelial cells migrate in unison and that gap junction communication plays a crucial role in
the migration of intestinal epithelial cells during intestinal healing after injury. They show
that epithelial cells, in particular IEC-6 cells, exposed to IFN- exhibit reduced gap junction
communication and, therefore, greatly reduced migration speed. In particular, they showed
that IFN eected this reduced communication by dephosphorylating Cx43 and by causing
Cx43 to move inside the cell. Interestingly, inhibited gap junction communication does not
appear to reduce epithelial cell proliferation nor does it appear to induce epithelial cell death
[76].
A key factor in gap junction communication is the phosphorylation and surface local-
ization of the gap junction protein Cx43. Any inhibition of phosphorylation of Cx43 will
lead to an inhibition of epithelial cell migration. Anand, et al [5] has demonstrated that
macrophage activation leads to production of nitric oxide. The nitric oxide, in turn, inhibits
the phosphorylation of Cx43 resulting in signicantly reduced cell migration.
Tight Junction Proteins.(Zonula Occludens) These include occludin, ZO-1,ZO-2, ZO-
3, claudin-1, and JAM. [74]. These proteins are formed between adjacent epithelial cells and
are closely linked with the actin-based cytoskeleton [53]. Among other functions, Zonula
Occludens serve as a barrier to keep bacteria and other molecules from passing through the
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epithelial layer into the underlying tissue. It has been discovered that tight junctions restrict
passage of molecules based on the size of the particles and, in fact, the size of the solutes
that are allowed to pass between cells varies at dierent locations in the intestine. In partic-
ular, the permeability to larger solutes decreases from the crypt to the villus [128]. Also, by
restricting transport across the epithelium, the tight junctions serve to prevent equilibrium
across on both sides of the epithelium. In this way, a concentration gradient is maintained
across the epithelium. This concentration gradient is needed in order that the epithelium
can properly absorb and secrete substances [128].
Many factors eect the integrity and health of the tight junction proteins. For example,
there is a close connection between the presence of nitric oxide and increased epithelial layer
permeability. It is theorized that nitric oxide alters the expression and localization of some of
the tight junction proteins, in particular ZO1 [53]. Furthermore, it has been discovered that
IFN- causes a time-dependent down-regulation of the tight junction protein ZO1 [35], pg.
23. Some studies also indicate that TNF causes increased paracellular permeability [128].
Therefore, TNF may eect the tight junction protein.
DAMPs and Damaged cells. Injured cells send out danger/alarm signals. Cells
that send out such signals are cells that are exposed to bacteria, toxins, or cells that have
sustained mechanical damage. This is particularly true of cells that are in the process of
dying after an insult or injury. [88] Alarm signals might be in the form of any substance made
or modied by the dying cell. Cells that die under a normal process will not send out these
danger signals. [88] These alarm/danger signals are known as Damage-associated Molecular
Pattern molecules [DAMPs]. DAMPs tend to keep inammation going even when most or
all of the invading bacteria has been killed. Therefore, a cycle of damage - inammation -
damage can occur. [134]
LPS. LPS is a glycolipid on the outer membrane of gram-negative bacteria which com-
bines with other components and forms LPS/CD-14 [71], [126], LPS/CD-14 is recognized by
and becomes attached to TLR4.
The LPS/CD-14 complex leads to secretion of IL-1, IL-6, and TNF- in macrophages
[89].
TLR4. TLR4 is one member of the group of Toll-like receptors. Also referred to as
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pattern recognition molecules (PRMs) or pattern recognition receptors (PRRs). Toll-like re-
ceptors are normally expressed on the outside of the cell on what is known as the cell mem-
brane or plasma membrane and they recognize large molecules that are associated with
pathogens. These large molecules are sometimes referred to as pathogen-associated molecu-
lar patterns (PAMPs) or microorganism-associated molecular patterns (MAMPS) [55]. For
our study, the only toll-like receptors that we need to consider are TLR4 and TLR9. TLR4
recognizes lipopolysaccharide (LPS) which is on the outer membrane of gram-negative bac-
teria. TLR4 is expressed on many dierent types of cells. However, we are most interested
in TLR4's role on intestinal epithelial cells (IECs).
It has been discovered that TLR4 mediates phagocytosis of gram-negative bacteria by
IECs. This results in IECs translocating bacteria from the mucosa to underneath the ep-
ithelial layer in a transcellular manner [97].
On IECs, TLR4-LPS binding begins a signalling cascade inside the cell ultimately result-
ing in integrin activation. Often TLR4-LPS binding results in over-expression of integrins
resulting in reduced cell motility. Other adverse aects of TLR4-LPS binding are increased
epithelial cell apoptosis, inhibited cell-cell communication, and decreased cell proliferation
[41],[75]. Not surprisingly, there appears to be a strong correlation high levels of TLR4
expression and NEC severity [50]. In particular, high levels of TLR4 have been associated
with a decrease in goblet cells and, in turn, a reduction in the protective mucins that goblet
cells produce [123].
It has been observed that TLR4 increases during gut development. Fold expression of
TLR4 in the gut in mice was shown to increase approximately three-fold from embryonic
day 14 to day 18. Then goes back to day 14 levels right after birth. TLR4 expression then
increases but falls again after weaning [46],[122].
In humans, at the time of full-term birth, TLR4 expression drops greatly. On the other
hand, TLR4 expression remains high at the birth of the pre-term infant and continues to
remain high after birth (yet another disadvantage of prematurity) [50].
There are indications that Heat Shock Protein-70 (HsP70) regulates TLR4 signalling
resulting in decreased NEC severity [1].
TLR9. TLR9, like TLR4 is a Toll-like receptor. TLR9 is the receptor for bacterial
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Figure 14: Results of TLR4 signalling.
DNA (CpG-DNA). It has been determined that TLR4 and TLR9 have a reciprocal role,
i.e., increased signalling in one TLR is associated with decreased signalling of the other.
Studies have shown that, in enterocytes, activating TLR9 with CpG-DNA inhibited LPS-
mediated signalling by TLR4 [46]. Furthermore, NEC has been found to develop in a mucosal
environment of increased TLR4 expression and decreased TLR9 expression [46].
Integrins. Integrins are cell surface glycoproteins that are responsible for cell adhesion
to the extra cellular matrix on which the epithelium resides. Proper integrin expression is
critical for proper cell migration after an injury. Signals from inside the cell cause integrins to
become activated. Upon TLR4-LPS binding, a signalling cascade begins resulting in integrin
activation.
Extracellular ligands of integrins are primarily proteins of the ECM such as bronectin
and collagen. As a result of this binding to proteins of the ECM, the integrins form clusters
known as focal adhesions [73]. Integrins then transmit signals across the plasma membrane
and, in cooperation with growth-factor initiated signals determine various cell functions [9],
[63].
This concludes the survey of the medical research of NEC. The topics in this chapter
were presented as they relate to NEC. More general information about these topics may
be found in other sources. Janeway's Immunobiology [95] provides a good introduction to
the immune system. For cell signalling, see Marks, Klingmuller, and K. Muller-Decker [84].
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Tomkins [127] gives a general overview of the role of the cell and its place in creation.
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2.0 PREPARATIONS FOR CONSTRUCTION OF A NEC MODEL
Much information related to NEC was presented in the previous chapter. In that chapter,
many of the mechanisms and factors involved in NEC were explored and examined. Most
of that information will now be organized, summarized, and ltered down into a form that
can be used for a 3-D mathematical NEC model. Some of the material in that rst chapter
will not be used in a direct way to construct the NEC model but will be used to inform the
simulation runs later in the thesis. For example, when simulating prematurity in chapter
seven, underdeveloped peristalsis, which is a common problem for the pre-term infant, will
be simulated by including large amounts of bacteria near the epithelium. On the other hand,
some factors presented in chapter one that have common characteristics will be combined
into single factors for the purpose of the model. For example, the cytokines that have
inammatory eects will be combined into the general category of cytokines. In addition,
certain practical considerations must be kept in mind when constructing this model. This is
the rst 3-D model for NEC, it will be wise not to include too much detail in this rst model.
Also, there is currently very little quantitative clinical data concerning some of the specic
NEC factors covered in chapter one. As a result, some simplication and/or combining of
NEC factors is necessary. Therefore, the main goal of this chapter will be to identify the
most essential factors in NEC, generalize these factors as much as possible, and dene the
interaction among these factors. This work will result in the General Inammatory Cascade
presented in this chapter (see gure 21). In chapter three, this General Inammatory Cascade
will be used as a guide for the construction of the 3-D mathematical NEC model.
The General Inammatory Cascade will be presented after the construction of interme-
diate diagrams and cascades. It is possible to construct the General Inammatory Cascade
without these intermediate steps and diagrams. However, it is important that the reader
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understand the rationale for many of the simplications that will be done in this chapter.
Also, this intermediate information will provide ideas and motivation for a more advanced
NEC model in the future. That is, this intermediate information may supply the next level
of detail that can be included in a more extensive NEC model. This information will be
particularly relevant as soon as new clinical data becomes available that touches the factors
included in these intermediate steps.
2.1 INFLAMMATORY CASCADE
In this section, inammatory cascades and other diagrams will be developed based on the
information presented in chapter 1. An inammatory cascade which shows the interplay
between cytokines, bacteria, etc. is presented in gure 15. (This cascade is a generalization
based on the information presented in chapter 1.) In order to preserve clarity, PAF and its
role in the inammatory cascade is not included in gure 15 but in a separate gure (gure
16). In gure 15 we have the following important information (this is all based on the
material presented in chapter 1):
1) Beginning along the bottom of the diagram, macrophages eliminate bacteria. At
the same time, bacterial contact with macrophages induces the production of IL-12,IL-18,
TNF-.
2) TNF- induces the production of IL-1, IL-2, IL-6, and IL-8. TNF- in combination
with IL-1, IL-2 induce NK cells to produce IFN- (this combination is indicated by the blue
++.) TNF- also induces the production of MMPs.
3) IL-12 and IL-18 individually induce the production of IFN- but in combination IL-12
and IL-18 produce even larger amounts of IFN- (this combination is indicated by the blue
++.)
4) IL-18 induces the production of IL-4,5,8,10,13.
5) Both IL-1 and TNF- induce the production of IL-6.
6) IL-6 induces the production of IL-1ra and TIMPs. IL-1ra in turn reduces the eects
of IL-1 by competing for the same binding sites as that cytokine. (IL-6 also leads to TGF-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Figure 15: Partial Inammatory Cascade. See the text for discussion. Symbols: Ma stands for activated
macrophages, Na for activated neutrophils, B for bacteria, the other symbols are self-explanatory. Box
color designations are as follows: inammatory cytokines and other destructive agents have white
background boxes; cytokines and other factors that play an anti-inammatory role have green background
boxes; phagocytes have yellow background boxes; free radicals have boxes with gray background. Arrow
color designations are as follows: a red arrow with a negative sign indicates downregulation or production
inhibition; a black arrow with a positive sign indicates upregulation; whenever two or more arrows meet at a
plus sign with a blue background, this indicates that two or more factors, when working together, induce the
production of a large amount of a substance. Note that activated neutrophils, like activated macrophages,
produce cytokines and nitric oxide. For clarity, this function of activated neutrophils is not shown in the
gure. Note, also, that some of the intermediate roles of the inammatory cells are not shown here. For
example, the diagram implies that TNF- and IFN- directly produce nitric oxide and O2- but in reality
TNF- and IFN- induce macrophages to produce these molecules. Also, IL-10 does not directly inhibit the
production of MMP's. Instead, IL-10 inhibits the T cell activation which, in turn, slows the production of
MMP's. Finally, the function of IL-4, IL-8, and IL-10 are shown near the middle of the diagram but the
production of these cytokines is shown in the upper left hand corner.
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Figure 16: PAF's role in the inammatory cascade
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Figure 17: Disruption and restoration of the epithelium. This diagram, unlike the inammatory cascades,
shows the physical eects on the structure of the epithelium. At the top of the illustration we see that nitric
oxide destroys gap junction protein (GJP), epithelial cells and tight junction protein(TJP). Also, ONOO-
destroys epithelial cells and IFN- downregulates the production of tight junction protein. At the bottom,
we see that nitric oxide, IFN-, and ONOO- inhibits epithelial restitution. Paradoxically, IFN- promotes
epithelial cell migration and, therefore, also contributes to epithelial restitution.
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Figure 18: Other factors involved in epithelial restitution/proliferation. Epithelial cells produce TGF-;
Lamina propria cells produce TGF-; Salivary glands produce EGF; Goblet cells produce TFF. TGF-,
EGF, and TFF all enhance epithelial cell migration. TGF- and EGF enhance epithelial cell proliferation
but TGF- inhibits epithelial cell proliferation.
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activation.)
7) TIMPs inhibit the production of MMPs.
8) IL-1 induces the production of IL-8.
9) IL-8 causes neutrophils to congregate near the site of inammation.
10) IL-10 inhibits production of TNF-, IL-1, IL-6, and IL-8.
11) Not shown is the fact that IL-10 may inhibit MMP production by inhibiting T cell
activation.
12) On the bottom right of the diagram, TNF- and IFN- causes macrophages to
produce Nitric Oxide and O 2 .
13) Also on the bottom right of the diagram, Nitric Oxide reacts with O 2 to produce
ONOO .
Other eects not explicitly shown:
14) IL-4, particularly with IL-13, inhibits macrophages' ability to phagocytize pathogen.
15) IL-4 inhibits macrophages' ability to produce nitric oxide.
PAF's role in the inammatory cascade is given in gure 16. Here it is shown that activated
macrophages and activated neutrophils produce PAF. PAF, in turn, leads to the activation
of IL-1, IL-6, and IL-8.
Disruption of the epithelium. Figure 17 shows how the inammatory cascade aects
the epithelium. Notice that nitric oxide interferes with the normal function of gap junction
proteins and, therefore, inhibits epithelial cell-cell communication which in turn inhibits
epithelial cell restitution. Nitric oxide also directly reduces the functional levels of tight
junction proteins and causes epithelial cell death. ONOO- destroys epithelial cells. IFN-
downregulates the production of some tight junction protein.
Also, note that gure 17 shows that IFN- both inhibits restitution and enhances resti-
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tution of the epithelium. This is based on the evidence, presented in chapter one, that IFN-
reduces gap junction communication [76] and, one would conclude, slows epithelial restitu-
tion. Other evidence, also presented in chapter one, suggests that IFN- promotes epithelial
cell migration [32].
Other factors involved in epithelial restitution/proliferation Figure 18 is a sim-
plication and summary of much of the information that was presented in the last chapter.
(See the discussion in chapter one and gure 10 in that chapter.) Recall from chapter one
that many of the growth factors such as HGF, and FGF peptides as well as the cytokines
IL-1, IL-2, IFN- aect the epithelium through TGF- dependent pathways. Therefore, in
gure 18 the functions of these particular growth factors, peptides and cytokine are repre-
sented simply by TGF-. On the other hand, the growth factor EGF plays such an important
role in epithelial proliferation and restitution that its explicit inclusion in gure 18 is war-
ranted. TGF-, which is produced by epithelial cells is explicitly included for similar reasons
- it plays an important role in epithelial proliferation. Members of the trefoil factor family
(TFF), which are produce by goblet cells, work in conjunction with glycoproteins on the
apical side (lumenal side) of the epithelium through an TGF- independent pathway (see
chapter one) and it is, therefore, explicitly included.
2.2 PHYSICAL DOMAIN FOR THE NEC MODEL.
Based on the discussion in chapter one, the lumen, the mucus, the epithelial layer, the extra
cellular matrix (ECM), the underlying tissue, and the blood (or circulatory system) are
important regions for the study of NEC. Ideally, all of these regions would be included in
the mathematical model. However, a model that includes six regions may be too complex.
So, the number of regions considered will be reduced. The mucus will not be included in
the mathematical model because it, like the epithelium, is part of the mucosa. Much of
what occurs in the mucus can be considered together with the epithelial layer. The integrity
of ECM is closely related to the integrity of the epithelium. Recall that the ECM is the
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Figure 19: This diagram shows how the presence of nitric oxide and IFN- results in epithelial
layer permeability.
foundation upon which the epithelial cells stand. Any degradation of the extra cellular matrix
will contribute to epithelial layer permeability. Therefore, extra cellular matrix permeability
and epithelium permeability will not be treated as separate functions. The extra cellular
matrix will not be included in the physical domain for the mathematical model. The function
of the ECM will be included in the function of the epithelium. This leaves us with four regions
as seen in gure 20.
2.3 GENERAL INFLAMMATORY CASCADE
As we move toward a mathematical model, it is desirable to use the information in gures
15, 16, and 17 to create one simplied General Inammatory Cascade. Toward this end,
we rst consider 15 and note the role of MMPs. It was shown in chapter one that the
primary action of the MMPs is to destroy the extra cellular matrix (ECM) but, as noted
above, ECM integrity will not be included explicitly in our model but will be considered
as part of epithelium integrity. Therefore, we will also not include MMPs nor TIMPs (the
prime function of which is to downregulate the MMPs). Instead, the MMPs degradation
of the epithelium/ECM, will be mathematically modeled, in chapter three, by cytokines
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Figure 20: This diagram shows the four regions that will be used in the NEC mathematical
model.
aecting epithelial layer integrity. This simplication is reasonable because the cytokine
TNF- induces the production of MMPs as can be seen from gure 15. On the other
hand, we will include the immune cells, activated macrophages, ma, and activated
macrophages, Na, in the General Inammatory Cascade. Next note that gures 15 and 16
indicate that activated macrophages and activated neutrophils, either directly or indirectly
induce the production of all the inammatory cytokines. (By "indirectly", it is meant that
activated macrophages and activated neutrophils induce the production of some cytokines
which, in turn, induce the production of the remaining cytokines shown in the gures.) That
is, activated macrophages and activated neutrophils induce the production of TNF-, IL-1
IL-12, IL-18, PAF, these in-turn induce the production of IL-1,IL-2, IL-4, IL-5, IL-8, IL-10,
IL-13, IFN- then IL-1 induces the production of IL-6. Therefore, it will be reasonable to
group all of the aforementioned inammatory cytokines under cytokines, c. Furthermore,
note that in gure 15 that the anti-inammatory cytokines such as IL-4, IL-10, IL-1ra
downregulate most of the inammatory cytokines. Therefore, these anti-inammatory
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cytokines, ca, may be grouped together.
Note that gure 15 indicates that the same factors that produce NO also produce O2-.
Furthermore, NO and O2- together produce ONOO-. Therefore, it is possible to include
nitric oxide, NO, in the General Inammatory Cascade and not O2- nor ONOO- as long
as we assign the aects of O2- and ONOO- to NO. For example, note that O2- destroys
bacteria so in the General Inammatory Cascade we will indicate that NO destroys bacteria.
Also, in gure 17 we see that ONOO- destroys epithelial cells and interferes with epithelial
layer restitution but this action mirrors the action of nitric oxide.
In gure 17 we see that nitric oxide (NO) destroys epithelial cells, tight junction protein
and gap junction protein. As noted in chapter one, gap junction protein is necessary for
epithelial cell communication and for coordinated epithelial cell migration. So, if we model
epithelial cell migration and proliferation together, we will not need to include gap junction
protein in our General Inammatory Cascade. That is, we will assume that nitric oxide will
cause destruction of the epithelial layer and inhibit its repair.
On the other hand, it would be wise to include tight junction protein, ZO1, in the
General Inammatory Cascade because it is possible for enough nitric oxide to be present to
destroy the tight junction protein, and therefore, create epithelial layer permeability, without
(or before) destroying epithelial cells.
In gure 17, we see that IFN- both helps and inhibits epithelial restitution. Based
on the evidence presented in chapter one, the net action of IFN- is more likely to inhibit
epithelial restitution than to promote restitution. Therefore, IFN- may be left out of the
general inammatory cascade and its action represented by cytokines, which inhibit epithelial
restitution.
epithelial cells, ec, are essential to the model and, of course will be included in the
General Inammatory Cascade. Note in gure 17 that many of the factors that contribute to
epithelial proliferation and restitution originate in the epithelium itself or originate naturally
in other parts of the body, i.e., the tissue and salivary glands. It will, therefore, be reasonable
to exclude all of the factors in gure 17 from the General Inammatory Cascade and represent
their eects by terms in the epithelial cell equation (this last part will be done in chapter
three).
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Damage (in the context of DAMPs) was covered in chapter one but it was not included
in gures 15, 16, or 17 because as noted in the rst chapter, many dierent components
produced or modied by injured or dying cells can play the role of DAMPs. Therefore,
DAMPs did not t in well with the well dened components shown in gures 15, 16, or 17.
On the other hand, DAMPs t well into the General Inammatory Cascade in which each
component may represent a more general class of components. Also, as noted in chapter
one, damage is a major player in keeping the inammatory cascade going, even after all of
the bacteria has been destroyed. Therefore, it is necessary to include damage, d, in the
General Inammatory Cascade.
Finally, bacteria, b, is essential for the model and, therefore, will be included in the
general inammatory cascade. So, the General Inammatory Cascade is given in gure 21.
This General Inammatory cascade may be though of as occurring in multiple regions, with
the understanding, of course, that epithelial cells are present only in the epithelial region.
In gure 21, the components are as follows:
b: bacteria - endotoxin, LPS; Interacting with activated neutrophils and activated
macrophages, induces the production of cytokines. This eect is indicated by the black
dashed lines in the diagram. At the same time, activated neutrophils and activated
macrophages destroy bacteria. (This is indicated by the red arrows pointing from activated
neutrophils and activated macrophages toward bacteria).
c: pro-inammatory cytokines. This group includes IL-1, IL-8, IL-12, IL-18, IFN-, TNF-
 and, perhaps IL-6 (although as indicated in chapter 1, IL-6 may have both inammatory
and anti-inammatory aects). These cytokines induce macrophages and neutrophils to
produce other cytokines (As indicated by the solid black lines going to and from activated
neutrophils and activated macrophages). Also, these cytokines induce macrophages and
neutrophils to produce nitric oxide. (This is indicated by the black dashed lines). Certain
cytokines such as TNF can induce epithelial cell death. (This is indicated by the red line
pointing from the cytokines to epithelial cells.)
ca: anti-inammatory cytokines - This group includes IL-4 and IL-10. These cytokines
tend to reduce the inammatory response by slowing down the production of cytokines,
activated neutrophils and activated macrophages. (This is indicated by the blue dashed
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Figure 21: General Inammatory Cascade. See the text for discussion. Symbols: ma stands for
activated macrophages, Na for activated neutrophils, b for bacteria, Ca for anti-inammatory cytokines, d
for damage, NO nitric oxide, ZO1 represents tight junction protein, ec represents epithelial cells. Arrow
color designations are as follows: a red arrow with a negative sign indicates downregulation or production
inhibition; a black arrow with a positive sign indicates upregulation.
lines in the diagram).
d: damage - Damage was covered in chapter 1 under DAMPs, Damage-associated Molec-
ular Pattern molecules. Damage might be thought of as the measure of the level of severity of
the inammation. DAMPs are induced by inammation in stressed/injured cells and which
serve to perpetuate inammation in a feed-forward fashion [43], [88], [135].
ec: epithelial cells - these cells line the intestinal wall and protect the underlying tissue
from bacterial invasion. Tight junction proteins, such as ZO1, seal the space between these
cells so that pathogen may not pass into the underlying tissue [53], [54].
m: macrophage - resting immune cells. (For clarity, these are not explicitly shown in the
diagram but will be included in the PDE model developed in chapter 3.) Macrophages are
activated by bacteria, cytokines, and damage.
ma: activated macrophage - activated immune cells. These cells phagocytose bacteria.
These cells release inammatory cytokines and nitric oxide.
n: neutrophil - resting immune cells normally found in the bloodstream. (For clarity,
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these are not explicitly shown in the diagram but will be included in the PDE model devel-
oped in chapter 3.) Neutrophils are activated by cytokines and damage.
na: activated neutrophil - activated immune cells that move from the blood stream
toward the site of infection. These cells release inammatory cytokines and nitric oxide.
NO: nitric oxide - this chemical is released by activated macrophages and activated
neutrophils after these inammatory cells come in contact with certain cytokines (this is
indicated by the black dashed lines coming from activated macrophages and activated neu-
trophils to nitric oxide. Nitric Oxide destroys the tight junction protein, ZO1, that seals the
space between epithelial cells [53], [54]. (This is indicated by the red arrow from the nitric
oxide to ZO1). Finally, the presence of nitric oxide in the epithelium leads to epithelial cell
apoptosis. (This is indicated by the red arrow from the nitric oxide to the epithelial cells).
ZO1: tight junction protein - keeps the epithelial cells in close apposition and prevents
the passage of bacteria into the underlying tissue. Nitric Oxide destroys this protein.
2.4 A TYPICAL SCENARIO
At this point, it will be wise to use the information in chapter one to put together a typical
NEC scenario, that is, a sequence of events in the progression of the disease. It will be
helpful to have such a scenario available when constructing the NEC mathematical model
and when doing simulations. There are many possible cases of scenarios. The following
example is a typical case of a premature, formula fed infant with no initial injury
to the intestinal barrier. To be sure, even this case has many possible variations within
it but we will pick one variation that includes all of the features of this particular case.
Under this scenario, formula feeding causes bacterial colonization of the lumen. Un-
derdeveloped peristalsis, a common problem in the premature infant, does not clear away
the bacteria (gure 22, # 1). Some of the bacteria that lingers for a long time near the
epithelium eventually passes through the protective epithelial cells and invades the under-
lying tissue (gure 22, # 2). Note that this bacterial translocation may occur by several
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dierent mechanisms (see gure 12 in chapter 1). Bacteria that gets into the underlying
tissue invokes an inammatory response. Macrophages interacting with the bacteria become
activated. The activated macrophages release cytokines, in particular, TNF- (gure 22, #
3 and # 4). The TNF- causes increased production of IL-1 [16] and MMP's [83] (gure
22, # 5). The activated macrophages also release the cytokines IL-12 and IL-18 which each
induce T and NK cells to produce IFN- (gure 22, # 6). Recall from chapter one that
IL-12 and IL-18 acting together cause an exponential increase in IFN- (gure 22, # 7).
Many of the cytokines that have been produced then act on the macrophages. In par-
ticular, TNF- and IFN- cause macrophages to produce inducible Nitric Oxide synthase
(iNOS) which, in turn, produces Nitric Oxide (NO) (gure 23, # 8 and # 9).
Large amounts of nitric oxide and cytokines near the epithelium lead to its destruction.
The nitric oxide causes both the death of epithelial cells as well as destruction of the tight
junction protein, such as ZO1, which normally seals the space between the epithelial cells.
As noted in chapter one, IFN- causes a time-dependent down-regulation of ZO1(gure 23,
# 10). Simultaneously, MMP's cause the degradation of the Basal Lamina that underlies the
the epithelial layer (gure 23, # 11). All of this together results in the greater permeability
of the epithelial layer.
The degraded epithelial layer provides only minimal protection for the underlying tissue.
Bacteria and other species may easily travel from the lumen into the underlying tissue (gure
23, # 12). After the bacterial invasion, the tissue becomes the location of a very aggressive
inammatory cascade that involves, among others, IL-1, IL-6, IL-8, IL-12, IL-18, IFN-,
TNF-, and HMGB1 (gure 24, # 13 and # 14).
While this is occurring, the epithelial layer attempts to repair itself. However, as noted
earlier, IFN- causes a signicant reduction in phosphorylated Cx43, a gap junction pro-
tein critical to cell-cell communication and epithelial cell migration. Nitric Oxide similarly
prevents the phosphorylation of Cx43. Interference with gap junction proteins results in
inhibited epithelial cell migration. Furthermore, over-activation of TLR-4 by lumen bacteria
results in over-expression of integrins. Too much integrin expression results in the epithelial
cells adhering too tightly to extra-cellular matrix (see chapter one). All of this results in
greatly reduced cell migration and in a sustained wound (gure 24, # 15).
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Figure 22: A typical NEC scenario (1 of 3). 1. Gram-negative bacterial colonization near the epithelium.
2. Bacteria pass through the epithelium and invades the underlying tissue. 3. Bacteria in the lumen comes
in contact with macrophages. 4. The macrophages respond by releasing cytokines such as TNF-. 5. TNF-
 increases production of Metalloproteinases (MMPs) and induces the release of cytokines such as IL-1 . 6.
Macrophages also release other cytokines such as IL-12 and IL-18. IL-12 and IL-18 each provoke the release
of IFN-. 7. IL-12 and IL-18 work together to induce the release of large amounts IFN-.
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Figure 23: A typical NEC scenario (2 of 3). 8. and 9. Macrophage/cytokine interaction leads to the
secretion of Nitric Oxide. 10. Nitric Oxide and IFN- lead to epithelial layer permeability. Nitric Oxide
destroys the tight junction protein that seals the space between the epithelial cells and IFN- downregulates
the production of the tight junction protein ZO1. 11. Metalloproteinases (MMPs) causes degradation of the
tissue underlying the epithelial cells. 12. After destruction of the tight junction protein and degradation of
the tissue underlying the epithelial cells, bacteria invades the underlying tissue.
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Figure 24: A typical NEC scenario (3 of 3). 13. and 14. Bacteria in the tissue results in an aggressive
inammatory response resulting in the release of cytokines such as IL-1, IL-6, IL-8, IL-12, IL-18, IFN-,
TNF-, HMGB1. 15. Nitric oxide and IFN- interferes with gap junction proteins. Bacteria contact with
the epithelial cells leads to over expression of integrins. All of this leads to reduced epithelial migration. 16.
Macrophages produce nitric oxide and O2 radicals which, in turn, produce ONOO-. 17. The NO/ONOO-
/O2 Radicals Cause Epithelial Cell Death/Tissue Death.
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The inammatory cascade is now unchecked. The production of nitric oxide and O2
radicals leads to the production of ONOO . [130](gure 24, # 16). These work together
to cause extensive tissue death (gure 24, # 17). The ultimate result will be organ failure
and possibly death to the infant.
In this chapter, much of the material from chapter one has been organized, summarized,
and put into a form that may now be used to construct a NEC model. In particular, the
General Inammatory Cascade (see gure 21) has been constructed. This General Inam-
matory Cascade, which shows the interaction among the major players in NEC, will provide
the basis for the NEC mathematical model. This cascade can be converted directly into a
basic mathematical model. Other information presented in the present chapter will be used
to add greater detail to the model. The NEC mathematical model will be constructed in
the next chapter.
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3.0 A PARTIAL DIFFERENTIAL EQUATION MODEL FOR NEC
This chapter presents a three dimensional mathematical model for NEC. The General In-
ammatory Cascade developed in chapter two (see gure 21), will be used as a blueprint for
the mathematical model. Other information presented in chapters one and two will be used
to create detail in the model.
Mathematical models for NEC and/or inammation have been developed in the past
[116], [29], [8], [129]. These models are extremely valuable and provide important insights
into the disease. Furthermore, many of the parameters, mathematical terms, and functions
developed in these papers will continue to be used in future NEC mathematical models. In
fact, a number of terms developed in Reynold.s et al. [116] that model inammation will be
used in the 3-D mathematical model developed in this chapter. (These will be noted below.)
However, the models mentioned above are all one dimensional, ordinary dierential equa-
tion (ODE) models and, therefore, simulate only the transient eects of NEC but do not fully
model its spatial eects. Only a 3-D model can accurately simulate diusion and advection
of the major players in NEC, account for the dierent eects of NEC in the dierent regions
in the body (as noted in chapter two, our mathematical model will include four dierent
regions, see gure 20), and fully integrate all the eects of epithelial cell degradation and
migration. Therefore, a 3-D model will ll a void in the NEC mathematical models.
Before going forward, it is important to note that several people, over a period of sev-
eral years, contributed to the development of the NEC PDE system presented in this chapter:
Joshua Sullivan, Ivan Yotov, Mark Tronzo, Christopher Horvat, Jared Barber, Yoram
Vodovotz, Je Upperman, Gilles Clermont.
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The author of this thesis will, here, present the PDE system and attempt to give justi-
cation for the structure of each equation. In the process, the close connections between the
PDEs and the data presented in chapters one and two will be noted.
3.1 DERIVATION OF PARTIAL DIFFERENTIAL EQUATIONS
In this section, the partial dierential equations for the NEC model will be constructed using
the General Inammatory Cascade, gure 21, as a guide.
Activated macrophages. Activated Macrophages will diuse in the direction of de-
creasing density of activated macrophages. Thus the activated macrophage equation will
have a diusion term, r  ( Dmarma). Activated macrophages will move in the direction
of increasing cytokines and increasing bacteria. So, the advection term may be written as
r  (macmarc+ mabmarb).
The source/sink will include a number of terms:
1) A decay term  kmama.
2) Since macrophages are activated by bacteria, cytokines, and damage, the source terms
kmbbm; kmccm; and kmddm are included. Therefore, when no anti-inammatory cytokines
are present, the source/sink terms become
 kmama + kmbbm+ kmccm+ kmddm:
However, when anti-inammatory cytokines are present, they down-regulate the production
of activated macrophages. This is modeled by multiplying these last three terms by R(ca):
 kmama +R(ca)(kmbbm+ kmccm+ kmddm) where R(ca) =
1
1 + kRca (ca=ca)
2
:
Note that the equation for R(ca) is obtained from [116]. Putting this all together, we get
@ma
@t
  r  (Dmarma   macmarc  mabmarb)
=  kmama +R(ca)(kmbbm+ kmccm+ kmddm):
61
Macrophages. (Resting) macrophages are normally located in the tissue and are considered
to be stationary until they are activated. Therefore, the equation for macrophages does not
include diusion or advection terms but only source/sink terms. Note that every activated
macrophage comes from a (resting) macrophage. Therefore, one of the terms from the
activated macrophage equation, namely R(ca)(kmbbm + kmccm + kmddm), is included here
but with a negative sign. Macrophages will be produced up to a maximum. Thus, the source
term km(mmax  m) is included. Putting these together gives us
@m
@t
= km(mmax  m) R(ca)(kmbbm+ kmccm+ kmddm):
Cytokines. The cytokine equation includes a diusion term but no advection term. The
source/sink terms are as follows:
1) There is a decay term  kcc.
2) Activated macrophages and activated neutrophils both produce cytokines. Whenever
anti-inammatory cytokines are absent, this is modeled by kcmama + kcnana. However,
whenever anti-inammatory cytokines are present, they down-regulate the production of
cytokines. This is modeled by multiplying these two terms by R(ca):
R(ca)(kcmama + kcnana) where R(ca) =
1
1 + kRca (ca=ca)
2
:
3) Whenever cytokines come in contact with macrophages and neutrophils, the cytokines
bind to receptors on these phagocytes to form cytokine-receptor complexes. These complexes
are then internalized into the phagocytes. (This was discussed in chapter 1. See under
macrophages.) This is modeled by knccn kmccm whenever anti-inammatory cytokines are
absent. Note that when anti-inammatory cytokines are present, they slow the production
of cytokines (see gure 21), therefore, the factor
 R(ca)(knccn+ kmccm)
Putting everything together, we have:
@c
@t
  r Dcrc =  kcc+R(ca)(kcmama + kcnana)
 R(ca)(knccn+ kmccm): (3.1)
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Anti-inammatory cytokines. The equation for anti-inammatory cytokines contains a
diusion term but no advection term. The source/sink terms are:
1) A decay term  kcaca.
2) A constant anti-inammatory cytokine growth term sc. This term is usually set to
zero (or an extremely small number) unless a known source of anti-inammatory cytokines,
such as breast milk, is present.
3) Activated macrophages, neutrophils, and damage induce the production of anti-
inammatory cytokines. Anti-inammatory cytokines slow down this production rate. It





where Q = R(ca)(kcamanana +ma + kcamadd):
kcaP is the rate of anti-inammatory cytokine production.
kcamad Eectiveness of damage in producing anti-inammatory cytokine.
kcamana Eectiveness of activated macrophages and activated neutrophils in producing anti-
inammatory cytokines.
Putting everything together, we have:
@ca
@t




Bacteria. The equation for bacteria contains a diusion term but no advection term. The
source/sink terms are:
1) In the place of a decay term we use a term from Reynolds, et al. [116] which represents
elimination of bacteria due to a baseline local immune response,  kbb=(1 + b=). Decay will
be slower with this term than if we had  kbb alone. This is particularly true whenever the
bacteria levels are high. Here  is the range for bacterial death and is usually set at :2.
(Obviously, the smaller the value of , the slower the decay rate.)
2) Also consistent with Reynolds, et al. [116] we include a logistic term kbgb(1  b=bmax).
3) Peptides in breast-fed milk causes the destruction of bacteria. This is modeled by
 kppb.
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4) Both activated macrophages and activated neutrophils phagocyte bacteria (see gure
21). This is modeled by kbmamab+ kbnanab. However, when anti-inammatory cytokines are
present, this is down-regulated in the usual way, so that this term becomes:
 R(ca)(kbmamab+ kbnanab)  kppb where R(ca) =
1
1 + kRca (ca=ca)
2
:
Putting everything together, we have:
@b
@t
  r Dbrb = kbgb(1  b=bmax)  kbb=(1 + b=)
 R(ca)(kbmamab+ kbnanab)  kppb: (3.3)
Nitric Oxide. The equation for Nitric Oxide includes a diusion term but no advection
term. The source/sink terms are:
1) A decay term  kNONO.
2) Activated macrophages and activated neutrophils both produce cytokines. Certain
cytokines then induce macrophages to produce Nitric Oxide. Therefore, both activated
macrophages and activated neutrophils induce, directly or indirectly, the production of Nitric
Oxide. However, there is a time-delay in the production of the Nitric Oxide. After testing
many types of mathematical terms to simulate this time-delay, it was found that the following








where kNOma and kNOna are the rates at which activated macrophages and activated neu-
trophils, respectively, produce Nitric Oxide.
Putting everything together, we have:
@NO
@t








Tight Junction Protein, ZO1. The tight junction protein, ZO1, keeps the space in
between epithelial cells sealed so that pathogen may not pass into the underlying tissue.
This protein does not move and is not diused. Therefore, the equation for ZO1 does not
contain a diusion term nor an advection term. Furthermore, ZO1 does not naturally decay.
So, no decay term is included. The source/sink terms look like this:
1) Nitric Oxide destroys the tight junction protein, ZO1, this is modeled by the term
 kZNNO  ZO1.
2) A certain amount of tight junction protein will be created for each epithelial cell, up
to maximum value of zec. (The equation for zec is given below.) This creation of tight
junction protein is given by:
kZecec (1  ZO1=zec):
As epithelial cells proliferate (or as they are destroyed), tight junction protein is created (or





Here zec serves as a limiting value for ZO1. One option would be to set zec to some constant
value (such as 1 or .95) but setting zec to some constant value might allow the density of ZO1
to grow well beyond the density of epithelial cells. This may be all right - as demonstrated
in chapter 1, in some cases ZO1 might ll in small open areas of the epithelium where no
epithelial cells exists. However, it was apparently decided that ZO1 should be modeled to
exist only between epithelial cells. Therefore, the expression for zec was made to be















(1  ZO1=zec)  kZNNO  ZO1 (3.5)
where







Activated neutrophils. For activated neutrophils, we have a diusion term,  r(Dnarna).
Activated neutrophils will move in the direction of increasing cytokines (see chapter 1). So,
the advection term may be written as r  (nacnarc).
The source/sink will include a number of terms:
1) A decay term  knana.
2) Since neutrophils are activated by cytokines and damage (see gure 21), the terms
knccn and knddn are included. Therefore, when no anti-inammatory cytokines are present,
the source/sink terms become
 knana + knccn+ knddn:
However, when anti-inammatory cytokines are present, they down-regulate the production
of activated neutrophils. This is modeled by multiplying these last two terms by R(ca):
 knana +R(ca)(knccn+ knddn) where R(ca) =
1
1 + kRca (ca=ca)
2
:
Putting this all together, we get
@na
@t
  r  (Dnarna   nacnarc) =  knana +R(ca)(knccn+ knddn):
Damage. Recall from chapters 1 and 2 that damage is correlated with DAMP molecules.
These DAMP molecules likely diuse. So, the damage equation has a diusion term but no
advection term. The source/sink will terms include:
1) A decay term  kdd.
2) Note as dened in chapter 2, damage is the measure of the level of severity of the
inammation. Therefore, even though nitric oxide, activated neutrophils, and macrophages
cause tissue destruction (see chapter 1 and gure 21), it is acceptable to include only cy-
tokines in our equation for damage. For that purpose, we use the type of term used in








Figure 25: Damage Production Term
here T = R(ca)c and the constant xdc is the range for damage/DAMP production.
Therefore, the term T = R(ca)c indicates that cytokines lead to the production of dam-
age while anti-inammatory cytokines, through R(ca), moderates this eect. Note that the
source term (3.7) has an upper bound of kdc. Using kdc = :35,xdc = :06, and q2 = 1:5 then
R(ca)c may be plotted against (3.7) to get gure 25.
@d
@t





Epithelial Cells Modeling of the epithelial cells is somewhat more complicated. Epithelial
cell migration speed is directly related to integrin activation. Optimum migration speed
occurs at some medium/optimal amount of integrin activation. Whenever integrin activation
is low, migration speed is low or zero. Likewise, epithelial cell migration speed is low at high
levels of integrin activation. Higher migration speeds occur at integrin activation levels
between these two extremes.
67
In this model it will be assumed, in the absence of bacteria that epithelial cells will
move at optimal speed, i.e., integrins are adhering at optimal levels. Bacteria is directly
related to integrin activation. Higher concentrations of bacteria results in higher levels of
integrin activation. Therefore, it will be assumed that the presence of any amount of bacteria
will begin a signalling process in the epithelial cells that will result in more than optimal




(bmax   b):25 + b:25 :
Let u =  (b)rec. Note that u is a velocity and is proportional to  rec. Therefore, a
basic diusion term would be
 r  ((b)rec) = r  u:
This is then multiplied by the Buckley-Leverett equation [23]
(ec) = h(ec; ec;max; q) =
eqc
eqc + (ec;max   ec)q :
from two-phase ow (Most usually we will have q = 2 and ec;max = 1.), to give the diusion
equation
 (ec)r  ((b)rec) = (ec)r  u:
Advection would, then, be represented by:
r((ec)u) = r(ec)  u = @
@ec
rec  u:
Note that we have assumed the velocity u =  (b)rec is constant. Also note that the
Buckley-Leverett equation is S-shaped and leads to no advection for ec = 0 and ec = ec;max





Figure (26) shows graphs from the Buckley-Leverett equation with exponent values q =
2; 4; 8. Figure (27) shows graphs from the Buckley-Leverett equation with fractional exponent
values q = 1=2; 1=4; 1=8. So the left hand side of the epithelial equation becomes:
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Figure 26: Buckley-Leverett equation. The horizonal axis represents epithelial cells concentration, ec,
ranging from 0 to 1. The vertical axis represents the output of the Buckley-Leverett equation, (ec).
Exponent values for the three graphs are, from left to right, q = 2; 4; 8. In each graph, we have ec;max = 1.
Figure 27: Buckley-Leverett equation. The horizonal axis represents epithelial cells concentration, ec,
ranging from 0 to 1. The vertical axis represents the output of the Buckley-Leverett equation, (ec).









+r  ((ec)u(ec; b)):
For epithelial proliferation, we have kpec multiplied by the logistic term (1   ec=ec;max).
Cytokines, activated neutrophils, and bacteria all contribute to epithelial cell death. There-
fore,epithelial cell death is modeled by  ka(na; c; b)ec where ka(na; c; b) is given by:
ka(na; c; b) =
eq0ca(na; c; b)
eq0ca(na; c; b) + (eca(na;max; cmax; bmax)  eca(na; c; b))q0
and eca(na; c; b) = na + kecnacc+ kecnabb:
Putting everything together, we get
@ec
@t
+r  ((ec)u(ec; b)) = kpec(1  ec=ec;max)  ka(na; c; b)ec:
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3.2 THE SYSTEM OF PARTIAL DIFFERENTIAL EQUATIONS
The entire system of partial dierential equations for the NEC model is given by:
@ec
@t
+r  ((ec)u(ec; b)) = kpec(1  ec=ec;max)  ka(na; c; b)ec
Where
ka(na; c; b) =
eca(na; c; b)
q0
eca(na; c; b)q0 + [eca(na;max; cmax; bmax)  eca(na; c; b)]q0
eca(na; c; b) = na + kecnacc+ kecnabb
(ec) =
e2c
e2c + (ec;max   ec)2
u(ec; b) =  (b)rec (b) = (bmax   b)
q
(bmax   b)q + bq
@b
@t




= km(mmax  m) R(ca)(kmbbm+ kmccm+ kmddm)
@ma
@t
  r  (Dmarma   macmarc  mabmarb)
=  kmama +R(ca)(kmbbm+ kmccm+ kmddm)
@c
@t
  r Dcrc =  kcc+R(ca)(kcmama + kcnana) R(ca)(knccn+ kmccm)
@ca
@t




















ZO1max(1  ZO1=zec)  kZNNO  ZO1
where








  r  (Dnarna   nacnarc) =  knana +R(ca)(knccn+ knddn)
@d
@t









T = R(ca)c Q = R(ca)(kcamanana +ma + kcamadd)
Notes:
1. The physical domain 
 is 3-dimensional consisting of four horizontal regions. The regions
from top to bottom are lumen 
1, epithelial layer 




2. Db; Dc; Dca ; Dd; Dna ; Dma ; DNO are diusion coecients for bacteria, cytokines, anti-
inammatory cytokines, damage, activated neutrophils, and activated macrophages, re-
spectively.
3. mac; mab; nac are advection coecients.
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3.3 THE NEC EQUATIONS IN THE FOUR REGIONS
Recall that the NEC equations will be applied over four regions (Lumen, Epithelial, Tissue,
and Blood). Of course, not all the NEC equations apply to all four regions. For example,
the epithelial equation and the ZO1 (tight junction) equation are only valid in the epithelial
region. Furthermore, the diusion coecients D will be dierent for each equation and in
each region. These diusion coecients also play a major role in the communication between
the regions. Communication between regions is a very important part of the NEC model
and is discussed in more detail in section 7.7 of chapter seven.
3.4 SUGGESTED CHANGES
As noted above, the author of this thesis was involved in the forming and modication of
the above PDE model. Yet, the author of this thesis suggests some further changes to the
PDE system:
1) Changes to the nitric oxide equation. The nitric oxide equation was originally
written with no diusion term. However, the group chose to add a diusion term to this
equation. The author of this thesis suggests that the diusion term be removed from this
equation or, if the diusion term is retained, other changes to the system should be made.
This author's reasoning is as follows:
On the one hand, if nitric oxide in our model is intended to simulate the aects of
nitric oxide only, then the diusion term should be removed. As indicated in the previous
chapters, nitric oxide decays very quickly and, therefore, will decay before it diuses. On
the other hand, if nitric oxide in our model is intended to simulate not only nitric oxide
but also components formed with the help of nitric oxide such as ONOO  then additional
terms must be added. In our current PDE model, nitric oxide destroys tight junction protein
but does nothing else. Now, ONOO  is not known to destroy tight junction protein but
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ONOO  is known to destroy epithelial cells. However, no such destruction of epithelial
cells by nitric oxide is included in our PDE model. (In our model, epithelial cell death by
nitric oxide is modeled in an indirect way - bacteria causes epithelial cell death). Therefore,
if we wish to retain the diusion term in the nitric oxide equation, terms should be added
to the epithelial equation (and other equations) to model the aects of ONOO  and other
components created by nitric oxide.
2) Changes to the tight junction protein equation. As noted in chapter 1, in some
cases ZO1 might ll in small open areas of the epithelium where no epithelial cells exist. In
the case of cell shedding, ZO1 moves under the exiting cell in order to ll the newly created




it might, in fact, be reasonable to set zec = ZO1max. Setting zec = ZO1max was avoided
by the group because we did not want there to be tight junction protein in places where no
epithelial cells existed. However, in view of the ndings noted in chapter 1, we now know
that such a condition is possible.
3) Changes to the equation for Q. Note that Q was created as:
Q = R(ca)(kcamanana +ma + kcamadd):
It would be more reasonable to multiply kcamana by both na and ma. So that we have:
Q = R(ca)(kcamana(na +ma) + kcamadd):
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4.0 ANALYSIS OF THE PDE SYSTEM
In this chapter, the system of partial dierential equations will be analyzed.
The most important part of the analysis of the system of partial dierential equations
in the NEC model is the investigation of the existence of a solution to the system. This
particular system of PDEs presents special challenges due unique nonlinearities in some
of the equations and the fact that some of the equations are coupled through these non
linearities.
Due to the specic coupling involved in the NEC mathematical system, the analysis of
the of the partial dierential equations may naturally be divided into three parts as follows.
Part I. Part I will consist of eight equations: the equations for bacteria, macrophages,








= km(mmax  m) R(ca)(kmbbm+ kmccm+ kmddm)
@ma
@t
  r  (Dmarma   macmarc  mabR(ca)marb)
=  kmama +R(ca)(kmbbm+ kmccm+ kmddm)
@c
@t

















  r  (Dnarna   nacnarc) =  knana +R(ca)(knccn+ knddn)
@d
@t










Q = R(ca)(kcamanana +ma + kcamadd)
Part II. Part II will consist of the epithelial equation:
@ec
@t
+r  ((ec)u(ec; b)) = kpec(1  ec=ec;max)  ka(na; c; b)ec
Where
ka(na; c; b) =
eca(na; c; b)
q0
eca(na; c; b)q0 + [eca(na;max; cmax; bmax)  eca(na; c; b)]q0
eca(na; c; b) = na + kecnacc+ kecnabb
(ec) =
e2c
e2c + (ec;max   ec)2
u(ec; b) =  (b)rec (b) = (bmax   b)
q
(bmax   b)q + bq









ZO1max(1  ZO1=zec)  kZNNO  ZO1
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where






It is not obvious here but the tensor D in each of the equations in Part I depends
upon the equation in Part II. (This dependence is more obvious in the computer code for
the simulations, which come later in the thesis.) This dependence will be neglected in the
following analysis. The equations in Part I do not depend at all on the equation in Part III.
Therefore, the existence and uniqueness of solutions for the aforementioned eight equations
in Part I may be found independently of the equations in Part II and Part III. This existence
and uniqueness study is done in Analysis of PDEs in Part I.
Notice that the equation in Part II (the epithelial equation) depends on the equations
from part I but does not depend on the equation in Part III (the tight junction protein
equation). Therefore, error bounds found in part I may be used to bound the error for the
epithelial cells. This study is done in Analysis of PDEs in Part II.
The equation in Part III (the tight junction protein equation) depends upon the equations
in Part I and Part II. Therefore, error bounds found in part I and Part II may be used to
bound the error for the tight junction protein. This study is done in Analysis of PDEs in
Part III.
4.1 NOTATION




















for 1  p <1
L1(
) = ff : 




) = ess supx2
 jf(x)j
H(div; 
) = ff 2 (L2(




jxij kAk1 = sup
x2Rn;x 6=0
kAxk1
kxk1 for x 2 R
n A 2 Rnn
Note that the above denition implies kAxk1  kAk1kxk1:
L1(Rnn) = fA 2 Rnn
kAk1 <1g
The following two theorems may be found in [38]
Theorem 4.1 (Banach's Fixed Point Theorem). Assume that
A : X ! X
where A is a nonlinear mapping and X is a Banach space. Further suppose that
kA[u1]  A[u2]k  kku1   u2k 8u1; u2 2 X
for some constant k such that k < 1. Then A has a unique xed point.
Theorem 4.2 (Schauder's Fixed Point Theorem - Version 1). Suppose that K is a
compact and convex space and M is a continuous mapping:
M : K ! K
then M has a xed point in K.
Theorem 4.3 (Schauder's Fixed Point Theorem - Version 2). Let A be a compact
and continuous mapping of a bounded, convex set S into S. Then A has a xed point in S.
Theorem 4.4 (Ascoli-Arzela Theorem). Let (X; d) be a compact space. A subset F of
C(X) is relatively compact if and only if F is equibounded and equicontinuous.
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Recall the shift operator Shift(h)f(x) = f(x+ h) where h 2 R3.
The following theorem is found in [21],
Theorem 4.5 (Kolmogorov-M.Riesz-Frechet). Let F be a bounded set in Lp(RN) with
1  p <1. Furthermore, suppose
lim
h!0
kShift(h)fkp = 0 uniformly in f 2 F
where Shift(h)f(x) = f(x+ h) for h 2 R3 is the shift operator.
Then the closure of Fj
 in Lp(
) is compact for any measurable set 
  RN with nite
measure.
Theorem 4.6 (Cauchy's inequality with "). Suppose that a; b > 0 and " > 0 then,




The following theorem may be found in [85]
Theorem 4.7 (Cauchy-Schwarz inequality). For u; v 2 L2(
),
j(u; v)j  kukkvk:
One form of the Gronwall Inequality is given by (see [78]),
Theorem 4.8 (The Gronwall Inequality). For any t 2 [t0; T ), if we have









; for t 2 [t0; T ):
Theorem 4.9 (Aubin-Lions Compactness Criteria). Suppose that X;Y; Z are Banach
Spaces and X  Y  Z. Suppose that X and Z are reective spaces. Furthermore suppose
that X is compactly embedded in Y and Y is continuously embedded in Z. Let
Q =
(
u 2 Lp(0; T ;X)
 @u@t 2 Lq(0; T ;Z)
)
for 1 < p; q <1
then Q is compactly embedded into Lp(0; T ;Y ).
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4.2 ANALYSIS OF PDES IN PART I
Representative system
The partial dierential equations in Part I are of two general types: (a) those equations
that are nonlinear in the "data" only, i.e., the nonlinearities reside in the right hand side
functions only. The equations of this type are the bacteria, macrophage, cytokine, anti-
inammatory cytokine, Nitric Oxide, and damage equations; (b) those equations that contain
nonlinearities in the advection terms. The equations of this type are activated macrophage
and activated neutrophil equations. Such equations are particularly dicult to analyze
because these nonlinearities are coupled to other equations in the system.
The particular features mentioned in (a) and (b) above may be represented by the fol-
lowing system of two equations:
@u1
@t
 r  (D1ru1   u1ru2) = f1(u1; u2) (4.1)
@u2
@t
 r  (D2ru2) = f2(u1; u2) (x; t) 2 
 (0; T ] (4.2)
ru1  n = 0 and ru2  n = 0 on  : (4.3)
where f1 and f2 are nonlinear functions of u1 and u2. Notice that (4.1) might represent the
activated macrophage equation or the activated neutrophil equations. On the other hand,
(4.2) might represent the bacteria, macrophage, cytokine, anti-inammatory cytokine, Nitric
Oxide, or damage equation. These are the only two types of equations that we have in Part
I.
Notice, for example, we do not have any "two-way" coupling in the advection terms, i.e.,
we do not have the following coupling in our system:
@u1
@t
 r  (D1ru1   u1ru2) = f1(u1; u2)
@u2
@t
 r  (D2ru2   u2ru1) = f2(u1; u2)
Therefore, in order to prove that the system of equations in Part I has a solution, it suces
to prove that (4.1), (4.2) has a solution.
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4.3 EXISTENCE AND REGULARITY OF WEAK MIXED SOLUTION
FOR THE LINEAR PROBLEM
The numerical method that will be used to solve the PDE system will be based on the
Mixed Finite Element Method. Therefore, it will be helpful to prove that the PDE system
has a weak mixed solution and to establish some regularity for that solution. First, it will
be shown that the linear problem has a mixed weak solution. After that, regularity will be
established for the weak mixed formulation. Then, in the next subsection, it will be shown
that the nonlinear mixed weak form has a solution.
Denition of the Weak Mixed Solution. Consider for f 2 L2(
) the PDE
ut  u = f (x; t) 2 
 (0; T ]
u(0) = g
ru  n = 0 on  
Set z =  ru) z+ru = 0
ut +r  z = f
z+ru = 0
Multiply by test functions and integrate. We say u 2 L2(
); z 2 V 0 is a weak mixed
solution if,
(ut; w) + (r  z; w) = (f; w) 8w 2 L2(
) (4.4)
(z; v)  (u;r  v) = 0 8v 2 V 0: (4.5)
The second equation was obtained by integrating by parts. Here V = H(div; 
)) and
V 0 = V \ fv : v  n = 0 on  g.
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4.3.1 Existence of Solution to Finite System.
Consider the basis i for V

















where i for i = 1; :::;m and i for i = 1; :::; n are functions of t only. Note that it := di=dt
and it := di=dt.
Substitute (4.6) and (4.7) into (4.4) and (4.5) and replace w and v by the basis functions
 mX
i=1
















i i;r  j

= 0 (4.9)
For (4.8), set j = 1; :::;m to get
0BBBBBB@
1 0    0 0
0 1    0 0
      
0 0    0 1
1CCCCCCACt +
0BBBBBB@
(r  1;  1)    (r  n;  1)
(r  1;  2)    (r  n;  2)
        








For (4.9), set k = 1; :::; n to get
0BBBBBB@
(1; 1)    (n; 1)
(1; 2)    (n; 2)
        
(1; n)    (n; n)
1CCCCCCAX 
0BBBBBB@
( 1;r  1)    ( m;r  1)
( 1;r  2)    ( m;r  2)
        



































(1; 1)    (n; 1)
(1; 2)    (n; 2)
        
(1; n)    (n; n)
1CCCCCCA B :=
0BBBBBB@
(r  1;  1)    (r  n;  1)
(r  1;  2)    (r  n;  2)
        















then the system may be written as
Ct +BX = F (4.10)
AX BTC = 0 (4.11)
C(0) = G:
So, from (4.11) we have X = A 1BTC. Substituting this into (4.10) gives:
Ct +BA
 1BTC = F: (4.12)
It can be shown that BA 1BT is SPD and BA 1BT 2 L1(Rnn), i.e., 9K such that
kBA 1BTk1  K. Note that (4.12) is a system of ordinary dierential equations in the
variable t. It is now necessary to show that (4.12) has a solution.
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Prove that there exists a solution to the system (4.12) of ODEs.
A solution to (4.12) will now be constructed on an arbitrary interval [0; T ]. Integrate (4.12)
























Banach's xed point theorem (Theorem 4.1) will be used to prove that this mapping has




BA 1BT(C1  C2) ds: (4.16)
Since BA 1BT and kBA 1BTk1  K is SPD, we have:
kH(C2) H(C1)kMaxNorm(T1)  KT1kC2  C1kMaxNorm(T1) (4.17)
where k  kMaxNorm(T ) := sup
0tT 
k  k1 and K is a constant:
Now pick T1 so that KT1 < 1. Then by Banach's xed point theorem (Theorem 4.1) there
exists a C such that H(C) = C on [0; T1]. Thus, there exists a solution to (4.12) on [0; T1].
Next, choose T2 so as to get a similar contraction, and therefore establish a solution, on
the interval [T1; T2]. Continue to prove the existence of solutions on these subintervals until
the entire interval [0; T ] is covered. In this way, a solution to (4.12) may be constructed on
any interval [0; T ].
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Thus, we have established that for any nite integers, m and n, the system
(umt ;  j) + (r  zn;  j) = (f;  j) (4.18)
(zn; k)  (um;r  k) = 0 (4.19)
has a solution (um; zn) 2 L1(0; T ;L2(
)) L1(0; T ;V 0).
4.3.2 Establish Bounds for Various Terms
In order to prove any regularity for the solution to the PDE system, it will rst be necessary
to establish bounds on various terms.
Establishment of a bound for kumkL1(0;T ;L2(
)) and kznkL2(0;T ;L2(
)).
Multiply (4.18) by j and multiply (4.19) by k to get:
(umt ; j j) + (r  zn; j j) = (f; j j) (4.20)
(zn; kk)  (um;rkk) = 0: (4.21)
Summing j = 1; :::;m and summing k = 1; :::; n and recalling (4.6),(4.7) gives:
(umt ; um) + (r  zn; um) = (f; um) (4.22)
(zn; zn)  (um;rzn) = 0: (4.23)
Substitute (4.23) into (4.22),use the Cauchy-Schwarz inequality (theorem 4.7) and Cauchy's


































Thus, if um(0) 2 L2(
) and f 2 L2(0; T ;L2(
)) then
fumg1m=1 is bounded in L1(0; T ;L2(
)) (4.25)
fzng1n=1 is bounded in L2(0; T ;L2(
)): (4.26)
Establishment of a bound for kumtkL2(0;T ;L2(
)) and kznkL1(0;T ;L2(
))
Now, multiply (4.18) by jt . Then, take the derivative of (4.19) with respect to t and
then multiply it by k to get
(umt ; jt j) + (r  zn; jt j) = (f; jt j) (4.27)
(znt ; kk)  (umt ;rkk) = 0: (4.28)
Summing j = 1; :::;m and k = 1; :::; n gives:
(umt ; umt) + (r  zn; umt) = (f; umt) (4.29)
(znt ; zn)  (umt ;r  zn) = 0: (4.30)














kumtk2 to the left hand side, multiply by 2 and integrate from 0 to t, for 0 < t  T ,Z t
0
kumtk2 + kznk2(t) 
Z t
0
kfk2 + kznk2(0): (4.32)
Thus, if zn(0) 2 L2(
);which is true if g 2 H1(
); and f 2 L2(0; T ;L2(
)) then
fzng1n=1 is bounded in L1(0; T ;L2(
)) (4.33)
fumtg1m=1 is bounded in L2(0; T ;L2(
)): (4.34)
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Where cj and yk are functions of t only.
Now, multiply (4.18) by cj and (4.19) by yk to get
(umt ; cj j) + (r  zn; cj j) = (f; cj j) (4.36)
(zn; ykk)  (um;rykk) = 0: (4.37)
Summing j = 1; :::; P and k = 1; :::; Q gives
(umt ; w) + (r  zn; w) = (f; w) 8w 2 spanf jgmj=1 (4.38)
(zn; v)  (um;r  v) = 0 8v 2 spanfkgnk=1: (4.39)
Since w; v are constructed from the basis functions  j; j and there is a solution to (4.18),(4.19),
this implies that there exists a solution to (4.38),(4.39).
Establishment of a bound on kr  znkL2(0;T ;L2(
))
Now, in (4.38) set w = r  zn,
(umt ;r  zn) + (r  zn;r  zn) = (f;r  zn): (4.40)
Then
kr  znk2  kfkkr  znk+ kumtkkr  znk: (4.41)
Dividing,
kr  znk  kfk+ kumtk: (4.42)
This implies,
kr  znk2  2kfk2 + 2kumtk2:
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Integrate from 0 to t and use (4.32)Z t
0






kfk2 + 2kznk2(0): (4.43)
Thus, if f 2 L2(0; T ;L2(
)) and zn(0) 2 L2(
) (which is true if g 2 H1(
)) then
fr  zng1n=1 is bounded in L2(0; T ;L2(
)): (4.44)
4.3.3 Convergence to a Solution of Linear Weak Mixed System
Now, integrate (4.38) and (4.39) from 0 to T .Z T
0
(umt ; w) +
Z T
0
(r  zn; w) =
Z T
0





(um;r  v) = 0: (4.46)
Note that from (4.25), (4.26), (4.33),(4.34), (4.44) all of the relevant sequences are bounded
in the appropriate spaces. Therefore, each of these sequences has a weakly convergent
subsequence in that space. Choose convergent subsequences fumL ; znLg of fum; zng such
that umL * u weakly and znL * z weakly. Set m = mL; n = nL and takemL !1; nL !1





(r  z; w) =
Z T
0






(u;r  v) = 0 8v 2 V 0(
): (4.48)
By choosing test functions (t)w and  (t)v where ;  2 C10 (0; T ) one can show that
(ut; w) + (r  z; w) = (f; w) 8w 2 L2(
) (4.49)
(z; v)  (u;r  v) = 0 8v 2 V 0(
): (4.50)
u(0) = g
holds for a.e. t 2 (0; T ].
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Establishment of a bound for kutkL1(0;T ;L2(
)) and kztkL2(0;T ;L2(
))
In (4.49) and (4.50) take the derivative with respect to t and set w = ut; v = zt
(utt; ut) + (r  zt; ut) = (ft; ut) (4.51)
(zt; zt)  (ut;r  zt) = 0: (4.52)

















kftk2 + kutk2(0): (4.54)
Thus, if g 2 L2(
)), f 2 L1(0; T ;L2(
)) and ft 2 L2(0; T ;L2(
)) then
zt 2 L2(0; T ;L2(
))
ut 2 L1(0; T ;L2(
)): (4.55)
Establishment of a bound for kuttkL2(0;T ;L2(
)) and kztkL1(0;T ;L2(
))
Take the derivative, with respect to t, of (4.49). Take two derivatives, with respect to t,
of (4.50) then set w = utt; v = zt
(utt; utt) + (r  zt; utt) = (ft; utt) (4.56)
(ztt; zt)  (utt;r  zt) = 0: (4.57)













kuttk2 to the left hand side, multiply by 2 and integrate from 0 to t,Z t
0
kuttk2 + kzntk2(t) 
Z t
0
kftk2 + kztk2(0): (4.59)
Thus, if zt(0) 2 L2(
) (which is true if g 2 H3(
)), f 2 L1(0; T ;L2(
)) and ft 2
L2(0; T ;L2(
)) then
zt 2 L1(0; T ;L2(
))
utt 2 L2(0; T ;L2(
)): (4.60)
Establishment of a bound on kr  ztkL2(0;T ;L2(
))
Take derivative of (4.49) with respect to t to get,
(utt; w) + (r  zt; w) = (ft; w)
Set w = r  zt
(utt;r  zt) + (r  zt;r  zt) = (ft;r  zt)
then
kr  ztk2  kftkkr  ztk+ kuttkkr  ztk
and
kr  ztk  kftk+ kuttk
Finally Z T
0







We know from (4.60) that the last term on the right hand side is bounded. So if we have
that ft 2 L2(0; T ;L2(
))
r  zt 2 L2(0; T ;L2(
)) (4.61)
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Establishment of a bound on kr  znkL1(0;T ;L2(
))
Go back to (4.40) and take the derivative with respect to t,
(utt;r  z) + (ut;r  zt) + 2(r  z;r  zt)




kr  zk2  kftkkr  zk+ kfkkr  ztk




kr  zk2  Ckftk2 + Ckr  zk2 + Ckfk2
+Ckr  ztk2 + Ckuttk2 + Ckutk2
Integrating from 0 to t:



















kutk2 + kr  zk2(0)
Apply the Gronwall Inequality, theorem 4.8, to get:
sup
0tT
















kutk2 + kr  znk2(0)
If f; ft 2 L2(0; T ;L2(
)) and because of the bounds (4.61), (4.34), and (4.60) we have
fr  zng1n=1 is bounded in L1(0; T ;L2(
)) (4.62)
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Establishment of a bound for kutttkL2(0;T ;L2(
)) and kzttkL1(0;T ;L2(
))
Take two derivatives, with respect to t, of (4.49). Take three derivatives, with respect
to t, of(4.50) and set w = uttt; v = ztt to get
(umttt ; umttt) + (r  zntt ; umttt) = (ftt; umttt) (4.63)
(zttt; ztt)  (uttt;r  ztt) = 0: (4.64)












kutttk2 to the left hand side, multiply by 2 and integrate from 0 to T ,Z t
0
kutttk2 + kzttk2 
Z t
0
kfttk2 + kzttk2(0): (4.66)
Thus, if ztt(0) 2 L2(
) (which is true if g00 2 H1(
)) and ftt 2 L2(0; T ;L2(
)) then
ztt 2 L1(0; T ;L2(
))
uttt 2 L2(0; T ;L2(
)): (4.67)
Establishment of a bound on kr  znttkL2(0;T ;L2(
))
Take two derivatives of (4.38) with respect to t to get,
(uttt; w) + (r  ztt; w) = (ftt; w)
Set w = r  ztt
(uttt;r  ztt) + (r  ztt;r  ztt) = (ftt;r  ztt)
then
kr  zttk2  kfttkkr  zttk+ kutttkkr  zttk
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and
kr  zttk  kfttk+ kutttk
Finally Z T
0







We know from (4.67) that the last term on the right hand side is bounded. So if we have
that ftt 2 L2(0; T ;L2(
))
r  ztt 2 L2(0; T ;L2(
)) (4.68)
Establishment of a bound on kr  ztkL1(0;T ;L2(
))
Take derivative of (4.49) with respect to t to get,
(utt; w) + (r  zt; w) = (ft; w)
Set w = r  ztt












kr  ztk2  Ckftk2 + Ckr  zttk2 + Ckuttk2
and










kuttk2 + kr  ztk2(0)
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We know from (4.67) and (4.68) that the right hand side is bounded. So if we have that
ft 2 L2(0; T ;L2(
))
r  znt 2 L1(0; T ;L2(
)) (4.69)
4.3.4 Regularity of Linear Weak Mixed System
Based on all of the foregoing bounds and convergence, we can state the following theorems:
Theorem 4.10 (Theorem A). Suppose g 2 H1(
) and f 2 L2(0; T ;L2(
)) then
(ut; w) + (r  z; w) = (f; w) 8w 2 L2(
)
(z; v)  (u;r  v) = 0 8v 2 V 0(
):
u(0) = g
ru  n = 0 on  
has a weak solution with z 2 L1(0; T ;L2(
)), r  z 2 L2(0; T ;L2(
)), u 2 L1(0; T ;L2(
)),
ut 2 L2(0; T ;L2(
)).
Theorem 4.11 (Theorem B). Suppose g 2 H3(
) and ft 2 L2(0; T ;L2(
)) then
(ut; w) + (r  z; w) = (f; w) 8w 2 L2(
)
(z; v)  (u;r  v) = 0 8v 2 V 0(
):
u(0) = g
ru  n = 0 on  
has a weak solution with zt 2 L1(0; T ;L2(
)), ut 2 L1(0; T ;L2(
)), utt 2 L2(0; T ;L2(
)),
r  z 2 L1(0; T ;L2(
)),r  zt 2 L2(0; T ;L2(
)).
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Theorems 4.10 and 4.11 aord a certain amount of regularity to the solution of the equa-
tions in Part I, later in the thesis more regularity of the solution will be required. The proof
of the following theorem follows from the classical elliptic regularity theory [47].
Theorem 4.12 (Theorem C). .
I. Suppose for m  0, we have
g 2 Hm+1(
) and f 2 L2(0; T ;Hm(
)) then
(ut; w) + (r  z; w) = (f; w) 8w 2 L2(
) (4.70)
(z; v)  (u;r  v) = 0 8v 2 V 0(
) (4.71)
u(0) = g (4.72)
ru  n = 0 on   (4.73)
has a weak solution with
u 2 L2(0; T ;Hm+2(
)) z 2 L2(0; T ;Hm+1(
)):
u 2 L1(0; T ;Hm+1(
)) z 2 L1(0; T ;Hm(
)):





2 L2(0; T ;Hm 2L(
)) for L = 0; 1; :::; k   1
then the system (4.70),(4.71),(4.72),(4.73) has a weak solution with
dku
dtk












2 L1(0; T ;Hm 2 2(k 1)(
)):
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4.4 THE NONLINEAR WEAK MIXED SYSTEM
In this section, we will establish the fact that the representative system of equations in
mixed form has a weak solution. No published analysis exists for this particular system of
equations in the weak mixed form. Analysis has been done in the weak form (but not the
weak mixed form) by A. Boy [20] on the following system:
@u1
@t
 r  (D1ru1   u1ru2) = 0 (4.74)
@u2
@t
 r  (D2ru2) = C1u1 + C2u2 (x; t) 2 
 (0; T ] (4.75)
ru1  n = 0 and ru2  n = 0 on  : (4.76)
As can be seen, the system in the Boy paper has the nonlinearity in the advection term but
lacks the nonlinear functions f1 and f2 that appear in our system (see (4.77),(4.78) below).
For that reason, the analysis of our system will be more dicult. Furthermore, the fact that
our analysis will done in the weak mixed form, makes the work here somewhat dierent than
the work in the Boy paper.
4.4.1 Development and Proof of nonlinear Theorems
As noted previously, we will consider the representative system:
@u1
@t
 r  (D1ru1   u1ru2) = f1(u1; u2) (4.77)
@u2
@t
 r  (D2ru2) = f2(u1; u2) (x; t) 2 
 (0; T ] (4.78)
ru1  n = 0 and ru2  n = 0 on   (4.79)
u1(x; 0) = u
0
1(x); u2(x; 0) = u
0
2(x); x 2 
:
We assume that D is suciently smooth, so that the theory from the last section applies.
Let,
z1 =  D1ru1 and z2 =  D2ru2 (4.80)
So, D 11 z1 =  ru1 and D 12 z2 =  ru2: (4.81)
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Multiplication by test functions and integration in 
 gives,
(u1t ; w)  (r  (D 12 z2u1); w) + (r  z1; w) = (f1; w) 8w 2 W (4.82)
(u2t ; w) + (r  z2; w) = (f2; w) 8w 2 W (4.83)
(D 11 z1; v) =  (ru1; v)) (D 11 z1; v) = (u1;r  v)  hu1; v  ni  8v 2 V 0 (4.84)
(D 12 z2; v) =  (ru2; v)) (D 12 z2; v) = (u2;r  v)  hu2; v  ni  8v 2 V 0 (4.85)
where
W = L2(
) V = H(div; 
)) V 0 = V \ fv : v  n = 0 on  g:
The last term in each of (4.84) and (4.85) is zero by the denition of V 0. Then the weak
mixed formulation of (4.77), (4.78), and (4.79) may be stated as :
Find u1; u2 2 W and z1; z2 2 V 0 such that
(u1t ; w)  (r  (D 12 z2u1); w) + (r  z1; w) = (f1; w) 8w 2 W (4.86)
(u2t ; w) + (r  z2; w) = (f2; w) 8w 2 W (4.87)
(D 11 z1; v) = (u1;r  v) 8v 2 V 0 (4.88)
(D 12 z2; v) = (u2;r  v) 8v 2 V 0 (4.89)
We will rst prove that solution to this system (4.86), (4.87), (4.88),(4.89) exists under
certain regularity assumptions on f1; f2. Then we will prove that these regularity assump-
tions hold for each of the equations in Part I of the NEC PDE system.
Assumption 1. For all 1 2 L2(0; T ;H2(
)) and 2 2 L2(0; T ;H3(
)) we have f2(1; 2) 2
L2(0; T ;H2(
)).
Assumption 2. For all 1 2 L2(0; T ;H2(
)) and 2 2 L2(0; T ;H3(
)) we have f1(1; 2) 2
L2(0; T ;H1(
)) and f2(1; 2) 2 L2(0; T ;H2(
)).
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Theorem 4.13 (Existence and Regularity for second set of equations). For any
u1 2 L2(0; T ;H2(
)), under Assumption 1, the system
(u2t ; w) + (r  z2; w) = (f2(u1; u2); w) 8w 2 W (4.90)
(D 12 z2; v) = (u2;r  v) 8v 2 V 0 (4.91)
u2(x; 0) = u
0
2(x) x 2 
:
such that f2 is Lipschitz continuous has a solution (u2; z2) such that
u2 2 L2(0; T ;H4(
)) z2 2 L2(0; T ;H3(
)):
u2t 2 L2(0; T ;H2(
)) z2t 2 L2(0; T ;H1(
)):
z2 2 L1(0; T ;H2(
)) r  z2 2 L1(0; T ;H1(
)):
Proof. Let u1 2 L2(0; T ;H2(
)) be xed. For any u2 2 L2(0; T ;H3(
)) by Assump-
tion 1, f2(u1; u2) 2 L2(0; T ;H2(
)). Then by the Theorem 4.12 developed in the previous
section, the linearized form of (4.90) and (4.91),
(2t ; w) + (r   2; w) = (f2(u1; u2); w) (4.92)
(D 12  2; v) = (2;r  v) (4.93)
has a solution 2 2 L2(0; T ;H4(
))  2 2 L2(0; T ;H3(
)).
d2=dt 2 L2(0; T ;H2(
)) d 2=dt 2 L2(0; T ;H1(
))
(Note that since u2 2 L2(0; T ;H3(
)) then z2 2 L2(0; T ;H2(
)).)
So, the above denes a mapping M such that:
M : (u2; z2)! (2;  2)
M : (L2(0; T ;H3(
)); L2(0; T ;H2(
)))! (L2(0; T ;H4(
)); L2(0; T ;H3(
))):
Now, since H4 is compactly imbedded in H3 and H3 is continuously imbedded in H2 then
by the Aubin-Lions Compactness Criteria, Theorem 4.9.
fu2 2 L2(0; T ;H4(
) : u2t 2 L2(0; T ;H2(
)g
is compactly imbedded into L2(0; T ;H3(
)):
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Now, since H3 is compactly imbedded in H2 and H2 is continuously imbedded in H1 then
by the Aubin-Lions Compactness Criteria, Theorem 4.9.
fz2 2 L2(0; T ;H3(
) : z2t 2 L2(0; T ;H1(
)g
is compactly imbedded into L2(0; T ;H2(
)):
Then by Schauder's Fixed Point Theorem 4.2, the mapping, M has a xed point. Thus,
there exists a solution, (u2; z2), to (4.92),(4.93) and
u2 2 L2(0; T ;H4(
)) z2 2 L2(0; T ;H3(
)): (4.94)
Now that a solution has been established, we may claim the additional regularity from
Theorem 4.12:
z2 2 L1(0; T ;H2(
)) r  z2 2 L1(0; T ;H1(
)):Q.E.D.
Strategy for proving that the system (4.86), (4.87),(4.88), and (4.89) has a so-
lution. Before stating the next theorem, which gives the existence of the solution of (4.1),






solution eu2; ez2 to
second equation.
!
Use the eu2; ez2
just found and u1; z1
to nd a solution 1;  1
to rst equation.
!
The result is a solution
(1;  1,eu2; ez2)
to the linearized system.
The above denes a mapping:
T : (u1; u2; z1; z2)  ! (1;  1 eu2; ez2): (4.95)
It will, then be proved that this mapping has a xed point.
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Theorem 4.14 (Existence and Regularity for the coupled equations). Consider the
system of equations,
(u1t ; w)  (r  (D 12 z2u1); w) + (r  z1; w) = (f1(u1; u2); w) 8w 2 W (4.96)
(u2t ; w) + (r  z2; w) = (f2(u1; u2); w) 8w 2 W (4.97)
(D 11 z1; v) = (u1;r  v) 8v 2 V 0 (4.98)
(D 12 z2; v) = (u2;r  v) 8v 2 V 0 (4.99)
u1(x; 0) = u
0
1(x); u2(x; 0) = u
0
2(x); x 2 
:
under Assumption 2, and if f1 and f2 are Lipschitz continuous then the system
(4.96),(4.97),(4.98), and (4.99) has a solution (u1; u2; z1; z2) such that
u1 2 L2(0; T ;H3(
)); u2 2 L2(0; T ;H4(
));
z1 2 L2(0; T ;H2(
)); z2 2 L2(0; T ;H3(
)):
Proof. Re-write (4.96),(4.97),(4.98), and (4.99) as
(u1t ; w) + (r  z1; w) = (f1(u1; u2); w) + (r  (D 12 z2u1); w) 8w 2 W (4.100)
(u2t ; w) + (r  z2; w) = (f2(u1; u2); w) 8w 2 W (4.101)
(D 11 z1; v) = (u1;r  v) 8v 2 V 0 (4.102)
(D 12 z2; v) = (u2;r  v) 8v 2 V 0 (4.103)
Linearize by
(1t ; w) + (r   1; w) = (f1(u1; u2); w) + (r  (D 12 z2u1); w) (4.104)
(2t ; w) + (r   2; w) = (f2(u1; u2); w) 8w 2 W (4.105)
(D 11  1; v) = (1;r  v) (4.106)
(D 12  2; v) = (2;r  v) 8v 2 V 0 (4.107)
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and choose
u1 2 L2(0; T ;H2(
)); u2 2 L2(0; T ;H3(
));
z1 2 L2(0; T ;H1(
)); z2 2 L2(0; T ;H2(
)):
Then by Theorem 4.13,(4.105) and (4.107) has a solution
u2 2 L2(0; T ;H4(
)) z2 2 L1(0; T ;H3(
)) r  z2 2 L1(0; T ;H2(
))
u2t 2 L2(0; T ;H2(
)) z2t 2 L2(0; T ;H1(
)):












) + k(r D 12 z2)u1kH1(








) + k(r D 12 z2)ru1k2L2(
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+kD 12 z24u1k2L2(
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) is bounded). Therefore,
f 1 2 L2(0; T ;H1(
)) and by Assumption 2 we have f2 2 L2(0; T ;H2(
)):
Then by the Theorem 4.12 from the previous section, the linearized system
(4.104),(4.105),(4.106), and (4.107) has a solution
1 2 Q = L2(0; T ;H3(
)) (4.108)
2 2 Q = L2(0; T ;H4(
)) (4.109)
 1 2 Q = L2(0; T ;H2(
)) (4.110)
 2 2 Q = L2(0; T ;H3(
)): (4.111)
We will the use these spaces to dene the space Q,
Q := L2(0; T ;H3(
)) L2(0; T ;H4(
)) L2(0; T ;H2(
)) L2(0; T ;H3(
)):
Recall that we chose,
u1 2 L2(0; T ;H2(
)); u2 2 L2(0; T ;H3(
));
z1 2 L2(0; T ;H1(
)); z2 2 L2(0; T ;H2(
)):
We will the use these spaces to dene the space QW,
QW := L2(0; T ;H2(
)) L2(0; T ;H3(
)) L2(0; T ;H1(
)) L2(0; T ;H2(
))
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The above denes a mapping T such that:
T : (u1; u2; z1; z2)! (1; 2;  1;  2)
T : QW ! Q:
Since H4 is compactly imbedded in H3 and H3 is continuously imbedded in H2
and
Since H3 is compactly imbedded in H2 and H2 is continuously imbedded in H1, then by the
Aubin-Lions Compactness Criteria, Theorem 4.9. Q is compactly imbedded into QW .
Thus, T is a continuous mapping T such that:
T : Q! Q:
Then by Schauder's Fixed Point Theorem 4.2, the mapping, T has a xed point. Thus,
there exists a solution, (u1; u2; z1; z2), to this system the system (4.100),(4.101),(4.102), and
(4.103) with regularity given by (4.108),(4.109),(4.110), and (4.111). Based on this regularity,
we have, in particular that,
u1 2 L2(0; T ;H3(
)); u2 2 L2(0; T ;H4(
));
z1 2 L2(0; T ;H2(
)); z2 2 L2(0; T ;H3(
)):
Now that a solution has been established, we may claim the additional regularity from
Theorem 4.12:
z1 2 L1(0; T ;H2(
)) r  z1 2 L1(0; T ;H1(
));
z2 2 L1(0; T ;H3(
)) r  z2 2 L1(0; T ;H2(
)):
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4.4.2 Uniqueness Mixed Weak Solution
Now that it has been shown that a solution exists to the Part I equations, it is necessary to
prove the uniqueness of that solution:
(u1t ; w)  (r  (D 12 z2u1); w) + (r  z1; w) = (f1(u1; u2); w) (4.112)
(u2t ; w) + (r  z2; w) = (f2(u1; u2); w) 8w 2 W (4.113)
(D 11 z1; v) = (u1;r  v) (4.114)
(D 12 z2; v) = (u2;r  v) 8v 2 V 0 (4.115)








2) is another solution.
Take the dierence between the two solutions:
((u1   u1)t; w) + (r  (z1   z1); w)
= (f1(u1; u2)  f1(u1; u2); w)
+(r  (D 12 (z2u1   z2u1); w) (4.116)
((u2   u2)t; w) + (r  (z2   z2); w)
= (f2(u1; u2)  f2(u1; u2); w) (4.117)
(D 11 (z1   z1); v)  (u1   u1;r  v) = 0 (4.118)
(D 12 (z2   z2); v)  (u2   u2;r  v) = 0 (4.119)
First Bound
Consider (4.117) and (4.119). Take the derivative with respect to t of (4.119)
((u2   u2)t; w) + (r  (z2   z2); w)
= (f2(u1; u2)  f2(u1; u2); w) (4.120)
(D 12 (z2   z2)t; v)  ((u2   u2)t;r  v) = 0 (4.121)
Set w = z2   z2 and v = (u2   u2)t
((u2   u2)t; (u2   u2)t) + (r  (z2   z2); (u2   u2)t)
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= (f2(u1; u2)  f2(u1; u2); (u2   u2)t) (4.122)
(D 12 (z2   z2)t; z2   z2)  ((u2   u2)t;r  (z2   z2)) = 0 (4.123)
Substitute (4.123) into (4.122) and use the Cauchy-Schwarz inequality (theorem 4.7) and
the fact that f2 is Lipschitz,





k(D 1=22 (z2   z2)k2
 (Cku1   u1k+ Cku2   u2k)k(u2   u2)tk: (4.124)









k(D 1=22 (z2   z2)k2
 Cku1   u1k2 + Cku2   u2k2: (4.125)
Multiply by 2 and then integrate from 0 to t,Z t
0




ku1   u1k2 + C
Z t
0
ku2   u2k2 + k(D 1=22 (z2   z2)k2(0): (4.126)
Second Bound
Consider (4.117)
((u2   u2)t; w) + (r  (z2   z2); w)
= (f2(u1; u2)  f2(u1; u2); w)
set w = r  (z2   z2)
((u2   u2)t;r  (z2   z2)) + (r  (z2   z2);r  (z2   z2))
= (f2(u1; u2)  f2(u1; u2);r  (z2   z2)):
Rearranging,and using the fact that f2 is Lipschitz,
kr  (z2   z2)k2  (k(u2   u2)tk+ Cku1   u1k+ Cku2   u2k)kr  (z2   z2)k:
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Dividing,
kr  (z2   z2)k  k(u2   u2)tk+ Cku1   u1k+ Cku2   u2k:
Square, integrate from 0 to t, and use (4.126)Z t
0




ku1   u1k2 + C
Z t
0
ku2   u2k2: (4.127)
This bound will be used shortly.
Now, consider again (4.116),(4.117),(4.118),(4.119) and set w = u1   u1 and v = z2   z2 to
get,
((u1   u1)t; u1   u1) + (r  (z1   z1); u1   u1)
= (f1(u1; u2)  f1(u1; u2); u1   u1)
+(r  (D 12 (z2u1   z2u1); u1   u1) (4.128)
((u2   u2)t; u2   u2) + (r  (z2   z2); u2   u2)
= (f2(u1; u2)  f2(u1; u2); u2   u2) (4.129)
(D 11 (z1   z1); z1   z1) = (u1   u1;r  (z1   z1)) (4.130)
(D 12 (z2   z2); z2   z2) = (u2   u2;r  (z2   z2)) (4.131)
Substitute (4.130) into (4.128 ), use the Lipschitz continuity of f1, and use the Cauchy-





ku1   u1k2 + kD 1=21 (z1   z1)k2 = (f1(u1; u2)  f1(u1; u2); u1   u1)
+(f1(u1; u

2)  f1(u1; u2); u1   u1)
+(r  (D 12 (z2u1   z2u1 + z2u1   z2u1); u1   u1)






















ku2   u2k2 +
C
2"1
ku1   u1k2 + Cku1   u1k2
+kr D 12 z2kL1(





(r  (u1   u1))(u1   u1)
+ku1kL1(






D 12 (z2   z2)(u1   u1):
Substitute r  (u1   u1) = D 11 (z1   z1), then use the Cauchy-Schwarz inequality (theorem





ku1   u1k2 + kD 1=21 (z1   z1)k2
 C"1
2
ku2   u2k2 +
C
2"1
ku1   u1k2 + Cku1   u1k2
+Cku1   u1k2 + C
"2
2




































kD 11 (z1   z1)k2 + C
"3
2
kr D 12 (z2   z2)k2 + C
"4
2






ku1   u1k2 + Ck(z1   z1)k2
 C"1
2
















kz1   z1k2 + C
"3
2
kr  (z2   z2)k2 + C
"4
2
k(z2   z2)k2: (4.132)





ku2   u2k2 + kD 1=22 (z2   z2)k2 = (f2(u1; u2)  f2(u1; u2); u2   u2)
+(f2(u1; u

2)  f2(u1; u2); u2   u2)
 (Cju2   u2j; ju2   u2j) + (Cju1   u1j; ju2   u2j)
 C"5
2
ku1   u1k2 +
C
2"5







ku2   u2k2 + Ck(z2   z2)k2  Cku1   u1k2 + Cku2   u2k2: (4.133)





(ku1   u1k2 + ku2   u2k2) + Ck(z1   z1)k2 + Ck(z2   z2)k2
 (C + C"1
2
















kz1   z1k2 + C
"3
2
kr  (z2   z2)k2 + C
"4
2
k(z2   z2)k2: (4.134)





(ku1   u1k2 + ku2   u2k2) + Ck(z1   z1)k2 + Ck(z2   z2)k2
 Cku1   u1k2 + Cku2   u2k2 + Ckr  (z2   z2)k2: (4.135)
Integrate 0 to t,
(ku1   u1k2(t) + ku2   u2k2(t)) + C
Z t
0




(ku1   u1k2 + ku2   u2k2) + C
Z t
0
kr  (z2   z2)k2
+ku1   u1k2(0) + ku2   u2k2(0): (4.136)
Use (4.127)
(ku1   u1k2(t) + ku2   u2k2(t)) + C
Z t
0




(ku1   u1k2 + ku2   u2k2) + Ck(D 1=22 (z2   z2)k2(0)
+ku1   u1k2(0) + ku2   u2k2(0): (4.137)
Use the Gronwall Inequality, theorem 4.8,
(ku1   u1k2(t) + ku2   u2k2(t)) + C
Z t
0
(k(z1   z1)k2 + k(z2   z2)k2)
 ect(k(D 12 (z2   z2)k2(0) + ku1   u1k2(0) + ku2   u2k2(0)): (4.138)
Obviously, if the initial conditions are the same, the solutions will be the same.
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4.4.3 Application of the Theorems to Individual Equations
In this section we will show that the right hand side functions in each equation of our PDE
system meets the hypothesis of theorems 4.13 and 4.14.
Bounds on various terms. There are certain terms that will occur repeatedly throughout
the thesis. Therefore, it will be helpful to nd bounds on these terms and then refer to these
bounds whenever necessary.
It is obvious by inspection of the Part I NEC equations that the variables in the equations
will always be non-negative. In any case, we list that fact as an assumption:
Assumption 3 ec; b; m; ma; c; ca; NO; na; d  0: (4.139)
Now, consider the terms





Note that since kRca  0 and our assumption (4.139), we have
0 < R(ca)  1 and T = R(ca)c  0: (4.140)







Q = R(ca)(kcamanana +ma + kcamadd): (4.142)
Since kcamana > 0 , kcamad > 0, (4.139) and (4.140) we have
















 mq1a  C and 0 
nq1a
1 + (na=na)q1
 nq1a  C (4.145)
for some C > 0.
Consider
kbb=(1 + b=): (4.146)
Since kb > 0;  > 0, and (4.139) ,
kbb=(1 + b=)  kb  C (4.147)
for some C > 0.
Application to Individual Equations. Now, we apply theorems 4.13 and 4.14 to the
individual equations of the NEC model. The equations will be analyzed in the ideal or-
der, i.e., so that the regularity established for some equations may be used in the subsequent































































 (Ck2d + Ckdckd)kdk2L2(0;T ;H2(
)) + Ck2dcT:
So, fd 2 L2(0; T ;H2(
)). Then by Theorem 4.13, (4.148), has a solution with









































So, fNO 2 L2(0; T ;H2(
)). Then by Theorem 4.13, (4.150), has a solution with











fca :=  kcaca + sca + kcaP
Q
1 +Q







  kcaca + sca + kcaP Q1 +Q2H2(
):






) + CT  Ckcak2L2(0;T ;H2(
)) + CT:
So, fca 2 L2(0; T ;H2(
)). Then by Theorem 4.13, (4.152), has a solution with





  r Dcrc =  kcc+R(ca)(kcmama + kcnana) R(ca)(knccn+ kmccm) (4.154)
Dene
fc :=  kcc+R(ca)(kcmama + kcnana) R(ca)(knccn+ kmccm)
choose c 2 L2(0; T ;H3(
)) and choose m;ma; n; na 2 L2(0; T ;H2(
)):
(Since each of these are solutions to their respective PDEs, we can say,
c 2 L1(0; T ;H2(
)) and m;ma; n; na 2 L1(0; T ;H1(









































































































































































































































In the last inequality above, the L4(





































Now, note that since c 2 L1(0; T ;H2(
)), we have rc 2 L1(0; T ;L6(
)) and since m;n 2
L2(0; T ;H2(
)) we have rm;rn 2 L2(0; T ;L6(
)) and 4m;4n 2 L2(0; T ;L6(
)). All of






































































































Each of the terms above are bounded. So, fc 2 L2(0; T ;H2(
)). Then by Theorem
4.13, (4.154), has a solution with





  r Dbrb = kbgb(1  b=bmax)  kbb=(1 + b=)
 R(ca)(kbmamab+ kbnanab)  kppb (4.156)
Dene
fb := kbgb(1  b=bmax)  kbb=(1 + b=) R(ca)(kbmamab+ kbnanab)  kppb
choose b 2 L2(0; T ;H3(
)) and choose ma; na 2 L2(0; T ;H2(
)):
(Since each of these are solutions to their respective PDEs, we can say,
b 2 L1(0; T ;H2(
)) and ma; na 2 L1(0; T ;H1(
)), see theorem 4.12.)
It has been shown that b  0, therefore, it is reasonable to assume that




























Notice that in each term, at least one of the functions is in L2(0; T ;H3(
)). Therefore, using
techniques similar to those in the analysis of the cytokine equation above, it can be shown
that all of the terms in (4.157) are bounded. So, fb 2 L2(0; T ;H2(
)). Then by Theorem
4.13, (4.156), has a solution with





= km(mmax  m) R(ca)(kmbbm+ kmccm+ kmddm): (4.159)
Dene
fm := km(mmax  m) R(ca)(kmbbm+ kmccm+ kmddm):
Choose m 2 L2(0; T ;H2(
)). Then m 2 L1(0; T ;H1(
)), see theorem 4.12.
In the following we will use the results (4.149),(4.155),and (4.158)
(i.e. d; c; b 2 L2(0; T ;H4(
)) which implies d; c; b 2 L1(0; T ;H3(























) + C: (4.160)
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Notice that in each term, at least one of the functions is in L2(0; T ;H3(
)). Therefore, using
techniques similar to those in the analysis of the cytokine equation above, it can be shown
that all of the terms in (4.160) are bounded. So, fm 2 L2(0; T ;H2(
)). Then by Theorem
4.13, (4.159), has a solution with
m 2 L2(0; T ;H4(
)): (4.161)




  r  (Dmarma   macmarc  mabR(ca)marb)
=  kmama +R(ca)(kmbbm+ kmccm+ kmddm): (4.162)
@c
@t
  r Dcrc =  kcc+R(ca)(kcmama + kcnana) R(ca)(knccn+ kmccm) (4.163)
@b
@t
  r Dbrb = kbgb(1  b=bmax)  kbb=(1 + b=)
 R(ca)(kbmamab+ kbnanab)  kppb (4.164)
Dene
fc :=  kcc+R(ca)(kcmama + kcnana) R(ca)(knccn+ kmccm);
fma :=  kmama +R(ca)(kmbbm+ kmccm+ kmddm) and
fb := kbgb(1  b=bmax)  kbb=(1 + b=) R(ca)(kbmamab+ kbnanab)  kppb:
Choose ma 2 L2(0; T ;H2(
)).
In the following we will use the results (4.149),(4.155),(4.158), and (4.161) (i.e. d; c; b;m 2
L2(0; T ;H4(
)) and since each of these are solutions to their respective PDEs, we can say,
d; c; b;m 2 L1(0; T ;H3(

























Using techniques similar to those in the analysis of the cytokine equation above, it can be
shown that all of the terms in (4.165) are bounded. So, fma 2 L2(0; T ;H1(
)). We have
already shown that fc; fb 2 L2(0; T ;H2(
)) (see cytokines and bacteria above). So, we
may apply Theorem 4.14 to conclude that the system (4.162), (4.163),(4.164) has a solution
with
ma 2 L2(0; T ;H3(
)) c 2 L2(0; T ;H4(
))
b 2 L2(0; T ;H4(
)): (4.166)
Activated Neutrophil Equation (coupled with the cytokine equation)
@na
@t
  r  (Dnarna   nacnarc)
=  knana +R(ca)(knccn+ knddn): (4.167)
@c
@t
  r Dcrc =  kcc+R(ca)(kcmama + kcnana) R(ca)(knccn+ kmccm) (4.168)
Dene
fna :=  knana +R(ca)(knccn+ knddn) and
fc :=  kcc+R(ca)(kcmama + kcnana) R(ca)(knccn+ kmccm):
Choose n; na 2 L2(0; T ;H2(
)).
In the following we will use the results (4.149) and (4.155) (i.e. d; c 2 L2(0; T ;H4(
)) and























Using techniques similar to those in the analysis of the cytokine equation above, it can be
shown that all of the terms in (4.169) are bounded. So, fna 2 L2(0; T ;H1(
)) and we
have already shown that fc 2 L2(0; T ;H2(
)) (see cytokines above). So, we may apply
Theorem 4.14 to conclude that the system (4.167), (4.168) has a solution with
na 2 L2(0; T ;H3(
)) c 2 L2(0; T ;H4(
)): (4.170)
4.4.4 Conclusion
We have shown that Theorems 4.13 and 4.14 may be applied the eight equations in PDE
Analysis - Part I. Therefore, the system of eight equations in PDE Analysis - Part
I has a weak solution.
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4.5 ANALYSIS OF PDES IN PART II
In this section we will consider the epithelial equation. This equation is challenging for
two reasons. First of all, it contains a dicult nonlinearity in its diusion term. Secondly,
the diusion term may go to zero in some cases. In this case, this PDE is a degenerate
parabolic PDE.
In this chapter, we will consider both the non-degenerate and the degenerate cases for this
PDE. Existence analysis will be provided for the non-degenerate case. An equation similar
to, but much more general than our equation, has been analyzed by by Alt and Luckhaus
[4]. However, the analysis in that paper is much more complicated than we require. So, the
analysis presented here will use many ideas from Alt and Luckhaus as well as from other
works but will be tailored to the specics in our equation.
For the degenerate case of our equation, many cite Alt and Luckhaus, although their
paper does not fully address the degeneracy the occurs. For example, Arbogast, Wheeler,
and Zhang [7] rely heavily on the Alt and Luckhaus paper. We will do the same here.
Therefore, there will be no need to do new analysis for the degenerate case in this thesis.
Instead, the degenerate case will be covered by making appropriate references to the work of
the aforementioned authors. After referencing the work of these authors, further regularity
will be established for the mixed weak form of the degenerate case.
Epithelial Equation
The epithelial equation is given by:
@ec
@t




e2c + (ec;max   ec)2
u(ec; b) =  (b)rec (4.172)
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ka(na; c; b) :=
(na + kecnacc+ kecnabb)
:45
(na + kecnacc+ kecnabb)
:45 + ((na;max   na) + kecnac(cmax   c) + kecnab(bmax   b)):45
(b) =
(bmax   b)q
(bmax   b)q + bq :
Equation (4.171) may be written as
@ec
@t
 r  ((ec)(b)rec) = fec(ec; b; na): (4.173)
Dene
fec(ec; b; na) := kpec(1  ec=ec;max) Aec
where
A = ka(na; c; b):
Note that (4.173) equation may be written as
@ec
@t
 r  ((b)rP (ec)) = fec(ec; b; na) (4.174)






rP (ec) = @P
@ec
rec + rxP (ec) = (ec)rec +
Z ec
0
rx(s) ds = (ec)rec:
Note that ec may, at times, be zero. B(ec) and rP (ec) will be zero whenever ec = 0. Such
a PDE is classied as a degenerate parabolic PDE. So, analysis of the epithelial equation
will include two cases: 1) the non-degenerate case (conditions under which ec will never
be zero) and 2) the degenerate case (conditions under which ec may be zero).
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4.5.1 Properties that apply to both the Non-Degenerate Case and the Degen-
erate Case
Before considering these two cases note that the right hand side of the epithelial equation
(4.173) is Lipschitz Continuous in both the degenerate case and the non-degenerate case:
jfec(ec2)  fec(ec1)j = j kp(ec2   ec1) 
1
ec;max
(e2c2   e2c1) A(ec2   ec1)j
=
 kp(ec2   ec1)  1ec;max (e2c2   e2c1) A(ec2   ec1)

=
 kp   1ec;max (ec2 + ec1) A
jec2   ec1 j:
Since ec is bounded, we have
jfec(ec2)  fec(ec1)j  Cjec2   ec1 j: (4.175)
For some C  0.









So, we can say
kP (ec)k2  keck2: (4.176)
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4.5.2 Properties that apply only to Non-Degenerate Case
Now, we consider the non-degenerate case. Once again consider (4.173). Note that na; kecnac;
c; kecnab; b; ka0 are all non-negative. If we assume that we have na;max  na; cmax 
c; bmax  b then
0  A  1:
So, (4.173) may be written as
@ec
@t
 r  (a(rec; ec)) = fec(ec; b; na) (4.177)
where a(rec; ec) = (ec)(b)rec.
Several properties for this epithelial equation, such as monotonicity and a growth condi-
tion, can only be proved for the non-degenerate case. This is done here:
For the non-degenerate case, there exists some constants ec;min; min such that:
ec  ec;min > 0 8ec and (b)  min > 0 8b:
So, obviously, we also have max = 1. Then
(ec) =
e2c




e2c;min + (ec;max   ec;min)2
:
So, we may say,
min :=
e2c;min
e2c;min + (ec;max   ec;min)2
> 0
and, obviously max = 1. Then
0 < min < max = 1:
Monotonicity
In the non-degenerate case, we can establish monotonicity of a(; )
(a(rec1 ; ec)  a(rec2 ; ec))  (rec1  rec2)




In the non-degenerate case, we can also establish a growth condition. First note that
jfec(ec)j = jkpec(1  ec=ec;max) Aecj  kpjecjj(1  ec=ec;max)j+ jAecj
 Cjecj+ Cjecj  2Cjecj:
Therefore,
jfec(ec)j2  C1e2c : (4.178)
Also, we have
a(rec; ec) = (ec)(b)rec  maxmaxrec  Crec:
Therefore,
ja(rec; ec)j2  Cjrecj2: (4.179)
So, by (4.178) and (4.179), there exists a C such that,
ja(rec; ec)j2 + jfec(ec)j2  C







Lower Bound for kP (ec)k













for some C > 0.
So, we can say
kP (ec)k  Ckeck:
123
Holder Continuity
Holder continuity is usually required in order to establish uniqueness of the solution. Unfor-
tunately, it is not possible to establish Holder continuity for the epithelial equation, even in
the non-degenerate case. First note that
(ec1)  (ec2) =
e2c1




e2c2 + (ec;max   ec2)2
=
(ec1   ec2)(e2c;max(ec1 + ec2)  2ec;maxec1ec2)
(e2c1 + (ec;max   ec1)2))(e2c2 + (ec;max   ec2)2)
 (ec1   ec2)(1
2(ec1 + ec2)  2(1)ec1ec2)
(:5)(:5)
 (ec1   ec2)(ec1 + ec2)
:25
:
In the above, we used the fact that ec1 ; ec2  0 and ec;max = 1. Now, the best we can get is
(ec1)(b)rec   (ec2)(b)rec 
(b)rec (ec1   ec2)(ec1 + ec2):25
:
Thus, we cannot establish Holder Continuity.
4.6 NON-DEGENERATE CASE - EXISTENCE OF A SOLUTION.
Here, it will be demonstrated that a solution exists in the non-degenerate case, (4.177). (In
this analysis, various standard techniques for analyzing PDEs will be used. Most of the
techniques used here may be found in Evans [38] and/or Alt and Luckhaus [4].) Consider
the orthonormal basis f ig1i=1 for H1(










 r  (a(rec; ec)) = fec(ec; b; na)





+ (a(recm ; ecm);r j) = (fecm ;  j)
for j = 1; :::;m.
Consider the time interval [0; h] for small h. Use backward Euler in place of the time





+ (a(recm ; ecm);r j) = (fecm ;  j):





+ (a(recm ; ecm);r j) = (fecm ;  j):







+ (a(recm ; ecm);r j)   (fecm ;  j):
































(jCj2   kecm(0)k2) + c1jCj2   c2jCj2:
Note that kecm(0)k2 is known. Now choose C so that jCj2   kecm(0)k2 > 0, then take h
small enough so that the right hand side becomes positive. Thus, vm(C) C  0 for jCj > 0.
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Therefore, there exists a solution C to vm(C) = 0 on the interval [0; h]. So, there exists a
solution at t = h. Therefore, the same process may be applied to the interval [h; h+ k], etc.
In this way, a solution may be established on [0; T ].





+ (a(recm ; ecm);r j) = (fecm ;  j) for j = 1; :::;m: (4.182)
Now, it will be necessary to bound the sequences that appear in this equation. Using (4.182)


























fecmg1m=1 is bounded in L1(0; T ;L2(
)) (4.184)
frecmg1n=1 is bounded in L2(0; T ;L2(
)): (4.185)
Putting (4.184) and (4.185) together, we have
fecmg1m=1 is bounded in L2(0; T ;H1(
)): (4.186)
In order to bound the time derivative consider,
(ecmt ;  j) + (a(recm ; ecm);r j) = (fecm ;  j):
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Here we will use a technique given by Evans [38]. Fix v 2 H1(
) with kvkH1(
)  1 where
v = v1 + v2: With the the property v1 2 spanf jgmj=1 and (v2;  j) = 0 for all j. Now,
(ecmt ; v
1) + (a(recm ; ecm);rv1) = (fecm ; v1)
(ecmt ; v
1) =  (a(recm ; ecm);rv1) + (fecm ; v1):
Since ecmt is in spanf jgmk=1, we have (ecmt ; v2) = 0: So,
(ecmt ; v) =  (a(recm ; ecm);rv1) + (fecm ; v1)
j(ecmt ; v)j  krecmkkrv1k + kfecmkkv1k
j(ecmt ; v)j  krecmkkv1kH1(
) + kfecmkkv1kH1(
)
j(ecmt ; v)j  krecmk + kfecmk:
Since this last inequality is true for all kvkH1(
)  1, we have
kecmtkH 1(
















is bounded in L2(0; T ;H 1(
)): (4.187)
In view of (4.179), we can say a(recm ; ecm)  Cjrecm j. So, by (4.185),
fa(recm ; ecm)g1m=1 is bounded in L2(0; T ;L2(
)): (4.188)








and fa(recm ; ecm)g1m=1 are all bounded.
Therefore, there exists a subsequence fecmLg1L=1 of fecmg1m=1 that converges weakly to
some y1 and such that f ddtecmLg1L=1 converges weakly to some y2.
Now, we must show that y2 is the weak derivative of y1. That is, we must show that (see








for all test functions h 2 C1c (0; T ).
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In order to deal with the convergence of a(), we will use the method of Browder and
Minty. This method is usually applied to elliptic equations (see for example Zhang [142])
but here we will apply it to our parabolic equation following the same basic steps.
By (4.184),(4.185),(4.187), and (4.188) we know that there exists an a such that





+ (a;r j) = (fecm ;  j): (4.189)





+ (a;rw) = (fecm ; w): (4.190)
From monotonicity we have
((a(recm ; ecm)  a(rw;w)); (recm  rw))  0
(a(recm ; ecm);recm)  (a(recm ; ecm);rw)
 (a(rw;w);recm) + (a(rw;w)  rw))  0: (4.191)
Now, recall (4.183),















  (a(recm ; ecm);rw)
 (a(rw;w);recm) + (a(rw;w);rw))  0:








 (a(rw;w);rec) + (a(rw;w);rw))  0: (4.193)








Substituting this into (4.193), we get
(a;rec)  (a;rw)  (a(rw;w);rec) + (a(rw;w);rw))  0
(a;rec  rw) + (a(rw;w);rw  rec)  0
(a   a(rw;w);rec  rw)  0:
For v 2 H1(







































Now take limn!1 1=n, to get
(a   a(rec; ec);rv)  0: (4.195)
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Using the same v 2 H1(








































Now take limn!1 1=n, to get
 (a   a(rec; ec);rv)  0 or (a   a(rec; ec);rv)  0: (4.196)
Putting (4.195) and (4.196) together we see that
(a   a(rec; ec);rv) = 0: (4.197)
Thus, we conclude that a = a(rec; ec). So, we can substitute a = a(rec; ec) into (4.189).
For the rest, we will follow the standard techniques used for a linear parabolic PDE, (see,
for example, Evans page 357 [38]):





where ci for i = 1; :::;m is a function of t only.
Multiply
(ecmt ;  j) + (a(recm ; ecm);r j) = (fecm ;  j) (4.199)
by cj to get:
(ecmt ; cj j) + (a(recm ; ecm);rcj j) = (fecm ; cj j):
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Summing j = 1; :::; P gives:
(ecmt ; w) + (a(recm ; ecm);rw) = (fecm ; w):Z T
0
(ecmt ; w) +
Z T
0




Substituting subsequences fecmLg and take limits to nd thatZ T
0







Thus, there exists a weak solution in the non-degenerate case,(4.177).
4.7 DEGENERATE CASE
As noted above, the degenerate case has been studied by others. Therefore, we will begin
by noting the results of these authors. After that, we will establish some regularity.
Near the beginning of this chapter, we put our equation into the form of (4.177) so that
we may apply the work done by Alt and Luckhaus [4] as well as work by Otto [105]. We will
use these works directly as well as Arbogast, Wheeler, and Zhang's [7] interpretation of the
work by Alt and Luckhaus.
Alt and Luckhaus analyze the following PDE in their paper.
@bj(u)
@t
 r  (aj(b(u);ru)) = f j(b(u)): (4.200)













In our case, b(ec) is just the identity function. So,




Therefore, our growth condition, (4.180), may be written as:
ja(rec; ec)j2 + jfec(ec)j2  C(1 + jrec1 j2 +	(ec)): (4.201)
4.7.1 Degenerate Case - Regularity
Therefore, based on the conditions listed above and the assumption that for (4.174) we have
fec 2 L2f(0; T ];L2(
)g, then according to Arbogast, Wheeler, and Zhang [7], the epithelial
PDE has a solution with:
ec 2 L1f(0; T ];L1(
)g @ec
@t
2 L2f(0; T ];H 1(
)g (4.202)
z 2 L2f(0; T ]; (L2(
))3g: (4.203)
Now, we will attempt to establish higher regularity as well as regularity for the mixed weak
form.
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4.7.2 Degenerate Case - Regularity of the Weak Form
Note that (4.202) and (4.203) give the minimum regularity for the degenerate parabolic
equation. It is normal to assume more regularity than what is given in (4.202). In fact,
Arbogast, Wheeler, and Zhang [7] themselves as well as well as Woodward and Dawson [141]
assume more regularity than (4.202). Here, the following regularity will be assumed:
ec 2 L2f(0; T ];L2(
)g @ec
@t
2 L2f(0; T ];L2(
)g: (4.204)
Using this as a starting point, more regularity will be developed here.
To begin with, we may use (4.176) along with (4.204) to get:






 r  ((b)rP (ec)) = fec(ec; b; na): (4.206)
Set  1z = rP (ec). Then the weak form becomes
(ect ; w) + (r  z; w) = (fec(ec; b; na); w) (4.207)
( 1z; v) = ( rP (ec); v): (4.208)
In the weak system (4.207), (4.208), integrate the second equation (4.208) by parts then set
w = P (ec) and v = z:
(ect ; P (ec)) + (r  z; P (ec)) = (fec ; P (ec))
( 1z; z) = (P (ec);r  z):
Combining these and applying the Cauchy-Schwarz inequality (theorem 4.7) we get,
Ckzk2  kfeckkP (ec)k+ kectkkP (ec)k:
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Apply Cauchy's inequality (theorem 4.6):
kzk2  C

kfeck2 + kP (ec)k2 + kectk2

: (4.209)



























z 2 L2(0; T ; (L2(
))3): (4.210)
In (4.207), set w = r  z
(ect ;r  z) + (r  z;r  z) = (fec ;r  z):
Apply the Cauchy-Schwarz inequality (theorem 4.7)
kr  zk2  kfeckkr  zk+ kectkkr  zk:
Apply Cauchy's inequality (theorem 4.6) and hide terms:





Integrate (4.211) Z t
0







using (4.204), we have
r  z 2 L2(0; T ;L2(
)): (4.213)
In (4.207), set w = ec
(ect ; ec) + (r  z; ec) = (fec ; ec):
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keck2 = kfeckkeck+ kr  zkkeck:
Cauchy's inequality (theorem 4.6):
d
dt
keck2 = Ckfeck2 + Ckeck2 + Ckr  zk2:










kr  zk2 + keck2(0):









kr  zk2 + keck2(0)
!
: (4.214)
Using (4.178) and (4.213) in (4.214) gives
ec 2 L1(0; T ;L2(
)): (4.215)
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4.8 ANALYSIS OF PDES IN PART III









ZO1max(1  ZO1=zec)  kZNNO  ZO1
where






We will show that this equation has a solution by explicitly nding the solution.








ZO1 = :03ec + 2ect
We will solve this using an integrating factor
I = e
R t





























We proved in PDE Analysis Part I that NO 2 W 1;2([0; T ];L2(
)) thus I is just a number.
Therefore, (4.216) implies that the ZO equation has a solution and (4.217) indicates that
ZO 2 L1(
). In the appendix it is demonstrated that the right hand side functions of
each of the equations in Part I are Lipschitz continuous. Lipschitz continuity is a necessary
condition for the numerical analysis that will done later in the thesis.
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Equation Regularity Equation Regularity
Bacteria b 2 L2(0; T ;H3(
)) Nitric NO 2 L2(0; T ;H3(
))
Oxide
Macrophage m 2 L2(0; T ;H3(
)) Tight ZO1 2 C([0; T ];H2(
))
Junction
Activated ma 2 C([0; T ];H2(
)) Activated na 2 C([0; T ];H2(
))
Macrophage Neutrophils
Cytokine c 2 L2(0; T ;H3(
)) Damage d 2 L2(0; T ;H3(
))
ec 2 L1(0; T ;L2(
))
Anti-In. ca 2 L2(0; T ;H3(
)) Epithelial ect 2 L2(0; T ;H 1(
))
Cytokine z 2 L2(0; T ; ((L2(
))3)
r  z 2 L2(0; T ;L2(
))
Table 2: Regularity of the weak solution of the NEC PDE system.
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5.0 FINITE ELEMENT ANALYSIS (CONVERGENCE ANALYSIS FOR
THE FULLY COUPLED SYSTEM OF PDES)
The purpose of this chapter is to prove that the numerical approximation of the PDE system
using the mixed nite element method will converge to the true solution of the system. For
each of the ten variables in our NEC PDE system, it will be demonstrated that the numerical
error v   vh is bounded, in some norm, by some power of h multiplied by a constant not
dependent upon h. This will then show that as h gets smaller, the numerical error gets
smaller and convergence to the true solution may be achieved.
Much of the analysis in this chapter, particularly the analysis for the eight equations in
Part I of the PDE system, is new. In particular, no mixed nite element method exists for
the particular type of coupled equations, represented by the system (5.6), (5.7) below. There
does exist a mixed nite element method for a similar equation:
@u1
@t
 r  (u1u2  Dru1) = f1(u1) (5.1)
(see Dawson[30] and Vassilev and Yotov[133]). However, in (5.1) u2 is the Darcy velocity,
a known quantity, which makes the analysis somewhat simpler than what we will have
in our system, (5.6), (5.7) below. On the other hand, Epshteyn and Kurganov [37] do
a nite element analysis on a coupled system very similar to our system. However, they
use a discontinuous Galerkin nite element method, a method somewhat dierent from the
mixed nite element method. Furthermore, the solution in this last paper was found in an
unbounded space, we will nd the solution in a bounded space. In any case, our analysis
will utilize some ideas from each of the above mentioned papers.
A mixed nite element method for an equation very similar to the equation in Part II
has been done in Arbogast, Wheeler, and Zhang [7]. Therefore, the analysis of the Part II
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equation will not add anything new to the general knowledge. Yet, in order that the analysis
for all of the equations in the NEC PDE system are included in this thesis, the analysis for
the Part II equation will be done here. Of course, our analysis will closely follow Arbogast,
Wheeler, and Zhang.
The Part III equation, although unique, does not pose any signicant challenges. The
analysis of the Part III equation is presented below.
The numerical analysis on the NEC PDE system will be done in three parts, according
to the natural grouping of the types of PDEs. This grouping is identical to the grouping
listed in the PDE analysis chapter. For convenience, that listing is repeated here:
Part I. Part I will consist of eight equations: the equations for bacteria, macrophages,








= km(mmax  m) R(ca)(kmbbm+ kmccm+ kmddm)
@ma
@t
  r  (Dmarma   macmarc  mabR(ca)marb)
=  kmama +R(ca)(kmbbm+ kmccm+ kmddm)
@c
@t
  r Dcrc =  kcc+R(ca)(kcmama + kcnana) R(ca)(knccn+ kmccm)
@ca
@t














  r  (Dnarna   nacnarc) =  knana +R(ca)(knccn+ knddn)
@d
@t










Q = R(ca)(kcamanana +ma + kcamadd):
Part II. Part II will consist of the epithelial equation:
@ec
@t
+r  ((ec)u(ec; b)) = kpec(1  ec=ec;max)  ka(na; c; b)ec
where
ka(na; c; b) =
eca(na; c; b)
q0
eca(na; c; b)q0 + [eca(na;max; cmax; bmax)  eca(na; c; b)]q0
eca(na; c; b) = na + kecnacc+ kecnabb
(ec) =
e2c
e2c + (ec;max   ec)2
u(ec; b) =  (b)rec (b) = (bmax   b)
q
(bmax   b)q + bq :









ZO1max(1  ZO1=zec)  kZNNO  ZO1






Note that the tensor D in each of the equations in Part I depends upon the equation in
Part II. In the analysis of this chapter, this dependence will be neglected. The equations
in Part I do not depend at all on the equation in Part III. Therefore, the error bounds for
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the aforementioned eight equations in Part I may be found independently of the equations
in Part II and Part III. These error bounds are derived in Analysis of PDEs in Part I.
Notice that the equation in Part II (the epithelial equation) depends on the equations
from part I but does not depend on the equation in Part III (the tight junction protein
equation). Therefore, error bounds found in part I may be used to bound the error for the
epithelial cells. This study is done in Analysis of PDEs in Part II.
The equation in Part III (the tight junction protein equation) depends upon the equa-
tions in Part I and Part II. Therefore, error bounds found in part I and Part II may be used
to bound the error for the tight junction protein. This study is done in Analysis of PDEs
in Part III.
Strategy for demonstrating convergence. In order to prove convergence of the nu-
merical approximation to the true solution for the NEC PDE system, it will be necessary
to determine the convergence rates in a specic order. First, the convergence rates for the
PDEs in Part I of the PDE system will be determined. It is most logical to analyze the
Part I equations rst because they are not dependent upon the equations in Part II and
III. The convergence rate of the Part I equations will be shown to be in some power of h
in terms of the L2 norm for each of the variables in Part I. Next, the equation in Part II,
the epithelial equation, will be analyzed. This equation is dependent upon three equations
from Part I. Namely, the bacteria, activated neutrophil and cytokine equations. Therefore,
the error bounds found in Part I for these three equations will be used to nd the error
bound for the numerical approximation of the epithelial equation of Part II. However, due
to the fact that the epithelial equation is degenerate parabolic, the numerical error will be
bounded in terms of the H 1 norm. Existing tools do not allow us to bound this error in
any stronger norm. Finally, the equation in Part III, the ZO1 equation, will be analyzed.
The ZO1 equation is dependent upon an equation from Part I, the NO equation, and the
epithelial equation from Part II. Since the numerical error for epithelial equation can only
be bounded in the H 1 norm, it will not be possible to bound the ZO1 error in the L2 norm.
Instead, a bound for the ZO1 error will be found in the H 1 norm. Thus, convergence for
the fully coupled system will be demonstrated in this chapter.
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5.1 CONDITIONS AND NOTATION FOR FEM SECTION.
Let 
 be a bounded domain in Rd where d = 1; 2 or 3. Let (; ) denote the L2(
) inner
product and k  k the L2(
) norm. Dene the spaces
W = L2(
) V = H(div; 
) V 0 = V \ fv : v  n = 0 on  g:
Let h be a quasiuniform family of nite element partitions of 
. Such that for E 2 h,
hE = max
x;y2E
kx  ykRd h = max
hE2h
hE




where E is the diameter of the largest circle (in 3-D, the largest sphere) that will t inside
the element E.
Let Wh; Vh denote mixed nite element approximating subspaces of W and V , respectively,
e.g., the Raviart-Thomas-Nedelec [98], [114] nite element spaces. Let V 0h = Vh \ V 0. Fur-
thermore, we have:
r  Vh = Wh and rhWh  (Wh)n:
(Where rh is the element-wise gradient.) The functions u1 and u2 are approximated by
u1;h 2 Wh and u2;h 2 Wh, respectively. On any element E 2 h, w 2 Wh is a polynomial,
discontinuous across the element boundaries.
In this paper, it will be necessary to utilize two dierent denitions for the normals to
the element boundaries. On each edge, e, in the nite element mesh a xed normal vector,
ne; is assigned. Since this normal is xed, it will be the same no matter which element is
under consideration. Then for any point, x; on each edge, the functions w+(x) and w (x)


















The 'jump' and 'average' terms will be dened in this way:
[w] = w+   w  w = 1
2
(w+ + w ) in 
:
On the boundary,  , we will assign ne so that it points outward. Thus,
[w] = w  w = w  on  :
In this paper, we also dene an outward normal nE on each element boundary. When con-
sidering any particular element, E, this normal will always point outward. Therefore, its
direction will be dierent depending upon the element under consideration.
We must dene the following projections:
1) The "" or Raviart-Thomas projection. There exists a projection operator h :
(H1(
))d ! Vh. If q 2 (H1(
))d then hq 2 Vh and
(r  (hq  q); wh) = 0 8wh 2 Wh: (5.2)
2) The L2 projection. There exists a projection operator Qh : L2(
)!Wh. If u 2 L2(
)
then Qhu 2 Wh and
(Qhu  u;wh) = 0 8wh 2 Wh: (5.3)
3) The 0 projection. If u 2 L2(
) then 0u is the projection of u into piecewise constants
and
(0u  u; 1) = 0: (5.4)
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4) Weighted projection. (The weighted projected will be used in the Part II equations.
)We dene a weighted projection operator Ph : (L2(
))
d ! Vh. If v 2 (L2(
))d then
Phv 2 Vh and
(a(; t)(Phv   v); vh) = 0 8vh 2 Vh: (5.5)
(a(; t) will be dened Part II).
Special Notation. In the following sections, we will use x = x hx and  x = xh hx.
su1 ; su2 ; sz1 ; sz2 are the regularities of u1; u2; z1; z2 respectively in H
s(
).




ru1 ; ru2 ; rz1 ; rz2 are the polynomial degrees of u1; u2; z1; z2 respectively.
Approximation Results: In this paper, the following approximation results will be used,


































for 0  m  :
In the above we have  = min(r + 1; s) and ;1 = min(r + 1; s;1)
where  = u1; u2; z1; or z2 as appropriate.
Inverse Inequalities:
For any polynomial, w, we have
kwk1  Ch 1kwk kwkH1(E)  Ch 1kwkE kwke  Ch 1=2kwkE:
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Trace Inequalities:
kwke  Ch 1=2(kwkE + hkrwkE) krw  nke  Ch 1=2(krwkE + hkr2wkE):
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5.2 FINITE ELEMENT ANALYSIS OF THE PDES IN PART I




 r  (D1ru1   u1ru2) = f1(u1; u2) (5.6)
@u2
@t
 r  (D2ru2) = f2(u1; u2) (x; t) 2 
 (0; T ] (5.7)
ru1  n = 0 and ru2  n = 0 on  ; (5.8)
where T > 0; D1 and D2 are positive denite tensors; f1 and f2 are nonlinear functions of
u1 and u2 but f1 and f2 are each Lipschitz continuous in both u1 and u2, i.e., there exist
constants L11,L12,L21, and L22 such that
jf1(x1; y)  f1(x2; y)j  L11jyjjx1   x2j (5.9)
jf1(x; y1)  f1(x; y2)j  L12jxjjy1   y2j (5.10)
jf2(x1; y)  f2(x2; y)j  L21jyjjx1   x2j (5.11)
jf2(x; y1)  f2(x; y2)j  L22jxjjy1   y2j: (5.12)
(Recall that in chapter 4, it was proven that conditions (5.9) through (5.12) hold for each
and every one of the equations in Part I.)
The initial condition is given by:
u1(x; 0) = u
0




These initial conditions will often be represented by u01 and u
0
2, respectively. In a previous
chapter, it was shown that a unique solution u1; u2 exists.
Mixed Method Formulation
Considering our system (5.6), (5.7), and (5.8) we set
z1 =  D1ru1 and z2 =  D2ru2 (5.13)
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So, D 11 z1 =  ru1 and D 12 z2 =  ru2: (5.14)
Then the weak formulation of (5.6), (5.7), and (5.8) may be stated as :
Find u1; u2 2 W and z1; z2 2 V 0 such that 8w 2 W ,
(u1t ; w)  (r  (u1D 12 z2); w) + (r  z1; w) = (f1; w) (5.15)
(u2t ; w) + (r  z2; w) = (f2; w) (5.16)
and 8v 2 V 0,
(D 11 z1; v) =  (ru1; v)) (D 11 z1; v) = (u1;r  v)  hu1; v  ni  (5.17)
(D 12 z2; v) =  (ru2; v)) (D 12 z2; v) = (u2;r  v)  hu2; v  ni  (5.18)
The last term in each of (5.17) and (5.18) is zero by the denition of V 0.
The second term on the left hand side of (5.15) may be written as
 (r  (u1D 12 z2); w) =  
X
E
(r  (u1D 12 z2); w)E:
Integration by parts on this term gives,










2 z2)  ne; [w])e (5.19)
If we substitute (5.19) into (5.15), we get 8w 2 W and 8v 2 V










2 z2)  ne; [w])e
+(r  z1; w) = (f1; w) (5.20)
(u2t ; w) + (r  z2; w) = (f2; w) (5.21)
(D 11 z1; v) = (u1;r  v) (5.22)
(D 12 z2; v) = (u2;r  v): (5.23)
Discrete Formulation
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For the discrete formulation, we replace u1; u2 by u1;h; u2;h 2 Wh; respectively and replace
z1; z2 by z1;h; z2;h 2 V 0h , respectively, with the exception that on each edge e, replace u1 and





2 z2;h  ne < 0
u+1;h if D
 1
2 z2;h  ne  0:
At t = 0 we dene u1h(x; 0) := u
0
1h
2 Wh and u2h(x; 0) := u02h 2 Wh by
(u01h   u01; w) = 0 and (u02h   u02; w) = 0 8w 2 Wh: (5.24)
This results in the following discrete formulation. Find u1;h; u2;h 2 Wh and z1;h; z2;h 2 Vh
such that for all w 2 Wh and for all v 2 Vh,






((D 12 z2;h)  ne; uup1;h[w])e
+(r  z1;h; w) = (f1(u1;h; u2;h); w) (5.25)
(u2;ht ; w) + (r  z2;h; w) = (f2(u1;h; u2;h); w) (5.26)
(D 11 z1;h; v) = (u1;h;r  v) (5.27)
(D 12 z2;h; v) = (u2;h;r  v): (5.28)
Stability and Error Analysis. In order to do the stability and error analysis for the mixed
nite element method we will use an approach that is similar to Epshteyn and Kurganov
[37]. This approach involves creating a set, a mapping, and then nding a xed point of
the mapping within the set. However, Epshteyn and Kurganov used the approach on a
discontinuous Galerkin application. We will be using this approach on the mixed method.
Therefore, the details in our analysis will be completely dierent from the details in the
Epshteyn and Kurganov paper. Furthermore, Epshteyn and Kurganov were satised nding
their solution in an unbounded set. We will prove that our solution exists in a bounded set,
a somewhat more lengthy process.
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(u1 ; u2 ; z1 ; z2) 2 H1([0; T ]) \ L1([0; T ]) \
Wu1h Wu2h Wz1h Wz2h ; (5.29)
such that there exists constants Cu1 ; Cu2 ; Cz1 ; Cz2 ; and
sup
t2[0;T ]
ku1  Qhu1k2  Cu11;
sup
t2[0;T ]
ku2  Qhu2k2  Cu22;Z T
0
kz1   hz1k2  Cz13;
sup
t2[0;T ]
kz2   hz2k2 +
Z T
0
kz2   hz2k2 +
Z T
0
kr  (z2   hz2)k2  Cz24
)
where
1 = 2 = 3 = 4 = h
2u1 2 + h2u2 + h2z1 + h2z2 2
For T  et, the value et is dened in the lines immediately after (5.77) below.
Wu1h ;Wu2h ;Wz1h ;Wz2h are the respective Raviart-Thomas spaces of piecewise polynomials of
degrees ru1 ; ru2 ; rz1 ; rz2 , respectively. Cu1 ; Cu2 ; Cz1 ; Cz2 are positive constants independent of
h and the polynomial degrees ru1 ; ru2 ; rz1 ; rz2 .
Note that the constants, Cu1 ; Cu2 ; Cz1 ; Cz2 , are determined below.
Denition. Dene the norm























Theorem 5.1. For any (u1 ; u2 ; z1 ; z2) 2 S there exist positive constantsMu1 ;Mu2 ;Mz1 ;Mz2










Proof. See Epshteyn and Kurganov [37]), proof of Lemma 5.1.
Linearized System:
In this section, the linearized system will be considered. Dene A on S as follows:
8(u1 ; z1 ; u2 ; z2) 2 S A(u1 ; z1 ; u2 ; z2) = (u1L ; z1L ; u2L ; z2L )















L ) is the solution to the linearized system:








z2  ne; u1Lup [w])e
+(r  z1L ; w) = (f1(u1L ; u2); w) (5.31)
(D 11 
z1
L ; v) = (
u1
L ;r  v) (5.32)
((u2L )t; w) + (r  z2L ; w) = (f2(u1 ; u2L ); w) (5.33)
(D 12 
z2
L ; v) = (
u2
L ;r  v) (5.34)
where u2 ; z2 2 S (these were inserted to linearize the system).







L ) = A(
u1 ; z1 ; u2 ; z2).
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Proof. The proof follows from the analysis in section 4.3.1.
Before moving on to the next theorem, the following notation will be introduced:
u1 = u1  Qhu1 u1 = u1L  Qhu1
u2 = u2  Qhu2 u2 = u2L  Qhu2
z1 = z1   hz1  z1 = z1L   hz1
z2 = z2   hz2  z2 = z2L   hz2.
Theorem 5.3. For any (u1 ; z1 ; u2 ; z2) 2 S we have A(u1 ; z1 ; u2 ; z2) 2 S.
(That is, A : S ! S.)







L ) = A(
u1 ; z1 ; u2 ; z2). Now, it will be proven that this unique






L ) is, in fact, in S.
Note that the exact solution satises:






((D 12 z2)  ne; uup1 [w])e
+(r  z1; w) = (f1(u1; u2); w) (5.35)
(D 11 z1; v)  (u1;r  v) = 0 (5.36)
(u2t ; w) + (r  z2; w) = (f2(u1; u2); w) (5.37)
(D 12 z2; v)  (u2;r  v) = 0 (5.38)
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Add and subtract Qhu1,Qhu2,hz1 or hz2 in the appropriate terms of (5.35),(5.36), (5.37)
and (5.38) to get:
(u1t  Qhu1t +Qhu1t ; w) +
X
E




((D 12 z2)  ne; (uup1  Qhuup1 +Qhuup1 )[w])e + (r  (z1   hz1 +hz1); w)
 (f1(u1; u2)  f1(Qhu1; u2) + f1(Qhu1; u2); w) = 0
(D 11 (z1   hz1 +hz1); v)  (u1  Qhu1 +Qhu1;r  v) = 0
(u2t  Qhu2t +Qhu2t ; w) + (r  (z2   hz2 +hz2); w)
 (f2(u1; u2)  f2(u1; Qhu2) + f2(u1; Qhu2); w) = 0
(D 12 (z2   hz2 +hz2); v)  (u2  Qhu2 +Qhu2;r  v) = 0
Use u1 = u1  Qhu1,etc.















((D 12 z2)  ne; (u1up)[w])e
 (r  z1 ; w) + (f1(u1; u2)  f1(Qhu1; u2); w) (5.39)
(D 11 hz1; v)  (Qhu1;r  v) =  (D 11 z1 ; v) + (u1 ;r  v) (5.40)
(Qhu2t ; w) + (r  hz2; w)  (f2(u1; Qhu2); w) =
 ((u2)t; w))  (r  z2 ; w) + (f2(u1; u2)  f2(u1; Qhu2); w) (5.41)
(D 12 hz2; v)  (Qhu2;r  v) =  (D 12 z2 ; v) + (u2 ;r  v) (5.42)
Subtract (5.39) from (5.31) and (5.40) from (5.32) to get:









z2  neu1Lup ; [w])e  
X
e
(D 12 z2  neQhuup1 ; [w])e
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((D 12 z2)  ne; (u1up)[w])e
+(r  z1 ; w)  (f1(u1; u2)  f1(Qhu1; u2); w)
(D 11 (
z1
L   hz1); v)  (u1L  Qhu1;r  v) = (D 11 z1 ; v)  (u1 ;r  v)
And Subtract (5.41) from (5.33) and (5.42) from (5.34) to get:
((u2L )t  Qhu2t ; w) + (r  (z2L   hz2); w)  (f2(u1 ; u2L )  f2(u1; Qhu2); w) =
((u2)t; w)) + (r  z2 ; w)  (f2(u1; u2)  f2(u1; Qhu2); w) (5.43)
(D 12 (
z2
L   hz2); v)  (u2L  Qhu2;r  v) = (D 12 z2 ; v)  (u2 ;r  v) (5.44)
Add and subtract the appropriate terms:


























z2  ne; Qhuup1 [w])e
+(r  (z1L   hz1); w)  (f1(u1L ; u2); w) + (f1(Qhu1; u2); w)






((D 12 z2)  ne; (u1up)[w])e
 (f1(u1; u2)  f1(Qhu1; u2); w) (5.45)
(D 11 (
z1
L   hz1); v)  (u1L  Qhu1;r  v) = (D 11 z1 ; v) (5.46)
((u2L )t  Qhu2t ; w) + (r  (z2L   hz2); w)  (f2(u1 ; u2L ); w) + (f2(u1 ; Qhu2); w)
 (f2(u1 ; Qhu2); w) + (f2(u1; Qhu2); w) =




L   hz2); v)  (u2L  Qhu2;r  v) = (D 12 z2 ; v) (5.48)
Set w = u1 in (5.45), v =  z1 in (5.46), w = u2 in (5.47), and v =  z2 in (5.48)to get:


























z2  ne; Qhuup1 [u1 ])e
+(r   z1 ; u1)  (f1(u1L ; u2); u1) + (f1(Qhu1; u2); u1)






((D 12 z2)  ne; (u1up)[u1 ])e
 (f1(u1; u2)  f1(Qhu1; u2); u1) (5.49)
(u1 ;r   z1) = (D 11 (z1L   hz1);  z1)  (D 11 z1 ;  z1) (5.50)
((u2L )t  Qhu2t ; u2) + (r  (z2L   hz2); u2)  (f2(u1 ; u2L ); u2) + (f2(u1 ; Qhu2); u2)
 (f2(u1 ; Qhu2); u2) + (f2(u1; Qhu2); u2) =  (f2(u1; u2)  f2(u1; Qhu2); u2) (5.51)
(u2 ;r   z2) = (D 12 (z2L   hz2);  z2)  (D 12 z2 ;  z2) (5.52)




























z2  ne(u1up + u1down); [u1 ])e
Note that whenever D 12 
z2  ne  0













(jD 12 z2  nej; [u1 ]2)e
Note that whenever D 12 
z2  ne < 0


















(jD 12 z2  nej; [u1 ]2)e
Note that whenever D 12 




u1 ] = (u1;+ + u1; )(u1;+   u1; ) = (u1;+)2   (u1; )2
Note that whenever D 12 





















z2  ne; (u1;+)2   (u1; )2)e

































(jD 12 z2  nej; [u1 ]2)e
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u2); w)  (f1(Qhu1; u2); w)
+(f1(Qhu1; 








((D 12 z2)  ne; (u1up)[u1 ])e
 (f1(u1; u2)  f1(Qhu1; u2); u1) + (D 11 z1 ;  z1) (5.54)





ku2k2 + kD 1=22  z2k2 = (f2(u1 ; u2L )  f2(u1 ; Qhu2); u2)
+(f2(
u1 ; Qhu2)  f2(u1; Qhu2); u2)










































(r D 12 z2 ; (u1)2)E + (f1(u1L ; u2)  f1(Qhu1; u2); u1)
+(f1(Qhu1; 
u2)  f1(Qhu1; u2); u1)  (f1(u1; u2)  f1(Qhu1; u2); u1)
+(u2u1 ; u1)  (Qhu1(u2   u2); u1)  (u1u2; u1) + (D 11 z1 ;  z1) (5.56)
We will consider the third and fourth terms on the right hand side of (5.56). Integrating by






















































z2   hz2))  ne(Qhuup1  Qhu 1 ); u1; )E (5.57)
We will consider the fth and sixth terms on the right hand side of (5.56). Integrating by




















































z2)  ne(Qhu 1  Qhuup1 ); u1; )E (5.58)

































































u2)  f1(Qhu1; u2); u1)
+(f1(Qhu1; 
u2)  f1(Qhu1; u2); u1)
 (f1(u1; u2)  f1(Qhu1; u2); u1)
+(u2u1 ; u1)  (Qhu1(u2   u2); u1)
 (u1u2; u1) + (D 11 z1 ;  z1)






ku2k2 + kD 1=22  z2k2 = (f2(u1 ; u2L )  f2(u1 ; Qhu2); u2)
+(f2(
u1 ; Qhu2)  f2(u1; Qhu2); u2)  (f2(u1; u2)  f2(u1; Qhu2); u2)
+(D 12 
z2 ;  z2) =: T19 + T20 + T21 + T22 (5.60)
Bounds on the terms T1; T2; :::





















hu1ku1ksu1 ;Eku1k  C
X
E
hu1ku1kE  "1Ch2u1 + 1
"1
ku1k2




































Ck(r D 12 (z2   hz2)kEku1kE
 "3kr  ((z2   hz2)k2 + 1
"3
ku1k2










































 "5h2u1;1 2Ck((z2   hz2))k2 + 1
"5
ku1k2
In the same way:






((r  (D 12 z2))Qhu1; u1)E 
X
E









2z2kr  z2k2E +
1
"7



















 "8Ch2z2kz2k2 + 1
"8
































 "9h2z2 2C + 1
"9
ku1k2
In the same way,



















u2)  f1(Qhu1; u2); u1)  kf1(u1L ; u2)  f1(Qhu1; u2)kku1k
 (jf1(u1L ; u2)  f1(Qhu1; u2)j; ju1 j)  (Cju2 jju1L  Qhu1j; ju1 j)
 Cku2k1ku1k2  Cku1k2
T13 = (f1(Qhu1; 
u2)  f1(Qhu1; u2); u1)  CkQhu1k1ku2   u2kku1k
 Cku2  Qhu2 +Qhu2   u2kku1k
 Cku2  Qhu2kku1k+ Chu2ku2ksu2ku1k
 "13Cku2  Qhu2k2 + 2
"13
ku1k2 + "13Ch2u2ku2k2su2
 "13Cku2  Qhu2k2 + 2
"13
ku1k2 + "13h2u2C
T14 = (f1(u1; u2)  f1(Qhu1; u2); u1)  ku2k1ku1  Qhu1kku1k








u2u1 ; u1)  ku2k1ku1k2  Cku1k2
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T16 =  (Qhu1(u2   u2); u1)  kQhu1k1ku2   u2kku1k
 Cku2  Qhu2 +Qhu2   u2kku1k
 Cku2  Qhu2kku1k+ Chu2ku2ksu2ku1k
 "16Cku2  Qhu2k2 + 2
"16
ku1k2 + "16Ch2u2ku2k2su2
 "16Cku2  Qhu2k2 + 2
"16
ku1k2 + "16h2u2C
















h2z1 + "18k z1k2
T19 = (f2(
u1 ; u2L )  f2(u1 ; Qhu2); u2)
 ku1k1ku2L  Qhu2kku2k  Cku2k2
T20 = (f2(
u1 ; Qhu2)  f2(u1; Qhu2); u2)
 kQhu2k1

ku1  Qhu1k+ kQhu1   u1k

ku2k
 Cku1  Qhu1kku2k+ Chu1ku1ksu1ku2k
 "20ku1  Qhu1k2 + C
"20
ku2k2 + "20h2u1ku1k2su1
T21 =  (f2(u1; u2)  f2(u1; Qhu2); u2)  ku1k1ku2  Qhu2kku2k











Put T1; T2; T3;   ; T16; T17; T18 into (5.59) assuming that h < 1 and noting that r  1, and





























































h2z1 + ("7 + "8)Ch
2z2 + ("9 + "10)Ch
2z2 2
+("13 + "16)Cku2  Qhu2k2 +




















































Since u1 2 L2(0; T ;H3(
)); then ru1 2 L2(0; T ;H2(
)) and ru1 2 L2(0; T ;L1(
)) we
have u1;1 = 1: Using this information, multiplying (5.61) by 2, choosing "18 carefully,











































kr  ((z2   hz2)k2 + ku1k(0)









































kr  ((z2   hz2)k2
#






















("13 + "16)CCu1 + ("4 + "5 + "6 + "3)CCz2















C(h2u1 2 + h2u2 + h2z1 + h2z2 2)
+

("13 + "16)CCu1 + ("4 + "5 + "6 + "3)CCz2


















+("4 + "5 + "6 + "3)CCz2
!#
(h2u1 2 + h2u2 + h2z1 + h2z2 2): (5.62)
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Dene Cu1 := 2C
 + 2.
Dene Cz1 := 2C
=C 0 + 2=C 0.
Now, if "3; "4; "5; "6; "13; "16 are chosen small enough then there exists a t1 such that for t  t1
the sum of the constants on the right hand side of (5.62) is less than Cu1 and less than C
0Cz1 .
Thus, (5.62) gives us a bound for ku1k2(t); R t
0
k z1k2. We will also require bounds for
ku2k2(t); R t
0
k z2k2; kr   z2k. This will be done below.
Equation for ku2k2(t)
Put T19; T20; T21; T22 into (5.60) assuming that h < 1 and noting that r  1, and D1; D2
















h2z2kz2k2 + "20ku1  Qhu1k2 (5.63)



























ku1  Qhu1k2 + ku2k2(0)





























Dene Cu2 := 2C
 + 2Cu1 .










Go back to (5.43) and (5.44), noting that (u2 ;r  v) = 0,(r  z2 ; w) = 0 ((u2)t; w)) = 0:
((u2L )t  Qhu2t ; w) + (r  (z2L   hz2); w)  (f2(u1 ; u2L )  f2(u1; Qhu2); w) =
 (f2(u1; u2)  f2(u1; Qhu2); w) (5.65)
(D 12 (
z2
L   hz2); v)  (u2L  Qhu2;r  v) = (D 12 z2 ; v) (5.66)
Take the derivative with respect to t of (5.66), then (5.65) and (5.66) become:
(u2t ; w) + (r   z2 ; w)  (f2(u1 ; u2L )  f2(u1; Qhu2); w) =
 (f2(u1; u2)  f2(u1; Qhu2); w) (5.67)
(D 12 
z2
t ; v)  (u2t ;r  v) = (D 12 z2t ; v) (5.68)






kD 1=22  z2k2 + ku2t k2 = (D 12 z2t ;  z2) + (f2(u1 ; u2L ); u2t )  (f2(u1 ; Qhu2); u2t )
+(f2(
u1 ; Qhu2); 
u2






kD 1=22  z2k2 + ku2t k2  kz2t kk z2k+ ku1k1ku2L  Qhu2kku2t k






k z2k2 + C
"1





ku1  Qhu1k2 + C
"3


































Multiply by 2 and integrate with respect to t, and apply the Gronwall Inequality, theorem
4.8:
k z2k2 + 2C
Z t
0



























kr   z2k2
Go back to (5.67):
(u2t ; w) + (r   z2 ; w)  (f2(u1 ; u2L )  f2(u1; Qhu2); w) =
 (f2(u1; u2)  f2(u1; Qhu2); w)
Set w = r   z2 :
kr   z2k2  ku2t kkr   z2k+ kf2(u1 ; u2L )  f2(u1; Qhu2)kkr   z2k
+kf2(u1; u2)  f2(u1; Qhu2)kkr   z2k
kr   z2k2  ("1 + "2 + "3 )kr   z2k2 + Cku2t k2 + Cku2k2 + Cku1  Qhu1k2
+Ch2u1 + Ch2u2
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kr   z2k2  C
Z t
0














Substitute (5.69) into (5.70):
Z t
0






































Combine equations (5.72), (5.69) and (5.71),





































































































































Apply the Gronwall Inequality, theorem 4.8, take the sup of both sides and use the denition
of the space S,





























Noting that all factors on the right hand side are constants except for h, there exists a


















CIIC + CIIICu1 + C
IV

h2u1 2 + h2u2 + h2z1 + h2z2 2
#
(5.76)
Since ku2k2 is non-negative, we can say
sup
t2[0;T ]
k z2k2  sup
t2[0;T ]

ku2k2 + k z2k2

Therefore, from (5.76), we can say
sup
t2[0;T ]












CIIC + CIIICu1 + C
IV

h2u1 2 + h2u2 + h2z1 + h2z2 2
#
(5.77)
Dene Cz2 := C
IIC + CIIICu1 + C
IV .
Now, the constants in the space S have been dened. Furthermore, we can now deneet = min (t1; t2). (Note that t1 is dened immediately after (5.62) and t2 is dened immedi-
ately after (5.64)).






L ) 2 S:
170
Now, prove that the mapping, A, has a xed point in S.
Theorem 5.4. The mapping A is continuous.
Proof. Choose any sequence





k(u1n ; u2n ; z1n ; z2n )  (u1 ; u2 ; z1 ; z2)kS = 0:






L ) dened by
(5.31),(5.32),(5.33),(5.34):










z2  neu1Lup ; [w])e
+(r  z1L ; w)  (f1(u1L ; u2); w) = 0 (5.78)
(D 11 
z1
L ; v) = (
u1
L ;r  v) (5.79)
(u2Lt ; w) + (r  z2L ; w)  (f2(u1 ; u2L ); w) = 0 (5.80)
(D 12 
z2
L ; v) = (
u2
L ;r  v): (5.81)



























n  neu1L;nup ; [w])e
+(r  z1L;n; w)  (f2(u1L;n; u2n ); w) = 0 (5.82)
(D 11 
z1
L;n; v) = (
u1
L;n;r  v) (5.83)
(u2L;nt ; w) + (r  
z2




L;n; v) = (
u2
L;n;r  v): (5.85)
Subtract (5.82),(5.83).(5.84), and (5.85) from (5.78),(5.79).(5.80), and (5.81), respectively













z2   u1L;nupD 12 z2n )  ne; [w])e
+(r  (z1L   z1L;n); w)  (f1(u1L ; u2)  f1(u1L;n; u2n ); w) = 0
(D 11 (
z1
L   z1L;n); v) = (u1L   u1L;n;r  v)
(u2Lt   u2L;nt ; w) + (r  (
z2
L   z2L;n); w)  (f2(u1 ; u2L )  f2(u1n ; u2L;n); w) = 0
(D 12 (
z2
L   z2L;n); v) = (u2L   u2L;n;r  v):
Add and subtract the appropriate terms to get:

















z2   u1L;nupD 12 z2n )  ne; [w])e
+(r  (z1L   z1L;n); w)  (f1(u1L ; u2)  f2(u1L;n; u2n ); w) = 0
(D 11 (
z1
L   z1L;n); v) = (u1L   u1L;n;r  v)
(u2Lt   u2L;nt ; w) + (r  (
z2
L   z2L;n); w)  (f2(u1 ; u2L )  f2(u1n ; u2L;n); w) = 0
(D 12 (
z2
L   z2L;n); v) = (u2L   u2L;n;r  v):
Dene bu1L := u1L   u1L;n bu2L := u2L   u2L;n bz1L := z1L   z1L;n bz2L := z2L   z2L;n
and set w = bu1L and v = bz1L and rearrange the terms:
(bu1Lt ; bu1L ) +X
E
(bu1L D 12 z2 ;rbu1L )E +X
e












z2   z2n )  ne; [bu1L ])e
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+(r  bz1L ; bu1L )  (f1(u1L ; u2)  f2(u1L;n; u2n ); bu1L ) = 0 (5.86)
(D 11 bz1L ; bz1L ) = (bu1L ;r  bz1L ) (5.87)
(bu2Lt ; bu2L ) + (r  bz2L ; bu2L )  (f2(u1 ; u2L )  f2(u1n ; u2L;n); bu2L ) = 0 (5.88)
(D 12 bz2L ; bz2L ) = (bu2L ;r  bz2L ): (5.89)







(bu1L D 12 z2 ;rbu1L )E +X
e




























n   z2)  ne; [u1L;n])e





kbu2L k2 + kD 1=21 bz2L k2 = (f2(u1 ; u2L )  f2(u1n ; u2L;n); bu2L ): (5.91)
Consider the seventh term on the left hand side of (5.90) (note that z2   z2n has already













































Note that whenever D 12 (
z2




)[u1L ] = (
u1;+












L;n   u1; L;n ) = ((u1;+L;n )2   (u1; L;n )2):
Also, whenever D 12 (
z2




)[u1L ] = (
u1; 











L;n   u1; L;n ) = ((u1;+L;n )2   (u1; L;n )2):




















n   z2)  ne; (u1;+L;n )2   (u1; L;n )2)e:






















u1L;n(r D 12 (z2n   z2))  ru1L;n dx:
Do the same things to the third term on the left hand side of (5.92). After making these





kbu1L k2   12X
E
(r D 12 z2 ; (bu1L )2)E + 12X
e










(jD 12 (z2n   z2)  nej; [bu1L;n]2)e
























kbu1L k2 + 12X
e
(jD 12 z2  nej; [bu1L ]2)e + 12X
e
(jD 12 (z2n   z2)  nej; [bu1L;n]2)e



















(r D 12 z2 ; (bu1L )2)E + 12X
E
(r D 12 (z2n   z2); (u1L;n)2)E
 Ckbu1L k2ku2k1;
 + Cku1L;nk1;
k(u2   u2n )kkbu1L k (5.93)
+Cku1L;nk1;






z2   z2n )  ne; [u1L ])e
+Ckr D 12 z2k1;







kbu2L k2 + kD 1=21 bz2L k2  Ckbu2L k2ku1k1;
 + Cku2L;nk1;
k(u1   u1n )kkbu2L k (5.94)
Since u1 ; u2 ; u1L;n;




kbu1L k; kr(u1L )k; kr D 12 z2k1;





(kbu1L k2 + kbu2L k2) + 12X
e






(jD 12 (z2n   z2)  nej; [bu1L;n]2)e + kD 1=21 bz1L k2 + kD 1=21 bz2L k2




CkD 12 (z2   z2n )kek[u1L ]ke + Ckr D 12 (z2n   z2)k:
Consider the fth term on the right hand side of (5.95):
X
e
CkD 12 (z2   z2n )kek[u1L ]ke 
X
e
CkD 12 (z2   z2n )ke(k(u1L )E
1






CkD 12 (z2   z2n )kE(ku1L kE1 + ku1L kE2) 
X
E
CkD 12 (z2   z2n )k: (5.96)
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(kbu1L k2 + kbu2L k2) + 12X
e






(jD 12 (z2n   z2)  nej; [bu1L;n]2)e + kD 1=21 bz1L k2 + kD 1=21 bz2L k2







kD 12 (z2   z2n )k+ Ckr D 12 (z2n   z2)k: (5.97)
Multiply (5.97) by 2 and integrate from 0 to t,










(jD 12 (z2n   z2)  nej; [bu1L;n]2)e + 2Z t
0






(kbu1L k2 + kbu2L k2) + C Z t
0
k(u1   u1n )k+ C
Z t
0
















kr D 12 (z2n   z2)k+ kbu1;t=0L k2 + kbu2;t=0L k2:
Apply the Gronwall Inequality, theorem 4.8,










(jD 12 (z2n   z2)  nej; [bu1L;n]2)e + 2Z t
0






k(u1   u1n )k+ C
Z t
0
k(u2   u2n )k+ C
Z t
0









kD 12 (z2   z2n )k+ C
Z t
0








k(u1n ; u2n ; z1n ; z2n )  (u1 ; u2 ; z1 ; z2)kS = 0 (5.99)
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the right hand side of (5.98) goes to zero. Thus, we have
kbu1L k2 + kbu2L k2 + 2 Z t
0
kD 1=21 bz1L k2 + 2Z t
0
kD 1=21 bz2L k2 = 0:
In a similar way, it can be shown that for 5.99
sup
t2[0;T ]
kbz2L k+ Z t
0






kA(u1n ; u2n ; z1n ; z2n )  A(u1 ; u2 ; z1 ; z2)kS = 0:
By this, the continuity of A is established. Q.E.D.
Theorem 5.5. The mapping A is compact.
Proof. Let
(u1 ; u2 ; z1 ; z2) 2 S:






L ), dened by
(5.31),(5.32),(5.33),(5.34):










z2  neu1Lup ; [w])e
+(r  z1L ; w)  (f1(u1L ; u2); w) = 0 (5.100)
(D 11 
z1
L ; v) = (
u1
L ;r  v) (5.101)
(u2Lt ; w) + (r  z2L ; w)  (f2(u1 ; u2L ); w) = 0 (5.102)
(D 12 
z2
L ; v) = (
u2
L ;r  v): (5.103)
Recall the shift operator Shift(h)f(x) = f(x+ h) where h 2 R3 . If we apply the shift op-
erator to (5.100),(5.101),(5.102),(5.103) and follow the same steps as in the proof of theorem
5.4, we get something similar to (5.98),















kD 1=21 Shift(h)z1L k2 + 2
Z t
0



































kr  (Shift(h)z2)k: (5.106)
Since the functions u2 ; z2 that appear on the right hand side of (5.104),(5.106)are in the
space S, these functions are Lipschitz continuous. Thus we may can conclude that
lim
h!0
kShift(h)u1L k = 0 uniformly:
The same may be said of kShift(h)z2L k, etc. Thus we may apply Kolmogorov-M.Riesz-
Frechet, theorem 4.5, and conclude that the mapping A is compact. Q.E.D.
Therefore, by the Schauder's Fixed Point Theorem - Version 2, theorem 4.3, the mapping A
has at least one xed point in S.
Error Analysis. Based on the previous analysis, we can say,
ku1;h  Qhu1kL1([0;T ];L2(
)) + ku2;h  Qhu2kL1([0;T ];L2(
))














kr  (z2;h   hz2)k2
!1=2
 C(hu1 1 + hu2 + hz1 + hz2 1): (5.107)
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5.3 FINITE ELEMENT ANALYSIS OF THE PDES IN PART II
Recall the epithelial equation:
@ec
@t
+r  ((ec)u(ec; b)) = kpec(1  ec=ec;max)  ka(na; c; b)ec (5.108)
Where
ka(na; c; b) =
eca(na; c; b)
q0
eca(na; c; b)q0 + [eca(na;max; cmax; bmax)  eca(na; c; b)]q0
eca(na; c; b) = na + kecnacc+ kecnabb
(ec) =
e2c
e2c + (ec;max   ec)2
u(ec; b) =  (b)rec (b) = (bmax   b)
q
(bmax   b)q + bq (5.109)
Equation (5.108) may be written as
@ec
@t
 r  ((ec)(b)rec) = (ec; b; na; c) (5.110)
Where
(ec; b; na; c) = kpec(1  ec=emaxc )  ka(na; c; b)ec
This equation may be written as
@ec
@t
 r  ((b)rP (ec)) = (ec; b; na; c) (5.111)





so that rP (ec) = @P
@ec




rx(s) ds = (ec)rec
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Note that ec may, at times, be zero. B(ec) and rP (ec) will be zero whenever ec = 0. There-
fore, (5.111) is a degenerate parabolic PDE.
Assumptions
In the PDE Analysis Part I, it was proven that na; b and c are at least in L
1(
). Fol-
lowing Arbogast, Wheeler, and Zhang [7] as well as Woodward and Dawson [141], we will
assume that:
ec 2 L1((0; T );L1(
)) and ect 2 L2((0; T );H 1(
))
Assume that there exists a constant C0 > 0, independent of time such that
kP (1)  P (2)k2  C0(P (1)  P (2); 1   2) 81; 2 2 L2(
) (5.112)
(This implies, among other things, that P is Lipschitz continuous)
Assume that for the function  we have 81; 2 2 L2(
); 9 C > 0 such that
k(1; b; na; c)  (2; b; na; c)k2  C(P (1)  P (2); 1   2) (5.113)
k(1; b; na; c)  (2; b; na; c)k  Ck1   2k (5.114)
and 8b1; b2 2 L2(
); 9 C > 0
k(; b1; na; c)  (; b2; na; c)k  Ckb1   b2k (5.115)
and 8na1 ; na2 2 L2(
); 9 C > 0
k(; b; na1 ; c)  (; b; na2 ; c)k  Ckna1   na2k (5.116)
and 8c1; c2 2 L2(
); 9 C > 0
k(; b; na; c1)  (; b; na; c2)k  Ckc1   c2k (5.117)
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Let
z =  (b)rP (ec): (5.118)
Note that (b) as given by (5.109) has an inverse, in particular,









Using (5.110),(5.118), and (5.119) we can nd the variational formulation:
hect ; wi+ hr  z; wi = h(ec; b; na; c); wi 8w 2 H10 (
) (5.120)
h 1z; vi + hrP (ec); vi = 0 8v 2 H(
; div) (5.121)
Using Green's,
hect ; wi+ hr  z; wi = h(ec; b; na; c); wi (5.122)
h 1z; vi   hP (ec);r  vi =  hP (ecD); v  ni (5.123)
Where n is normal to the boundary.

















(ec; b; na; c) ds+ ec(0) (5.125)











(ec; b; na; c) ds; w
+
+ hec(0); wi 8w 2 L2(
) (5.126)




Semi-discrete mixed nite element method











(ech ; bh; nah ; ch) ds; wh
+
+ hec(0); whi (5.128)
h 1zh; vhi   hP (ech);r  vhi =  hP (ecD); vh  ni (5.129)
For all wh 2Wh  L2(
) and for all vh 2 Vh  H(
; div)
5.3.1 Analysis of semi-discrete scheme
The following analysis depends heavily on a paper by Arbogast, Wheeler, and Zhang [7].
Let ec be the true solution of the variational form (5.126),(5.127) and ech be the solution of
the semi-discrete form (5.128),(5.129). Subtracting (5.126),(5.127) from (5.128),(5.129), we
get










[(ech ; bh; nah ; ch)  (ec; b; na; c)] ds; wh
!
( 1(zh   z); vh)   (P (ech)  P (ec);r  vh) = 0
Using the notation of Arbogast, Wheeler, and Zhang [7]:
 = zh   z  =
Z t
0




the last two equations become
(ech   ec; wh) +
 





[(ech ; bh; nah ; ch)  (ec; b; na; c)] ds; wh
!
( 1; vh)   (P (ech)  P (ec);r  vh) = 0
182
By (5.2),




[(ech ; bh; nah ; ch)  (ec; b; na; c)]ds; wh)
!
8wh 2Wh (5.130)
(a; vh)  (QhP (ech) QhP (ec);r  vh) = 0 8vh 2 Vh (5.131)
Set wh = QhP (ech) QhP (ec) 2 Wh
Set vh = Ph  = h  + (h   Ph)z 2 Vh this is because Ph zh = h zh = zh
Important! From this point on, we let a =  1.




[(ech ; bh; nah ; ch)  (ec; b; na; c)]ds;QhP (ech) QhP (ec))
!
(a;Ph )  (QhP (ech) QhP (ec);r  Ph ) = 0
Use Ph  = h  + (h   Ph)z




[(ech ; bh; nah ; ch)  (ec; b; na; c)]ds;QhP (ech) QhP (ec))
!
(a;Ph )  (QhP (ech) QhP (ec);r  h  +r  (h   Ph)z) = 0




[(ech ; bh; nah ; ch)  (ec; b; na; c)]ds;QhP (ech) QhP (ec))
!
(a;Ph )  (QhP (ech) QhP (ec);r  h )  (QhP (ech) QhP (ec);r  (h   Ph)z) = 0
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Add these two equations








QhP (ech) QhP (ec);r  (h   Ph)z

Now, note that since z 2 L2(J ; (L2(
))d) we have  = zh   z 2 L2(J ; (L2(
))d)
and since Ph  2 Vh, we can use (5.5) to say that:
(a(Ph  );Ph )) = 0 and so (aPh;Ph ) = (a;Ph ) 8vh 2 Vh:
In our equation, we now have








QhP (ech) QhP (ec);r  (h   Ph)z

(5.132)
Consider the rst term on the left hand side of the error equation, (5.132) :
(ech   ec; QhP (ech) QhP (ec)) = (ech  Qhec; QhP (ech) QhP (ec))
= (ech  Qhec; P (ech)  P (ec)) = (ech   ec + ec  Qhec; P (ech)  P (ec))
= (ech   ec; P (ech)  P (ec))  (Qhec   ec; P (ech)  P (ec))
If we integrate from 0 to t,Z t
0








(Qhec   ec; P (ech)  P (ec)) ds (5.133)
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Before considering the second term on the left hand side of (5.132) recall
(a(; t)(Ph(t)v   v); vh)) = 0 8vh 2 Vh
Set v = 
(a(; t)(Ph(t)  ); vh)) = 0 8vh 2 Vh






 ds = 
(at(Ph(t)  ); vh)) + (a((Ph(t))t   ); vh)) = 0 8vh 2 Vh
Set vh = Ph 
(at(Ph(t)  );Ph )) + (a((Ph(t))t   );Ph )) = 0
Using (5.5), we say
(at(Ph(t)  );Ph )) + (a((Ph(t))t   Ph);Ph )) = 0
(at(Ph(t)  );Ph )) + (a(Ph(t))t;Ph ))  (aPh;Ph )) = 0




(aPh ;Ph ) =
Z










(aPh ;Ph )   (atPh ;Ph )
#
Put this into equation (5.134), we get







(aPh ;Ph )   (atPh ;Ph )
#
(5.135)






ka1=2Ph k2   1
2
(atPh ;Ph ) (5.136)
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Integrating from 0 to t, we getZ t
0
(aPh;Ph ) ds =
Z t
0









(atPh ;Ph ) ds (5.137)
Integrating (5.132) in time from 0 to t, substituting (5.133) and (5.137) givesZ t
0
(ech   ec; P (ech)  P (ec)) ds  
Z t
0
(Qhec   ec; P (ech)  P (ec)) ds
Z t
0





















(QhP (ech) QhP (ec);r  (h   Ph)z)ds:
Moving some terms to the right hand side, we get the following error equation:Z t
0



















(Qhec   ec; P (ech)  P (ec)) ds 
Z t
0











(atPh ;Ph ) ds































kQhP (ech) QhP (ec))k2 ds








































kQhP (ech) QhP (ec))k2 ds




















































kQhP (ech) QhP (ec)k2 +
1
2"2















kQhec   eck2 + "1
2











(zh   z)ds  
Z t
0
















(at(Ph(t) zh   zh);Ph ) ds +
Z t
0
(at(Ph(t)z   z);Ph ) ds




(at(Ph(t)z   z);Ph ) ds
























Substituting T1 through T5 into (5:138), we getZ t
0



























kQhP (ech) QhP (ec)k2 +
1
2"2








































Before continuing, note that from (5.112), we can say,
kP (ech)  P (ec)k2  C0(P (ech)  P (ec); ech   ec) (5.139)
This will be used in what follows.
Using the fact that kQhP (ech) QhP (ec)k  CkP (ech)  P (ec)k, we haveZ t
0






































































kP (ech)  P (ec))k2 ds (5.140)
Using (5.139):Z t
0


























































































kPh(t)z   zk2ds+ C7
Z t
0

































Note that the Gronwall Inequality, theorem 4.8, can be applied to the terms that have the
constants C5 and C8. Also, the Gronwall Inequality can be applied to the terms that have




























































































Furthermore, since all the terms are positive, we get:
Bound 1 (Degenerate Case)Z t
0




































We may also go back to (5.142) and use (5.112) and the denition of kPh k and, again,
use the fact that all terms are positive, to get:
Bound 2 (Degenerate Case)Z t
0





































Bound in the H 1 Norm
So far, we have succeeded in nding a bound in the error P (ech) P (ec) in the L2 norm.
We now desire to nd a bound in the error ech   ec in some norm. Once again, we follow
Arbogast, Wheeler, and Zhang [7] to get such a bound in the H 1 norm.
Let ' 2 H10 and Qh' 2 Wh. Where ' is the L2 projection of ' onto Wh. Then
hech   ec; 'i = hech   ec; ' Qh'+Qh'i
= hech   ec; ' Qh'i + hech   ec; Qh'i
= hech  Qhec +Qhec   ec; ' Qh'i + hech   ec; Qh'i
= hech  Qhec; ' Qh'i + hQhec   ec; ' Qh'i + hech   ec; Qh'i
Note that ech  Qhec 2 Wh and ' Qh' is orthogonal to Wh. So, the rst term on the right
hand side is zero. So, we have
hech   ec; 'i = hQhec   ec; ' Qh'i + hech   ec; Qh'i
Then by (5.130),




[(ech ; bh; nah ; ch)  (ec; b; na; c)]ds;Qh'
!
  (r  h ; Qh')
Since r  h  2 Wh, we have hr  h ; Qh'i = hr  h ; 'i




[(ech ; bh; nah ; ch)  (ec; b; na; c)]ds;Qh'
!
  (r  h ; ')
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Integration by parts gives




[(ech ; bh; nah ; ch)  (ec; b; na; c)]ds;Qh'
!
+ (h ;r')  (h ; ')@

Since ' 2 H10 , the last term on the right hand side is zero. So, we have




[(ech ; bh; nah ; ch)  (ec; b; na; c)]ds;Qh'
!
+ (h ;r')




k(ech ; bh; nah ; ch)  (ec; b; na; c)kdskQh'k+ kh kkr'k




kr'kL2  k'kH1 and k'kL2  k'kH1


















k(ech ; bh; nah ; ch)  (ec; b; na; c)kds+ kh k
!























k(ech ; bh; nah ; ch)  (ec; b; na; c)kds+ kh k
!
Add and subtract the appropriate functions of  within the second term on the right hand
side. Add and subtract
R t
0
Phzds inside the last term on the right hand side and using (5.115)




kQhec   eckh +
Z t
0

























































































































































































Bound 3 (Error bound in H 1 Norm - Degenerate Case)
Thus, (5.146) gives an error bound for ech   ec in the H 1 norm. Note that in (5.146)
the terms kQhec   eck; kPh(t)z   zk; kr  (z   Phz)k; kr  (hz   z)k; k
R t
0
(z   hz) dsk;
and k R t
0
(Phz   z) dsk will be bounded using approximation results. Bounds on the terms
kbh   bk,knah   nak, and kch   ck were found in the numerical analysis for the equations in
Part I of the PDE system.
Note: A careful look at Bound 3 indicates that in order to get convergence of at least
h, it is required that P (ec) 2 H3(
).
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5.4 FINITE ELEMENT ANALYSIS OF THE PDES IN PART III










 kZNNO  ZO1 (5.147)
where






The initial condition is given by:
ZO1(x; 0) := ZO10(x) on 

(Note that ZO10(x) will usually be represented by ZO10.)
Note that the right hand side of (5.147) is dependent upon an equation (the NO equation)
from Part I of PDE equations and upon the equation (the epithelial equation) from Part II
of PDE equations. We found an error bound for the numerical approximation of the Part
I equations in terms of the L2 norm but the error bound for Part II equation was found in
terms of the H 1 norm. Therefore, it will probably not be possible to nd an error for the
numerical approximation of ZO1 in a norm any stronger than H 1. Therefore, the goal in
this section is to nd an error bound in that norm.
In order to simplify the following calculations the parameters in (5.147) and (5.148) will
be replaced with their actual values:
ZO1t = (:03ec + 2ect)(1  ZO1=zec)  :75NO  ZO1 (5.149)
zec = :95 + :05ec: (5.150)

















NO  ZO1 + ZO1(0):
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Weak Formulation
Set W := H10 (
). The weak formulation of the above equation may be stated as follows:
nd ZO1 2 W such that
(ZO1; w) = :03
Z t
0




















(NO  ZO1; w) + (ZO1(0); w) 8w 2 H10 (
): (5.151)
Discrete Formulation
Let Wh denote the nite element approximating subspace of W . Then the semidiscrete
formulation may be described as: nd ZO1h 2 Wh such that
(ZO1h; w) = :03
Z t
0




















(NOh  ZO1h; w) + (ZO1h(0); w) 8w 2 Wh (5.152)
At t = 0 dene ZO1h(x; 0) := ZO1
0
h 2 Wh by:
(ZO10h   ZO10; w) = 0 8w 2 Wh: (5.153)
The subtracting (5.152) from (5.151) and using (5.153) we get the error equation,
(ZO1  ZO1h; w) = :03
Z t
0








































T5 8w 2 Wh:
Bounds on each term
In the following analysis, we will need the following three assumptions:















 is a constant that depends only on f and 
:
Note that any functions that are in L1(
), such as ZO1, will automatically satisfy (5.154).
Based on the results of Part I of the PDE analysis, we know that kNOkL1(
) is bounded
and using the results of Part I of the numerical analysis, we know that kNOhk is bounded.
Here we will make the further assumption:
Assumption 2. kNOhk1 is bounded.
We previously assumed that ec is a non-negative function. Therefore, it is reasonable to
make the following assumption:
Assumption 3.  4  ech .
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Note that the terms T1 and T2 are already in a form that may be analyzed. For T3 and
















(:95 + :05ec)(:95 + :05ech)
; w
!









 :95ZO1(ect   ecth )

















 :05ZO1hec(ect   ecth )
(:95 + :05ec)(:95 + :05ech)
; w
!
= (f41(ZO1  ZO1h); w) + (f42(ect   ecth ); w) + (f43(ZO1  ZO1h); w)
+(f44(ec   ech); w) + (f45(ect   ecth ); w):
T5 = ( NO  ZO1 +NOh  ZO1 NOh  ZO1 +NOh  ZO1h; w)
= (( NOh)(ZO1  ZO1h); w) + (ZO1(NOh  NO); w)
 (( NOh)(ZO1  ZO1h); w) + kZO1kL1kNOh  NOkkwk
 (( NOh)(ZO1  ZO1h); w) + kZO1kL1kNOh  NOkkwkH1(
):
Put these terms into the error equation to get:
(ZO1  ZO1h; w)  C
Z t
0








((f32 + f44)(ec   ech); w) + C
Z t
0











Take the sup and note that the functions f31 and f33 are bounded. Apply (5.154) to the



























































In the PDE section Part III, we proved that kZO1kL1 is bounded. By Assumption 2,





















Result - Bound in H 1 norm.


















For (5.155), the bound on kect ecthkH 1(
) with convergence of h (as long as P (ec) 2 H3(
))
was found in the numerical analysis of the Part II equations. A bound on kNOh   NOk
with convergence h2NO was found in the numerical analysis of the Part I equations. Thus,
kZO1 ZO1hkH 1(
) is bounded by h, as long as the regularity of NO and the power of rNO
is great enough.
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5.5 CONCLUSION FOR FINITE ELEMENT ANALYSIS CHAPTER
It was demonstrated in this chapter that convergence for the fully coupled NEC system is
attainable. Convergence for the equations in Part I, using the L2 norm, was O(h2) for
 = b;m; c; ca; NO; d; ec; ZO1 and O(h
2 2) for  = ma; na. By using this result, it was
found that convergence for the epithelial equation in Part II, using the H 1 norm, was O(h)
(as long as we have P (ec) 2 H3(
)). Finally, using the results of Part I and Part II, it was
found that convergence for the tight junction equation in Part III, using the H 1 norm, was
O(h). All of these results are summarized in the following two tables.
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Equation Error Norm Conv Notes
Rate
Bacteria kbh   bk L2(
) h2b
Macrophage kmh  mk L2(
) h2m
Activated
Macrophage kmah  mak L2(
) h2ma 2
Cytokine kch   ck L2(
) h2c
Anti-In.
Cytokine kcah   cak L2(
) h2ca
Table 3: Convergence Rates for fully coupled system (1 of 2).
202
Equation Error Norm Conv Notes
Rate
Nitric
Oxide kNOh  NOk L2(
) h2NO
Activated
Neutrophils knah   nak L2(
) h2na 2
Damage kdh   dk L2(
) h2d
Requires
Epithelial kech   eckH 1(
) H 1(
) h P (ec) 2 H3(
)
Tight
Junction kZO1h   ZO1kH 1(
) H 1(
) h
Table 4: Convergence Rates for fully coupled system (2 of 2).
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6.0 CONVERGENCE TESTS
6.1 CODE TO TEST COUPLED ADVECTION EQUATION
The author of this thesis wrote MATLAB code in order to do convergence tests on the system
@u
@t
 r  (D1ru  urv) = f1(u; v) (6.1)
@v
@t
 r  (D2rv   vru) = f2(u; v): (6.2)
Note that this system is more general than the system in our NEC model in that (6.2)
contains the term r  (D2rv   vru) instead of just r  D2rv. The test runs below will
include this more general case as well as cases similar to the NEC model.
Even though the purpose of these tests is determine the convergence of the mixed method,
for comparison purposes code was also written for the Implicit Finite Dierence Method,
Explicit Finite Dierence Method, and Cell-Centered Finite Dierence Method. Due to the
unusual non-linearities in the PDE system, a short description of equations for each of these
methods is given here.
6.1.1 Implicit Finite Dierence
This section covers the Implicit Finite Dierence Method. The left hand side of equation















































































































































































The rst partial dierential equation
Thus, the discretization of equation (6.1) simplies to:
g := K1 uix;iy +K2 uix;iyvix+1;iy +K3 uix;iyvix 1;iy +K4 uix 1;iyvix+1;iy +
K5 uix 1;iyvix 1;iy +K6 uix;iyvix;iy+1 +K7 uix;iyvix;iy 1 +K8 uix;iy 1vix;iy+1 +
K9 uix;iy 1vix;iy 1 +K10 uix 1;iy +K11 uix;iy +K12 uix+1;iy +K13 uix;iy 1 + (6.7)
K14 uix;iy +K15 uix;iy+1 +K18 vix 1;iyuix;iy +K19 vix;iyuix;iy +K20 vix+1;iyuix;iy +
K18 vix;iy 1uix;iy +K19 vix;iyuix;iy +K20 vix;iy+1uix;iy   f1(x; y; t) +K17umix;iy
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Where K1 = 1=(4t); K2 = C11=(2  (4x)2); K3 =  K2; K4 =  K2; K5 = K2; K6 =
C12=(2  (4y)2); K7 =  K6; K8 =  K6; K9 = K6; K10 =  C21=(4x)2; K11 = ( 2) 
K10; K12 = K10; K13 =  C22=(4y)2; K14 = ( 2) K13; K15 = K13; K17 =  K1; K18 =
C11=(4x)2; K19 = ( 2)K18; K20 = K18; K21 = C12=(4y)2; K22 = ( 2)K21; K23 = K21.
Note that f1(x; y; t) is term number 16. Therefore K16 = 1 and is not shown here. K17
is shown last here for clarity because it is associated with the "m" time step. Unless other-
wise noted all superscripts are m+ 1.
The second partial dierential equation
Likewise, the discretization of equation (6.2) simplies to:
h = J1 vix;iy + J2 vix;iyuix+1;iy + J3 vix;iyuix 1;iy + J4 vix 1;iyuix+1;iy +
J5 vix 1;iyuix 1;iy + J6 vix;iyuix;iy+1 + J7 vix;iyuix;iy 1 + J8 vix;iy 1uix;iy+1 +
J9 vix;iy 1uix;iy 1 + J10 vix 1;iy + J11 vix;iy + J12 vix+1;iy + J13 vix;iy 1 + (6.8)
J14 vix;iy + J15 vix;iy+1 + J18 uix 1;iyvix;iy + J19 uix;iyvix;iy + J20 uix+1;iyvix;iy +
J18 uix;iy 1vix;iy + J19 uix;iyvix;iy + J20 uix;iy+1vix;iy   f2(x; y; t) + J17vmix;iy:
Where J1 = 1=(4t); J2 = D11=(2  (4x)2); J3 =  J2; J4 =  J2; J5 = J2; J6 =
D12=(2 (4y)2); J7 =  J6; J8 =  J6; J9 = J6; J10 =  D21=(4x)2; J11 = ( 2)J10; J12 =
J10; J13 =  D22=(4y)2; J14 = ( 2)  J13; J15 = J13; J17 =  J1; J18 = C11=(4x)2; J19 =
( 2)  J18; J20 = J18; J21 = D12=(4y)2; J22 = ( 2)  J21; J23 = J21.
Note that f2(x; y; t) is term number 16. Therefore J16 = 1 and is not shown here. J17
is shown last here for clarity because it is associated with the "m" time step. Unless other-






















We need to nd a vector u such that FF(u) = 0. Due to the non-linearities, this system of
equations will be solved using Newton's method, i.e., u will be found by iteratively solving:
u = u A 1(x)FF(x):











































Therefore, the derivatives of g and h will be required:




= K1 +K11 +K14 + (K19 +K22)vix;iy + (K3 +K18)vix 1;iy
+(K2 +K20)vix+1;iy + (K7 +K21)vix;iy 1 + (K6 +K23)vix;iy+1
@g
@uix 1;iy
















= (K3 +K18)uix;iy +K5uix 1;iy
@g
@vix+1;iy
= (K2 +K20)uix;iy +K4uix 1;iy
@g
@vix;iy 1
= (K7 +K21)uix;iy +K9uix;iy 1
@g
@vix;iy+1
= (K6 +K23)uix;iy +K8uix;iy 1:




= J1 + J11 + J14 + (J19 + J22)uix;iy + (J3 + J18)uix 1;iy
+(J2 + J20)uix+1;iy + (J7 + J21)uix;iy 1 + (J6 + J23)uix;iy+1
@h
@vix 1;iy












= (J19 + J22)vix;iy
@h
@uix 1;iy
= (J3 + J18)vix;iy + J5vix 1;iy
@h
@uix+1;iy
= (J2 + J20)vix;iy + J4vix 1;iy
@h
@uix;iy 1
= (J7 + J21)vix;iy + J9vix;iy 1
@h
@uix;iy+1
= (J6 + J23)vix;iy + J8vix;iy 1:
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These will result in equations g1; g2; :::; gn; h1; h2; :::; hn.
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.Node Numbering for the Implicit and Explicit Finite Dierence Method
Dirichlet Boundary Conditions
The nodes are numbered using L1 = ix+(Nodes in y direction iy)(Nodes in x direction).

























x0 x1 ::: xN xN+1








where the u1; :::; un are represented by u(1); :::; u(n) and the v1; :::; vn are represented by
u(n+ 1); :::; u(2n).
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.Node Numbering for the Implicit and Explicit Finite Dierence Method
Neumann Boundary Conditions
The nodes are numbered using L1 = ix+(Nodes in y direction iy)(Nodes in x direction).





























































x0 x1 x2 ::: xN 1 xN xN+1










where the u1; :::; un are represented by u(1); :::; u(n) and the v1; :::; vn are represented by
u(n+ 1); :::; u(2n).
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6.1.2 Explicit Finite Dierence
K1 u
m
ix;iy +K2 uix;iyvix+1;iy +K3 uix;iyvix 1;iy +K4 uix 1;iyvix+1;iy +
K5 uix 1;iyvix 1;iy +K6 uix;iyvix;iy+1 +K7 uix;iyvix;iy 1 +K8 uix;iy 1vix;iy+1 +
K9 uix;iy 1vix;iy 1 +K10 uix 1;iy +K11 uix;iy +K12 uix+1;iy +K13 uix;iy 1 + (6.9)
K14 uix;iy +K15 uix;iy+1 +K18 vix 1;iyuix;iy +K19 vix;iyuix;iy +K20 vix+1;iyuix;iy +
K18 vix;iy 1uix;iy +K19 vix;iyuix;iy +K20 vix;iy+1uix;iy +K17uix;iy = f1(x; y; t):
Where K1 = 1=(4t); K2 = C11=(2  (4x)2); K3 =  K2; K4 =  K2; K5 = K2; K6 =
C12=(2  (4y)2); K7 =  K6; K8 =  K6; K9 = K6; K10 =  C21=(4x)2; K11 = ( 2) 
K10; K12 = K10; K13 =  C22=(4y)2; K14 = ( 2) K13; K15 = K13; K17 =  K1; K18 =
C11=(4x)2; K19 = ( 2)K18; K20 = K18; K21 = C12=(4y)2; K22 = ( 2)K21; K23 = K21.
Note that f1(x; y; t) is term number 16. Therefore K16 = 1 and is not shown here. K17
is shown last here for clarity because it is associated with the "m" time step. Unless other-
wise noted all superscripts are m  1.
J1 v
m
ix;iy + J2 vix;iyuix+1;iy + J3 vix;iyuix 1;iy + J4 vix 1;iyuix+1;iy +
J5 vix 1;iyuix 1;iy + J6 vix;iyuix;iy+1 + J7 vix;iyuix;iy 1 + J8 vix;iy 1uix;iy+1 +
J9 vix;iy 1uix;iy 1 + J10 vix 1;iy + J11 vix;iy + J12 vix+1;iy + J13 vix;iy 1 + (6.10)
J14 vix;iy + J15 vix;iy+1 + J18 uix 1;iyvix;iy + J19 uix;iyvix;iy + J20 uix+1;iyvix;iy +
J18 uix;iy 1vix;iy + J19 uix;iyvix;iy + J20 uix;iy+1vix;iy + J17vix;iy = f2(x; y; t):
Where J1 = 1=(4t); J2 = D11=(2  (4x)2); J3 =  J2; J4 =  J2; J5 = J2; J6 =
D12=(2 (4y)2); J7 =  J6; J8 =  J6; J9 = J6; J10 =  D21=(4x)2; J11 = ( 2)J10; J12 =
J10; J13 =  D22=(4y)2; J14 = ( 2)  J13; J15 = J13; J17 =  J1; J18 = C11=(4x)2; J19 =
( 2)  J18; J20 = J18; J21 = D12=(4y)2; J22 = ( 2)  J21; J23 = J21.
Note that f2(x; y; t) is term number 16. Therefore J16 = 1 and is not shown here. J17
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is shown last here for clarity because it is associated with the "m" time step. Unless other-
wise noted all superscripts are m  1.
6.1.3 Cell-Centered Finite Dierence Method
Cell Numbering for Cell-centered nite dierence
     
     
     
     
     
     























Left Boundary      
u1 u2 u3
z1=2 z3=2 z5=2 z7=2
u1=2 u3=2 u5=2 u7=2
- - -  
4x 4x 4x
So, if we have r Dru. Set z = Dru. Then
z1=2 = D1=2
u1   u1=2
(4x=2) and z3=2 = D3=2
u2   u1
4x








D3=2u2  D3=2u1   2D1=2u1 + 2D1=2u1=2
(4x)2
If D = 1. Then
r  ru1 = u2   3u1 + 2u1=2
(4x)2
Right Boundary
Right Boundary     
zn 5=2 zn 3=2 zn 1=2 zn+1=2
un 5=2 un 3=2 un 1=2 un+1=2
- - -  
4x 4x 4x
So, if we have r Dru. Set z = Dru. Then
zn+1=2 = Dn+1=2
un+1=2   un




If D = 1. Then
r  ru1 = 2un+1=2   3un + un 1
(4x)2
6.2 TEST RUNS
The following pages contain convergence tests based on various test equations, methods, and
boundary conditions for the types of equations in Part I of the PDE system. The methods
include implicit nite dierence, explicit nite dierence, and cell centered nite dierence.
Even though the typical equations in Part I of the PDE system include an equation with
an advection term coupled with an equation with no advection term, other cases are included
in the tests which follow. For example in Cases 1 and 3 both of the coupled equations contain
advection terms. These are of particular interest because it has not been proven that such
PDEs (nor the associated numerical methods) always have solutions. Case 4 contains two
coupled equations neither of which has an advection term. Case 2, contains the typical
coupling of the equations in Part I of the PDE system - one equation with an advection
term, and one equation with no advection term.








Number of Node Points
:















































at t = 2:
x = 0.00 to 1.00 and y = 0.00 to 1.00 Time = 2.00 sec to 7.00 sec.
Dirichlet Boundary Conditions.
Implicit Finite Dierence ||{ Function Numbers 8 and 9
Delta X Delta Y Delta T SRSS SAV MAX Error
0.20000 0.20000 0.024876 0.00043062 0.00034962 0.00086695
0.16667 0.16667 0.024876 0.00028619 0.00022819 0.00062912
0.14286 0.14286 0.024876 0.00020176 0.00015824 0.00046375
0.07692 0.07692 0.024876 0.00004734 0.00003438 0.00011859
Convergence Rate = 2.16 (Based on the Maximum Error).
Explicit Finite Dierence - No Upwinding | Function Numbers 8 and 9
Delta X Delta Y Delta T SRSS SAV MAX Error
0.20000 0.20000 0.000500 0.00043034 0.00034933 0.00086646
0.16667 0.16667 0.000500 0.00028592 0.00022792 0.00062862
0.14286 0.14286 0.000050 0.00020151 0.00015798 0.00046322
0.07692 0.07692 0.000050 0.00004711 0.00003416 0.00011806
Convergence Rate = 2.16 (Based on the Maximum Error)
Cell Centered Finite Dierence - Upwinding { Function Numbers 8 and 9
Delta X Delta Y Delta T SRSS SAV MAX Error
0.20000 0.20000 0.000050 0.00140068 0.00087865 0.00451430
218
0.16667 0.16667 0.000050 0.00101304 0.00062353 0.00354081
0.14286 0.14286 0.000050 0.00076371 0.00046374 0.00283941
0.07692 0.07692 0.000050 0.00023244 0.00013494 0.00106125





 r  (D1ru1   u1ru2) = (2t  4t2(1 + x2 + y2))ex2+y2




 r  (D2ru2) = (1  18t  4y2t)e4x+y2
on [0; :5] [0; :5] 2  t  7
u1 = t
2ex




x2+y2 and u2 = 2e
4x+y2 at t = 2:
Results
x = 0.00 to 0.50 and y = 0.00 to 0.50 Time = 2.00 sec to 7.00 sec.
Dirichlet Boundary Conditions.
Implicit Finite Dierence ||{ Function Numbers 12 and 13
Delta X Delta Y Delta T SRSS SAV MAX Error
0.10000 0.10000 0.098039 0.52831048 0.37976163 1.13428824
0.03846 0.03846 0.098039 0.23052810 0.15107538 0.55326673
0.03125 0.03125 0.098039 0.18987872 0.12304563 0.47302421
0.02500 0.02500 0.098039 0.15369333 0.09859691 0.39135379
0.02174 0.02174 0.098039 0.13446556 0.08579368 0.34693499
Convergence Rate = 0.85 (Based on the Maximum Error).
Explicit Finite Dierence - No Upwinding { Function Numbers 12 and 13
Delta X Delta Y Delta T SRSS SAV MAX Error
0.10000 0.10000 0.000500 0.52818714 0.37967200 1.13410669
0.03846 0.03846 0.000050 0.23039674 0.15098086 0.55305044
0.03125 0.03125 0.000050 0.18974669 0.12295091 0.47281510
0.02500 0.02500 0.000050 0.15356077 0.09850211 0.39115397
0.02174 0.02174 0.000050 0.13433274 0.08569888 0.34673113
Convergence Rate = 0.85 (Based on the Maximum Error).
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Cell Centered Finite Dierence - Upwinding { Function Numbers 12 and 13
Delta X Delta Y Delta T SRSS SAV MAX Error
0.10000 0.10000 0.000050 0.60547023 0.48115077 1.30528104
0.03846 0.03846 0.000050 0.22996059 0.16125296 0.58496432
0.03125 0.03125 0.000050 0.18800082 0.12888287 0.48879547
0.02500 0.02500 0.000050 0.15152485 0.10171055 0.40131272
0.02174 0.02174 0.000050 0.13239148 0.08784893 0.35162598
Convergence Rate = 0.91 (Based on the Maximum Error).
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Neumann Boundary Conditions for Case 2
Spatial Domain { x = 0.00 to 0.50 and y = 0.00 to 0.50 Time = 2.00 sec to 7.00 sec
Neumann Boundary Conditions
Explicit Finite Dierence - No Upwinding { Function Numbers 12 and 13
Delta X Delta Y Delta T SRSS SAV MAX Error
0.10000 0.10000 0.000005 12.77238570 10.33884141 18.92834610
0.04167 0.04167 0.000005 2.26910258 1.97228186 3.28782200
0.03333 0.03333 0.000005 1.47215238 1.31112482 2.10428574
0.02632 0.02632 0.000005 0.93706418 0.85777338 1.31156866
0.02273 0.02273 0.000005 0.71139595 0.66248244 0.97826721





 r  (D1ru1   u1ru2) = (2t  4t2(1 + x2 + y2))ex2+y2




 r  (D2ru2   u2ru1) = (1  18t  4y2t)e4x+y2
+2t3(2 + 4x+ 2x2 + 4y2)e4x+x
2+2y2
on [0; :5] [0; :5] 2  t  7
u1 = t
2ex




x2+y2 and u2 = 2e
4x+y2 at t = 2
Note that these are functions 12 and 14 in the code.
Results
Implicit Finite Dierence ||{ Function Numbers 12 and 14
x = 0.00 to 0.50 and y = 0.00 to 0.50 Time = 2.00 sec to 7.00 sec.
Dirichlet Boundary Conditions.
Delta X Delta Y Delta T SRSS SAV MAX Error
0.10000 0.10000 0.098039 0.22152365 0.19252587 0.42037679
0.03846 0.03846 0.098039 0.09096140 0.07646009 0.19700125
0.03125 0.03125 0.098039 0.07429931 0.06196773 0.16254211
0.02500 0.02500 0.098039 0.05969120 0.04941398 0.13205175
0.02174 0.02174 0.098039 0.05201304 0.04287958 0.11566309
Convergence Rate = 0.94 (Based on the Maximum Error).
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,Explicit Finite Dierence - No Upwinding { Function Numbers 12 and 14
**No Solution**
Delta X Delta Y Delta T SRSS SAV MAX Error
0.10000 0.10000 0.000005 **No Solution**
0.03846 0.03846 0.000005 **No Solution**
Cell Centered Finite Dierence - Upwinding { Function Numbers 12 and 14
**No Solution**
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Case 4 (Diusion Only, Equations not coupled)
@u1
@t
 r  (D1ru1) = (2t  4t2(1 + x2 + y2))ex2+y2
@u2
@t
 r  (D2ru2) = (2t  4t2(1 + x2 + y2))ex2+y2
on [0; 1] [0; 1] 2  t  7
u1 = t
2ex





x2+y2 and u2 = 4e
x2+y2 at t = 2
Note that these are functions 11 and 11 in the code.
Results
Implicit Finite Dierence ||{ Function Numbers 11 and 11
x = 0.00 to 1.00 and y = 0.00 to 1.00 Time = 2.00 sec to 7.00 sec
Dirichlet Boundary Conditions
Delta X Delta Y Delta T SRSS SAV MAX Error
0.20000 0.20000 0.024876 0.97960738 0.92570389 1.44478352
0.16667 0.16667 0.024876 0.67174248 0.62781339 1.05640592
0.14286 0.14286 0.024876 0.48812595 0.45194552 0.77341119
0.07692 0.07692 0.024876 0.13695343 0.12249615 0.23645546
0.06250 0.06250 0.024876 0.09008938 0.07981570 0.15812972
Convergence Rate = 1.92 (Based on the Maximum Error).
Explicit Finite Dierence - No Upwinding { Function Numbers 11 and 11
Delta X Delta Y Delta T SRSS SAV MAX Error
0.20000 0.20000 0.000500 0.97721845 0.92337131 1.44132091
0.16667 0.16667 0.000050 0.66945500 0.62560563 1.05312373
0.14286 0.14286 0.000050 0.48588182 0.44980142 0.77035057
0.07692 0.07692 0.000050 0.13483303 0.12054486 0.23320608
0.06250 0.06250 0.000050 0.08799651 0.07790955 0.15484686
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Convergence Rate = 1.94 (Based on the Maximum Error).
Cell Centered Finite Dierence - Upwinding { Function Numbers 11 and 11
Delta X Delta Y Delta T SRSS SAV MAX Error
0.20000 0.20000 0.000050 2.79983922 2.28396678 7.00094784
0.16667 0.16667 0.000050 1.98465021 1.61033163 5.24666498
0.14286 0.14286 0.000050 1.47663050 1.19412742 4.06794314
0.07692 0.07692 0.000050 0.43921360 0.35271975 1.36536394
0.06250 0.06250 0.000050 0.29101280 0.23346200 0.93007695
Convergence Rate = 1.79 (Based on the Maximum Error).
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7.0 SIMULATION RESULTS
Simulation results are presented in this chapter. These simulations were created in MAT-
LAB using the PDE system from chapter three. The PDE system was discretized using
a cell-centered nite dierence method. Which, technically, is a form of the Mixed Finite
Element Method. Unlike all of the other code in this thesis, which was written
solely by the author, the writing of the code in this chapter was a collaborative
eort. Among those who contributed to the writing of the code:
Joshua Sullivan, Ivan Yotov, Chris Horvat, and Mark Tronzo (the author of this thesis).
The purpose of this chapter is to show that the most critical features of NEC are rea-
sonably modeled by the PDE system presented in this thesis. It must be noted that there
is currently not enough data available to accurately determine the parameters in the NEC
model. Furthermore, it is very likely that new NEC discoveries will prompt further changes
to the equations in the PDE system. Therefore, we are not claiming that the com-
puter runs presented here exactly match actual disease conditions. Instead, we
hope to demonstrate that our NEC PDE system is exible enough that with
proper parameter selection and minor changes to the equations the model will
be able to simulate the general patterns of the disease. So one should not focus
upon the actual numbers shown in the following graphs but upon the general patterns.
(For those interested in "the next step", i.e. an attempt to more accurately simulate
NEC with the PDE model presented in this chapter, we point out that Jared Barber has
signicantly updated and rened the MATLAB code presented in this chapter.
His results are presented in our paper [14].)
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Computer runs were made in order to simulate actual NEC conditions. In particular,
dierent combinations of the following were used:
1) Two Types of feedings: formula-fed and breastfed. Within the breastfed category,
several levels of anti-microbial peptides were used. (These dierent levels are simulated by
using dierent values of the parameter kpp, which is the rate of the destruction of bacteria
by the anti-microbial peptides in breast milk.)
2) Two dierent levels of infant maturity: Premature infants and term infants.
3) Three dierent epithelial injury levels: no injury to the epithelium, partial injury
to the epithelium and total injury to the epithelium.
Various combinations of the conditions in 1) through 3) above are represented in the cases
which follow.
For the most part, the initial conditions are the same for each NEC component in all
four regions with the following exceptions: (resting) macrophages are set to 0 in the lumen
and to their maximum value in the other three regions; (resting) neutrophils are set to their
maximum value in the blood and to 0 in the other three regions; epithelial cell density and
ZO1 density is zero in all regions except the epithelial layer.
7.1 NORMAL CASE - TERM INFANT, NO INJURY TO THE
EPITHELIUM.
We will begin by presenting a normal case. Of course, many cases might be considered nor-
mal. Here we are dening our normal case as a term infant with no injury to the epithelium
but the epithelium is not perfect, its density is not quite 100 %. (Recall from chapter one
that during the process of natural cell death and proliferation, gaps in the epithelium of 1%
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to 3 % are very common.) kpp is set at .25, higher than with formula feeding but lower than
with regular breast feeding. The results are shown in gures 28 and 29. Notice that the
epithelial density begins at .98 and ZO1 begins at .99, indicating the imperfection in the
epithelial layer. Immediately, this epithelial density drops to .95 but levels o while ZO1
rises to 1. (Recall from chapter one that it is believed that ZO1 will ll in small gaps in the
epithelium created by missing cells. That would explain why ZO1 is slightly greater than
the epithelial density in some cases.) The run begins with bacteria in the tissue, lumen, and
epithelial layer but approaches zero in all of those layers except the lumen where it levels
o at a positive value. At the beginning of the run, damage is zero in all four layers but
quickly rises in the tissue, lumen, and epithelial layer but approaches zero in all of those
layers. Cytokines rise in all four layers but eventually level o. Similar observations may be
made of the other components.
So, what we see in our normal case is not perfection but the players in NEC under
control. The epithelium is not perfectly sealed but is dense enough to prevent any signicant
bacterial invasion into the underlying tissue. Bacteria is either eliminated or remains at a
constant, non-threatening level. Damage occurs in several regions but is quickly repaired.
7.2 CASE - PREMATURITY, NO INJURY TO THE EPITHELIUM.
These cases will consider the premature infant that has no injury to the epithelium. The
main assumption of this group of runs is that the premature infant has reduced peristalsis.
Recall from chapter one that peristalsis aids in moving bacteria and other material along the
lumen. When peristalsis is not fully functioning or underdeveloped, as is often the case in
the premature infant, gram-negative bacteria may, over time, build up near the epithelium.
Therefore, these runs will begin with high levels of gram-negative bacteria near the epithe-
lium (simulated by setting bmax = 5:0).
Formula Fed kpp = :05; bmax = 5. The rst simulation under this case was run with
formula feeding. It was assumed that with formula feeding only a very small amount of anti-
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Figure 28: Normal Case - Term Infant, No Injury to the epithelium (1 of 2). The 18 graphs shown in this
gure show the amount of each component in the epithelial and lumen layers. (For example, the graph in
the bottom left corner shows the amount of activated macrophages in the epithelial layer.) For each graph,
the vertical axis indicates the quantity of the substance and the horizontal axis indicates time, in hours.
Figure 29: Normal Case - Term Infant, No Injury to the epithelium (2 of 2). The 18 graphs shown in this
gure show the amount of each component in the blood and tissue layers. (For example, the graph in the
bottom left corner shows the amount of activated macrophages in the blood layer.)
230
microbial peptides will be present, simulated by setting kpp = :05. The results are shown in
gure 30, 31, and 32. Figure 30 indicates that epithelial layer density is dropping steadily.
This is very bad. Recall from chapter two that the resulting permeability of that layer will
lead to bacterial invasion of the underlying tissue and usually a very bad outcome. Further
bad indicators are that damage and nitric oxide are rising in certain layers.
Breast Fed kpp = :5; bmax = 5. This run was made assuming breast feeding. In this
case, moderate levels of anti-microbial peptides were assumed, simulated by setting kpp = :5.
The results are shown in gure 33, 34, and 35. This case does is not good. Unlike the previous
case, the epithelial density is not dropping quickly but not quite stable either. Furthermore,
damage is rising in that layer. At the same time, rising cytokines, damage, and nitric oxide
in the blood and tissue are serious problems.
Breast Fed kpp = :7; bmax = 5. This run was made assuming breast feeding. In this
case, higher levels of anti-microbial peptides were assumed, simulated by setting kpp = :7.
The results are shown in gure 36, 37, and 38. Toward the end of the run, many NEC
factors are approaching normal levels (compare to the normal case in the last section).
Rising epithelial density is a very good sign. However, increasing damage in the blood, if
continued unchecked, will be a problem.
Breast Fed kpp = 1; bmax = 5. This run was made assuming breast feeding. In this
case, high levels of anti-microbial peptides was assumed, simulated by setting kpp = 1. The
results are shown in gure 39, 40, and 41. The results in this case are extremely good. The
epithelium is approaching full density and, similar to the normal case from the last section,
and all of the NEC factors are either approaching zero or under control.
The epithelial layer for the four cases in this section are shown in gure 42.
7.3 CASE - TERM INFANT, PARTIAL INJURY TO EPITHELIUM.
In these runs, a full term infant with a partial injury to the epithelium will be simulated.
Note that `partial injury' will indicate that there is a circular area in the epithelial layer that
is at 33% of its maximum density and `total injury' means that there is a circular area in
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Figure 30: Simulation for Prematurity, No Injury, Formula Fed kpp = :05; bmax = 5 (1 of 2). The 18
graphs shown in this gure show the amount of each component in the epithelial and lumen layers. (For
example, the graph in the bottom left corner shows the amount of activated macrophages in the epithelial
layer.) For each graph, the vertical axis indicates the quantity of the substance and the horizontal axis
indicates time, in hours. In this particular case, the steady decrease in epithelial layer density will allow
bacterial invasion of the underlying tissue which can lead to a very bad outcome.
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Figure 31: Simulation for Prematurity, No Injury, Formula Fed kpp = :05; bmax = 5 (2 of 2). The 18 graphs
shown in this gure show the amount of each component in the blood and tissue layer. (For example, the
graph in the bottom left corner shows the amount of activated macrophages in the blood layer.) In this case,
nitric oxide and damage are increasing in some layers.
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Figure 32: Simulation for Prematurity, No Injury, Formula Fed kpp = :05; bmax = 5. The purpose of
this gure is to give an average visual picture of what is happening physically. This graph should not be
considered as accurate as the other graphs for this simulation. In order not to clutter the diagram, only a
limited number of components are shown: bacteria in the lumen, nitric oxide in the epithelium (represented
by the small gray balls), epithelial cells (represented by the yellow balls), tight junction protein (represented
by the red bars), bacteria in the tissue, and damage to the tissue (represented by the black areas).
234
Figure 33: Simulation for Prematurity, No Injury, Breast Fed kpp = :5; bmax = 5 (1 of 2). The 18 graphs
shown in this gure show the amount of each component in the epithelial and lumen layers. (For example,
the graph in the bottom left corner shows the amount of activated macrophages in the epithelial layer.) For
each graph, the vertical axis indicates the quantity of the substance and the horizontal axis indicates time,
in hours. In this case, epithelial density is not dropping quickly but not quite stable either. Damage is rising
in the epithelial layer.
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Figure 34: Simulation for Prematurity, No Injury, Breast Fed kpp = :5; bmax = 5 (2 of 2). The 18 graphs
shown in this gure show the amount of each component in the blood and tissue layer. (For example, the
graph in the bottom left corner shows the amount of activated macrophages in the blood layer. In this case,
rising cytokines, damage, and nitric oxide in the blood and tissue are serious problems.)
236
Figure 35: Simulation results for Prematurity, No Injury, Breast Fed kpp = :5; bmax = 5. The purpose of
this gure is to give an average visual picture of what is happening physically. This graph should not be
considered as accurate as the other graphs for this simulation. In order not to clutter the diagram, only a
limited number of components are shown: bacteria in the lumen, nitric oxide in the epithelium (represented
by the small gray balls), epithelial cells (represented by the yellow balls), tight junction protein (represented
by the red bars), bacteria in the tissue, and damage to the tissue (represented by the black areas).
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Figure 36: Simulation results for Prematurity, No Injury, Breast Fed kpp = :7; bmax = 5 (1 of 2). The 18
graphs shown in this gure show the amount of each component in the epithelial and lumen layers. (For
example, the graph in the bottom left corner shows the amount of activated macrophages in the epithelial
layer.) For each graph, the vertical axis indicates the quantity of the substance and the horizontal axis
indicates time, in hours. In this case, rising epithelial density is a very good sign.
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Figure 37: Simulation results for Prematurity, No Injury, Breast Fed kpp = :7; bmax = 5 (2 of 2). The
18 graphs shown in this gure show the amount of each component in the blood and tissue layer. (For
example, the graph in the bottom left corner shows the amount of activated macrophages in the blood layer.)
In this case, increasing damage in the blood, if continued unchecked, will be a problem.
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Figure 38: Simulation results for Prematurity, No Injury, Breast Fed kpp = :7; bmax = 5. The purpose of
this gure is to give an average visual picture of what is happening physically. This graph should not be
considered as accurate as the other graphs for this simulation. In order not to clutter the diagram, only a
limited number of components are shown: bacteria in the lumen, nitric oxide in the epithelium (represented
by the small gray balls), epithelial cells (represented by the yellow balls), tight junction protein (represented
by the red bars), bacteria in the tissue, and damage to the tissue (represented by the black areas).
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Figure 39: Simulation for Prematurity, No Injury, Breast Fed kpp = 1; bmax = 5 (1 of 2). The 18 graphs
shown in this gure show the amount of each component in the epithelial and lumen layers. (For example,
the graph in the bottom left corner shows the amount of activated macrophages in the epithelial layer.) The
results in this case are extremely good. The epithelium is approaching full density and, similar to the normal
case from the last section, and all of the NEC factors are either approaching zero or under control. For each
graph, the vertical axis indicates the quantity of the substance and the horizontal axis indicates time, in
hours. The colored vertical graphs are logs of, from left to right, ca; d; ec; b; c;m;ma; NO;ZO1;
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Figure 40: Simulation for Prematurity, No Injury, Breast Fed kpp = 1; bmax = 5 (2 of 2). The 18 graphs
shown in this gure show the amount of each component in the blood and tissue layer. (For example, the
graph in the bottom left corner shows the amount of activated macrophages in the blood layer.)
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Figure 41: Simulation for Prematurity, No Injury, Breast Fed kpp = 1; bmax = 5. The purpose of this gure
is to give an average visual picture of what is happening physically. This graph should not be considered as
accurate as the other graphs for this simulation. In order not to clutter the diagram, only a limited number
of components are shown: bacteria in the lumen, nitric oxide in the epithelium (represented by the small
gray balls), epithelial cells (represented by the yellow balls), tight junction protein (represented by the red
bars), bacteria in the tissue, and damage to the tissue (represented by the black areas).
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Figure 42: Comparison between formula fed and breast fed for prematurity and no injury. All of these
cases use bmax = 5. These graphs show the epithelial layer. The top graph is the formula fed case. Next, is
breast fed with kpp = :5. The third graph from the top, is breast fed with kpp = :7. The bottom graph is
breast fed with kpp = 1.
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the epithelial layer that has zero density.
Formula Fed kpp = 0. The simulation run using the initial conditions of a partial
injury and formula feeding is shown in gure 43. The end result is sustained inammation.
High levels of bacteria remain in the lumen. Epithelial cells reach a steady state of 87%
concentration, indicating an injury that has not healed completely and the injury is no
longer in the process healing. This unhealed injury will provide a permanent pathway for
the bacteria in the lumen to pass through the epithelial layer into the underlying tissue.
Notice that damage is high and sustained in both the lumen and epithelial layer (the graphs
marked d lumen and d epith in gure 43). Damage is also high and sustained in the tissue
layer (the time graph of the tissue layer is not shown here). High concentrations of cytokines
in the epithelial layer indicate an ongoing pro-inammatory response that contributes to
damage in that layer. One of the few favorable indicators is the tight junction protein, ZO1
nearing 100 % concentration, an indication that the para cellular space between epithelial
cells is being sealed with functional ZO1. Overall, however, this is a very unhealthy outcome.
Figure 46 shows several snapshots in time of the epithelial layer density. Notice that the
wound, at rst, appears to be healing but, by the end of the run, a substantial wound remains.
(Note that the color scale is changing in each graph. In the last graph, red represents .88,
yellow represents .86, and blue represents .83.) The average, visual representation of this
case is given in gure 44.
Breast Fed kpp = :7. Figure 45 shows the results of starting with a partial injury and
breast feeding. In contrast to the formula fed case, we see here a healthy outcome. Epithelial
layer concentration has reached 100% indicating that this layer is completely healed. Damage
has decreased to zero in the two layers shown in the time graph. (The damage is also zero in
the time graph of the tissue layer which is not shown here.) The bacterial concentration is
zero in both layers. We can see that the body's anti-inammatory immune response is aiding
the healing process, as evidenced by the zero concentration of pro-inammatory cytokines.
The tight junction protein is at 100 % concentration, indicating that the cell walls are being
fully repaired. Figure 47 shows snapshots of the epithelial layer. The wound closes very
quickly and is fully healed by the end of the run. (Note that the color scale is changing
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Figure 43: Simulation results for Case Partial Injury, Formula Fed. The 18 graphs shown in this gure
show the amount of each component in the epithelial and lumen layers. (For example, the graph in the
bottom left corner shows the amount of activated macrophages in the epithelial layer.) For each graph, the
vertical axis indicates the quantity of the substance and the horizontal axis indicates time, in hours.
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Figure 44: Case - Partial Injury Formula Fed. The purpose of this gure is to give an average visual
picture of what is happening physically. This graph should not be considered as accurate as the other graphs
for this simulation. In order not to clutter the diagram, only a limited number of components are shown:
bacteria in the lumen, nitric oxide in the epithelium (represented by the small gray balls), epithelial cells
(represented by the yellow balls), tight junction protein (represented by the red bars), bacteria in the tissue,
and damage to the tissue (represented by the black areas). Also, unlike the some of the previous graphs,
cytokines in the tissue are shown here. 247
Figure 45: Simulation results for Case Partial Injury, Breastfed, kpp = :7. The 18 graphs shown in this
gure show the amount of each component in the epithelial and lumen layers. (For example, the graph in
the bottom left corner shows the amount of activated macrophages in the epithelial layer.) For each graph,
the vertical axis indicates the quantity of the substance and the horizontal axis indicates time, in hours.
in each graph. In the last graph, red/yellow/green represents .99999 and blue represents
.9999.) This is in stark contrast to the slow, inecient wound closing in Case Partial Injury
Formula Fed (Figure 46).
The epithelial layer for these cases are shown in gure 48.
7.4 CASE - TERM INFANT, TOTAL INJURY TO EPITHELIUM.
In these runs, a full term infant with a total injury to the epithelium will be simulated. Note
that `total injury' indicate that there is a circular area in the epithelial layer that has zero
density.
Formula Fed kpp = 0. The case of formula fed is shown in gure 49. Again we see an
unhealthy outcome. This example shows the epithelial layer concentration rising at about






















































































































































Figure 46: Wound Closing for Case Partial Injury, Formula Fed. These snapshots show the progression


























































































































































Figure 47: Wound Closing for Case Partial Injury, Breastfed. These snapshots show the progression of the
wound. The wound heals very quickly.
Figure 48: Comparison between formula fed and breast fed for term infant and partial injury. These graphs
show the epithelial layer. The top graph is the formula fed case. kpp = 0. The bottom graph is breast fed
with kpp = :7.
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sign, indicating that the injury to the epithelial layer is actually getting worse. The tight
junction protein, ZO1, is also deteriorating near the end of the run, further increasing the
permeability of the epithelial layer. Nitric oxide levels are also on the rise. Nitric oxide will
cause further damage to the tight junction protein. Damage, as in the previous formula fed
case, is high and is increasing over time. Damage does not exhibit any asymptotic behavior,
indicating it will continue to increase if the system is stimulated further. Bacteria is again
not eliminated fully in the epithelial layer and remains at high levels in the lumen. The
cytokine presence in the lumen and epithelial layers is non-zero and increasing over time,
indicating an increasing, self-sustaining pro-inammatory response that contributes to the
increasing damage throughout the system.
Breast Fed, kpp = :7. Figure 50. We see here a system approaching full recovery.
Unlike the total injury formula fed case, the epithelial cell concentration is very close to
100%, indicating that the injury is practically fully healed. Damage is approaching zero
everywhere. Bacterial content is eliminated swiftly in both layers. As a direct result of the
anti-inammatory cytokines, the pro-inammatory cytokine presence has decreased to zero
in the system. This decrease in inammation leads to reduced damage, leading to system
recovery. Figure 51 shows snapshots of the epithelial layer. Notice how the wound closes
smoothly and eciently. (Note that the color scale is changing in each graph. In the last
graph, red represents .9999, yellow represents .9997, and blue represents .9995.)
We next examine two cases that vary the eect of the anti-microbial peptides in breast
milk. These simulations were carried out using total injury. The parameter involved is kpp.
For normal cases, kpp = :7. The following two cases show how rst by reducing kpp by several
orders of magnitude and secondly by doubling kpp aects the system outlook.
Breast Fed, kpp = :000125 and kpp = 1:25, respectively. Notice that when the
eect of the anti-microbial peptides is reduced, by setting kpp = :000125, Figure 52, the
system recovery appears to slow down. The epithelial cell concentration is approximately
83 %, and still rising - it appears that recovery is only a matter of time. On the other
hand, when the eect of the anti-microbial peptides is increased, by setting kpp = 1:25
(see Figure 53), the system recovery appears to speed up slightly as compared with the
kpp = :7 case. The epithelial cell layer reaches its full concentration, 100 %, very quickly.
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Figure 49: Simulation results for Case Total Injury, Formula Fed. The 18 graphs shown in this gure show
the amount of each component in the epithelial and lumen layers. (For example, the graph in the bottom
left corner shows the amount of activated macrophages in the epithelial layer.) For each graph, the vertical
axis indicates the quantity of the substance and the horizontal axis indicates time, in hours.
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Figure 50: Simulation results for Case Total Injury, Breast Fed kpp = :7. The 18 graphs shown in this
gure show the amount of each component in the epithelial and lumen layers. (For example, the graph in
the bottom left corner shows the amount of activated macrophages in the epithelial layer.) For each graph,
































































































































































Figure 51: Wound Closing for Case Total Injury, Breast Fed kpp = :7. These snapshots show the progression
of the wound. The wound closes very quickly.
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Therefore, it appears that changing the eects of the anti-microbial peptides relates only
to the speed of the recovery, not the fact of the recovery. However, when we look at the
damage to the tissue for the three cases Case Total Injury, breastfed with kpp = :7, Case
Total Injury, breastfed with kpp = :000125 and Case Total Injury, breastfed with kpp = 1:25
(see Figure 54), we notice something very important: damage is high and sustained for Case
Total Injury, breastfed with kpp = :000125, which uses the lowest value of kpp. On the other
hand, damage is under control for the two cases of high kpp.
These test cases show the direct eect of varying the presence of anti-microbial peptides
in breast milk. Based on these cases, we can say that below some value of kpp, the parameter
that simulates anti-microbial peptides in the computer code, the system has an unhealthy
outcome. On the other hand, above some critical concentration of kpp the system has a
healthy outcome. As one continues to increase kpp above this critical value, recovery will be
proportionally faster.
7.5 SUMMARY OF SIMULATIONS
The simulations in this chapter show several things. First of all, a good result is char-
acterized by the quantities of all components staying within reasonable limits and all the
components staying under control. A good result does not necessarily mean that all NEC
quantities remain at ideal levels. For example in section 7.1 (the normal case), the steady
state epithelial density is 95 %. This is not perfect but is dense enough to prevent a pathogen
invasion into the underlying tissue. In this same simulation, bacteria in the lumen are never
eradicated. However, they do attain a manageable steady state level. On the other hand,
a bad result is characterized by at least some of the undesirable NEC factors continuing to
increase throughout the simulation or leveling o at too high of a value toward the end of
the simulation. This can be seen in section 7.2 (prematurity, no injury) in the circumstance
of formula feeding. Here, damage in the tissue and the blood remains high at the end of the
run. Furthermore, nitric oxide remains high in some regions. Another characteristic of a bad
result is low epithelial density throughout the entire simulation. This can be seen in section
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Figure 52: Simulation results for Case Total Injury, Breast Fed kpp = :000125. The 18 graphs shown in this
gure show the amount of each component in the epithelial and lumen layers. (For example, the graph in
the bottom left corner shows the amount of activated macrophages in the epithelial layer.) For each graph,
the vertical axis indicates the quantity of the substance and the horizontal axis indicates time, in hours.
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Figure 53: Simulation results for Case Total Injury, Breast Fed kpp = 1:25. The 18 graphs shown in this
gure show the amount of each component in the epithelial and lumen layers. (For example, the graph in
the bottom left corner shows the amount of activated macrophages in the epithelial layer.) For each graph,
the vertical axis indicates the quantity of the substance and the horizontal axis indicates time, in hours.
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Figure 54: Tissue Damage for Case Total Injury, breastfed with kpp = :000125 (Top), Case Total Injury,
breastfed with kpp = :7 (Middle), and Case Total Injury, breastfed with kpp = 1:25 (Bottom).
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7.3 (term infant, partial injury) in the circumstance of formula feeding. In this simulation,
the epithelial density appears to be reaching a level density. However, the density is not high
enough to prevent bacterial invasion of the underlying tissue.
Secondly, consistent breast feeding, simulated in these runs by high values of kpp, will
usually lead to good results. This fact can be seen throughout the cases in this chapter.
Even in the dicult case of total injury to the epithelium, consistent breast feeding led,
eventually, to a good outcome.
Thirdly, an unhealthy NEC outcome is the result of at least two undesirable events or
factors. One bad factor is not enough for an unhealthy NEC outcome. For example, in
section 7.2 (prematurity, no injury), the high levels of bacteria near the epithelium led to a
bad NEC outcome when combined with formula feeding. On the other hand, in this same
section it was shown that high levels of bacteria near the epithelium did not lead to an
unhealthy outcome in the circumstance of consistent breast feeding, (simulated by kpp = 1).
Furthermore, a survey of the other simulations in this chapter will reveal the fact that injury
alone, prematurity alone, or formula feeding alone will not result in a bad NEC outcome.
7.6 CONCLUSIONS
The general pattern of the graphs generated by our NEC model very closely resembles what
one would expect under actual disease conditions. For example, it was shown that an initial
large injury to the epithelial layer followed by formula feeding resulted in an ever-escalating
inammatory cascade with a very bad outcome. On the other hand, an initial small injury
to the epithelial layer combined with breast feeding resulted in a very positive outcome. In
the cases studied, the peaks and valleys of each graph occurred in very realistic patterns.
However, the actual value of the peaks and valleys in the graphs as well as the relative time
at which they occur are areas for future study and renement. This renement may be
achieved through better parameter estimation and better evaluation of the uncertainties in
the parameter values.
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7.7 A COMPUTATIONAL NOTE OF THE APPLICATION OF THE NEC
EQUATIONS TO DIFFERENT DOMAINS
The calculations done in this chapter were done in three dimensions, using the cell-centered
nite dierence method. For computational purposes, each region was divided into compu-
tational cells. The computational domain, discretized into a grid of computational cells, is
shown in gure 55. (The third dimension, going into the page, is not shown.) As the cells
get smaller, the number of cells increases and so does the accuracy of the solution. However,
decreasing the size of the cells greatly increases the computation time.
Obviously, some of the equations in the NEC model apply only in certain domains, for
example, the epithelial equation and the ZO1 (tight junction) equation are only valid in the
epithelial layer. (That is why these components are zero in other regions.) Even though
some of the NEC equations are valid in all four regions, they have dierent vertical and
horizontal diusion coecients, D, depending upon the region. For example, the bacteria
equation's diusion coecient is greater in the blood region than in the tissue region.
These vertical and horizontal diusion coecients aect the rates at which the NEC
components move from computational cell to computational cell within each region. The
vertical diusion coecients also eect how the NEC components move from region to region.
Diusion coecients for computational cells along the interface of two regions are calculated
by nding the harmonic average of the diusion coecients in both of the regions.
Another consideration for diusion coecients is epithelial layer permeability. In the
computer code, diusion coecients into and out of the epithelial region increase as ZO1
(the tight junction protein) decreases. Recall from chapters one through three that tight
junction protein seals the para cellular space between epithelial cells. So, as ZO1 is destroyed,
epithelial layer permeability increases. Furthermore, ZO1 density is highly correlated to
epithelial cell density - as epithelial cells die and create "holes" in the epithelium, ZO1
decreases. Therefore, it is reasonable to inversely correlate ZO1 density with epithelial
permeability, i.e., we increase diusion coecients into and out of the epithelial region as
ZO1 decreases and we decrease diusion coecients into and out of the epithelial region as
ZO1 increases.
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Figure 55: The computational domain, discretized into grid of computational cells. Two dimensions are
shown, the third dimension which goes into the page, is not shown.
Finally, we consider the tissue/blood barrier. Under normal circumstances, this barrier
has a low level of permeability. However, as damage in the tissue increases, this barrier will
be compromised. Therefore, in the code, the vertical diusion coecient between these two
layers increases as damage increases.
259
8.0 CONCLUSIONS AND FUTURE WORK
As noted in the introduction, the purpose of this thesis is twofold. First of all this work
presents a three dimensional mathematical model of Necrotizing Enterocolitis(NEC). NEC
models published previously were all one dimensional, ordinary dierential equation models.
These one dimensional models are extremely valuable, however, they do not model important
spatial aspects of the disease. The model in this thesis consists of a system of partial
dierential equations (PDEs) that models both the temporal and spacial aspects of NEC.
Secondly, this work analyses that NEC PDE system. That is, existence, uniqueness, and
regularity analysis is done on the entire PDE system. Also, a mixed nite element analysis
is done on the system of equations. This second purpose has signicance for the NEC
PDE system and it has signicance independent of the NEC PDE system. For the NEC
system, this analysis provides a strong mathematical foundation for the equations and their
interrelation with each other. On the other hand, some of the classes of equations in the
NEC PDE system occur, in a slightly dierent form, in other contexts but, in some cases,
no existence, uniqueness, and regularity results for these equations exist in the literature.
The same may be said of the mixed nite element analysis of some of the equations in the
system - no published analysis exists. Therefore, the PDE analysis and the nite element
analysis include new and important results.
As seen in the last chapter, the NEC model presented in this thesis incorporates the
most signicant features of NEC. Furthermore, the simulations presented in that chapter
are consistent with the progression of the disease as seen in actual NEC patients. The model
may now be used to simulate other NEC scenarios.
The existence, uniqueness, and regularity for the NEC PDE system was developed in
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chapter four. The analysis of the nonlinear coupled system in Part I,
@u1
@t
 r  (D1ru1   u1ru2) = f1(u1; u2)
@u2
@t
 r  (D2ru2) = f2(u1; u2) (x; t) 2 
 (0; T ]
ru1  n = 0 and ru2  n = 0 on  
where f1 and f2 are nonlinear functions is new. It was proven that the system does indeed
have a weak solution and regularity was established. Furthermore, regularity was established
for all of the NEC variables.
Furthermore, mixed nite element convergence was established for each of the NEC
variables. The mixed method nite analysis for the Part I equations is new and it is perhaps
the most signicant result of the thesis. That analysis consisted of nding a solution in the
bounded set S.
Future Work.
There are many possibilities for future work for the NEC model. For example, it may
be helpful to include more detail in the epithelial layer and extra cellular matrix. This may
mean including cell migration in the model as well adding an extra cellular matrix region to
the model.
Further work may also be done in the area of analysis. The PDEs analyzed in chapters
four and ve were relevant to the NEC system. However, it would be benecial to do
existence, uniqueness, and regularity studies as well as nite element analysis on a more
general system that contains more complicated coupling. For example, instead of the Part
I type equations (see chapter four), one might study a system that has "two-way" coupling
in the advection terms:
@u1
@t
 r  (D1ru1   u1ru2) = f1(u1; u2)
@u2
@t
 r  (D2ru2   u2ru1) = f2(u1; u2)
Some computer convergence tests were done for the system above and it was found that there
was no convergence in some cases(see chapter six) when using the explicit nite dierence
method. On the other hand, there was convergence for all of the implicit cases that were
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tested. However, no formal analysis was done on this system. Such an analysis would be
interesting but very dicult in view of the challenges that the two-way coupling presents.
The existence and regularity analysis for the PDE in part II was presented in chapter
four. The results for the degenerate case heavily depended on the excellent paper by Alt and
Luckhaus [4]. However, Alt and Luckhaus, make certain assumptions that do not always
apply to the degenerate case. For example, for our Part II equation, (see equation (4.177)
in chapter four :
@ec
@t
 r  (a(rec; ec)) = fec(ec; b; na)
Alt and Luckhaus would make the assumption that
(a(rec1 ; ec)  a(rec2 ; ec))  (rec1  rec2)  minminjrec1  rec2 j2:
(See [4], page 314 assumption 3.) We showed that this assumption is, in fact, valid for the
non-degenerate case but it will often not be true for the degenerate case. Therefore, further




FEM ANALYSIS PART II NON-DEGENERATE CASE
In chapter 5 of this thesis, the mixed nite element analysis of the degenerate case of PDEs
in Part II of the NEC system were presented. Below is the analysis of the non-degenerate
case.
Assumptions Following Arbogast, Wheeler, and Zhang, we assume for the non-degenerate
case we have,
0 < C 0  Pec  C 00 (A.1)
For some positive constants C 0 and C 00. Which, of course, implies that
0 < C 0  P (ech)  P (ec)
ech   ec
 C 00 (A.2)
and
C 0jech   ecj  jP (ech)  P (ec)j  C 00jech   ecj (A.3)
1
2
CA(ech   ec)2 
Z ech
ec
(P ()  P (ec)) d  1
2
CB(ech   ec)2 (A.4)
We may replace the rst term on the left hand side of (5.145) with (A.3) to get the
following error bound:Z t
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Bound 4 (Error bound in L2 Norm - Non-Degenerate Case)Z t
0

















kr  (hz  zkds
)
(A.5)
Thus, (A.5) gives an error bound for ech   ec in the L2 norm.




During the update of the NEC computer code, many of the parameters in the code were
renamed and a few new parameters were added. The old and new parameter names are
listed in the next three tables along with the current numerical values of these parameters.
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New Name Value Old Name Checked
kbg 0.9 kbg *
kb 1.5 kb *
kRca 1.0 knc *
kbma 1.8 kab *
kbna 1.8 kNab *
kpp 0-.25 kcab *
km 0.12 km *
kmb 0.1 kbm *
kmc 0.076 kcm *
kmd 0.02 kdm *
kma 0.05 kma *
kc 1.0 kc *
kcma 0.2 kmac *
kcna 0.05 kNac *
knc 0.04 kcN *
kcamana 0.25 NEW *
Table 5: Renaming of parameters (1 of 3).
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New Name Value Old Name Checked
kcamad 48 kcnd *
kca 0.1 kca *
kcaP 0 or .04 kcnn *
kNO 2.0 kNO *
kNOma 10,000 kmaNO *
kNOna 10,000 knaNO *
kna 0.05 kNa *
knd 0.018 kdN *
kd 0.02 kd *
kdc 0.35 kdn *
kZec 0.03 kZO1 *
kZect 2.0 NEW Previously 1
kZN 0.75 kNZ *
kP 0.25 kP *
kecnab 0.25 NEW *
kecnac 0.5 NEW *
Table 6: Renaming of parameters (2 of 3).
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New Name Value Old Name Checked
bmax 20 bmax *
ca 0.2800 kb *
cmax 0.3500 cmax *
dmax .92 dmax *
ec;max 1.0000 ec;max *
 0.2  *
Dec 0.000003 Dec *
zec 0.05 zec *
mac .0001 0 *
nac 0.0001 2 *
mab 0.0001 1 *
ma 0.01 ma *
mmax 0.67 m0 *
na 0.01 na *
na;max 0.62 na;max *
nb 1 nb *
q0 0.45 New *
q1 3.5 q1 *
q2 1.5 q2 *
sca 0 or .0125 sc *
xdc 0.06 xdn *
ZO1max 1 ZO1max *
Table 7: Renaming of parameters (3 of 3).
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APPENDIX C
LIPSCHITZ CONTINUITY RELATED TO PDES IN PART I
In this section, we will show that the right hand side functions of each of the equations in
Part I are Lipschitz continuous. Lipschitz continuity is a necessary condition for the numer-














fca :=  kcaca + sca + kcaP
Q
1 +Q
Set A = kcamanana +ma + kcamadd. We previously showed that na;ma; ca are bounded and

























  kcaca2 + kcaca1 + kcaPA(1 + kRca(ca1=ca)2 +A)  kcaPA(1 + kRca(ca2=ca)2 +A)(1 + kRca(ca2=ca)2 +A)(1 + kRca(ca1=ca)2 +A)

=
  kcaca2 + kcaca1 + kcaPAkRca(c2a1   c2a2)c2a(1 + kRca(ca2=ca)2 +A)(1 + kRca(ca1=ca)2 +A)

Set B = kcaPAkRca
c2a(1 + kRca(ca2=ca)
2 +A)(1 + kRca(ca1=ca)2 +A)
then
jfca(ca2)  fca(ca1)j = j   kcaca2 + kcaca1   B(ca1 + ca2)(ca2   ca1)j
= j( kca   B(ca1 + ca2))(ca2   ca1)j
 Cj(ca2   ca1)j (C.2)
This last inequality is true because the terms in the denominator of B are all positive, ca is








e2c + (ec;max   ec)2
u(ec; b) = (b)rec (C.4)
ka(na; c; b) :=
(na + kecnacc+ kecnabb)
:45
(na + kecnacc+ kecnabb)
:45 + ((na;max   na) + kecnac(cmax   c) + kecnab(bmax   b)):45
Dene
fec := kpec(1  ec=ec;max) Aec
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where
A = ka0ka(na; c; b)
Note that na; kecnac; c; kecnab; b; ka0 are all non-negative and if we can assume that we
have na;max  na; cmax  c; bmax  b then
0  A  1
jfec(ec2)  fec(ec1)j = j kp(ec2   ec1) 
1
ec;max
(e2c2   e2c1) A(ec2   ec1)j
=
 kp(ec2   ec1)  1ec;max (e2c2   e2c1) A(ec2   ec1)

=
 kp   1ec;max (ec2 + ec1) A
jec2   ec1 j
Since ec is bounded, we have
jfec(ec2)  fec(ec1)j  Cjec2   ec1 j (C.5)




  r Dbrb = kbgb(1  b=bmax)  kbb=(1 + b=)
 R(ca)(kbmamab+ kbnanab)  kppb (C.6)
Dene
fb := kbgb(1  b=bmax)  kbb=(1 + b=) R(ca)(kbmamab+ kbnanab)  kppb
jfb(b2)  fb(b1)j = j kbgb2(1  b2=bmax)  kbb2=(1 + b2=)
+b2( R(ca)kbmama  R(ca)kbnana   kpp)
  kbgb1(1  b1=bmax) + kbb1=(1 + b1=)
 b1( R(ca)kbmama  R(ca)kbnana   kpp)j
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=
 kbg(b2   b1)  kbg
bmax
(b2   b1)  kb b2 + b1b2=  b1   b1b2=
(1 + b1=)(1 + b2=)






(1 + b1=)(1 + b2=)
 R(ca)kbmama  R(ca)kbnana   kpp
jb2   b1j
jfb(b2)  fb(b1)j  Cjb2   b1j (C.7)
Since the bacteria equation is coupled with the activated macrophage equation, we will also
have to show that fb is Lipschitz continuous in ma:
jfb(ma2)  fb(ma1)j = j  R(ca)kbmab(ma2  ma1)j




  r  (Dnarna   nacnarc) =  knana +R(ca)(knccn+ knddn)
Dene
fna :=  knana +R(ca)(knccn+ knddn)
Note that the last two terms on the right hand side do not depend on na and also note that
kna  0, so
jfd(na2)  fd(na1)j = j   knana2   ( knana1)j = knajna2   na1 j (C.9)
Since the activated neutrophil equation is coupled with the cytokine equation, we will also
have to show that fna is Lipschitz continuous in c:
jfna(c2)  fna(c1)j = j R(ca)kncn(c2   c1)j
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  r  (Dmarma   macmarc  mabmarb)
=  kmama +R(ca)(kmbbm+ kmccm+ kmddm)
Dene
fma :=  kmama +R(ca)(kmbbm+ kmccm+ kmddm)
Note that the last three terms on the right hand side do not depend on ma and also note
that kma  0, so
jfma(ma2)  fma(ma1)j = j   kmama2   ( kmama1)j = kmajma2  ma1 j (C.11)
Since the activated macrophage equation is coupled with the cytokine equation, we will also
have to show that fma is Lipschitz continuous in c:
jfma(c2)  fma(c1)j = j R(ca)kmcm(c2   c1)j
jfma(c2)  fma(c1)j  Cjc2   c1j (C.12)
The activated macrophage equation is also coupled with the bacteria equation, so we will
also have to show that fma is Lipschitz continuous in b:
jfma(b2)  fma(b1)j = j R(ca)kmbm(b2   b1)j















Note that the second term on the right hand side does not depend on d and also note that
kd  0, so






















  r Dcrc =  kcc+R(ca)(kcmama + kcnana) R(ca)(knccn+ kmccm) (C.18)
Dene
fc :=  kcc+R(ca)(kcmama + kcnana) R(ca)(knccn+ kmccm)
jfc(c2)  fc(c1)j = j   kcc2  R(ca)(kncc2n+ kmcc2m)  ( kcc1  R(ca)(kncc1n+ kmcc1m))
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= jc2( kc  R(ca)kncn R(ca)kmcm)  c1( kc  R(ca)kncn R(ca)kmcm))
= j   kc  R(ca)kncn R(ca)kmcmjjc2   c1j
Using (4.140), the fact that n is xed and m  mmax, a constant. So,
jfc(c2)  fc(c1)j  Cjc2   c1j (C.19)
Since the cytokine equation is coupled with the activated macrophage equation, we will also
have to show that fc is Lipschitz continuous in ma:
jfc(ma2)  fc(ma1)j = j R(ca)kcmac(ma2  ma1)j
jfc(ma2)  fc(ma1)j  Cjma2  ma1 j (C.20)
The cytokine equation is coupled with the activated neutrophil equation, we will also have
to show that fc is Lipschitz continuous in na:
jfc(na2)  fc(na1)j = j R(ca)kcna(na2   na1)j




= km(mmax  m) R(ca)(kmbbm+ kmccm+ kmddm)
Dene
fm := km(mmax  m) R(ca)(kmbbm+ kmccm+ kmddm)




VERTICAL GRAPHS FOR THE SIMULATION CHAPTER.
Figure 56: Normal Case - Term Infant, No Injury to the epithelium. The colored vertical graphs are logs
of, from left to right, ca; d; ec; b; c;m;ma; NO;ZO1: This graph is associated with gure 28 in the Simulation
Results chapter.
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Figure 57: Simulation results for Case Partial Injury, Formula Fed. The colored vertical graphs are logs
of, from left to right, ca; d; ec; b; c;m;ma; NO;ZO1: This graph is associated with gure 43 in the Simulation
Results chapter.
Figure 58: Simulation results for Case Partial Injury, Breastfed. kpp = :7. The colored vertical graphs
are logs of, from left to right, ca; d; ec; b; c;m;ma; NO;ZO1: This graph is associated with gure 45 in the
Simulation Results chapter.
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Figure 59: Simulation results for Case Total Injury, Formula Fed. The colored vertical graphs are logs of,
from left to right, ca; d; ec; b; c;m;ma; NO;ZO1. This graph is associated with gure 49 in the Simulation
Results chapter.
Figure 60: Simulation results for Case Total Injury, Breast Fed kpp = :7. The colored vertical graphs
are logs of, from left to right, ca; d; ec; b; c;m;ma; NO;ZO1: This graph is associated with gure 50 in the
Simulation Results chapter.
Figure 61: Simulation results for Case Total Injury, Breast Fed kpp = :000125. The colored vertical graphs
are logs of, from left to right, ca; d; ec; b; c;m;ma; NO;ZO1: This graph is associated with gure 52 in the
Simulation Results chapter.
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Figure 62: Simulation results for Case Total Injury, Breast Fed kpp = 1:25. The colored vertical graphs
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